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 Preface 
This thesis is divided in two parts. The former has been carried out at the Universitá degli Studi 
di Milano, department of Pharmaceutical Sciences, in the research group of Professor Anna 
Sparatore. This project treats the synthesis of new sulfurated compounds with the aim of 
obtaining anticancer agents acting through a multitarget mechanism. This part, entitled "design 
and synthesis of new derivatives of natural and synthetic systems endowed with anticancer 
activity, through a multitarget mechanism" is discussed from page 1 to page 149. 
The latter has been developed at Swiss Federal Institute of Technology in Zurich (ETH Zurich), 
Institute of Pharmaceutical Sciences (IPW), under the supervision and in the research group of 
Professor Dario Neri. This project explains the advantages of using DNA-encoded chemical 
libraries (DECLs) in drug discovery process. In particular, since in the majority of cases DECLs 
require at least one-step of amide bond formation between amino modified DNA and a carboxylic 
acid, we optimized a new methodology of synthesis in order to facilitate the construction of 
single-pharmacophore libraries (DECLs). This part, entitled "optimized reaction conditions for 
amide bond formation in DNA-encoded combinatorial libraries" is discussed from page 151 to 
page 187. 
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ABSTRACT 
The scientific research on cancer therapy has made important progresses during last years, but 
mortality for some types of cancer keeps increasing. Cancer chemotherapy can not be considered 
completely satisfactory and, due to the extreme toxicity of anticancer drugs, it becomes essential 
to identify new compounds more potent and less toxic. It is well known that inflammatory 
conditions in selected organs increase the risk of cancer. Compounds of the inflammatory tumour 
microenvironment include leukocytes, cytokines, complement components and are orchestrated 
by transcription factors, such as STAT3 and NFkB. Therefore, drugs able to inhibit one or both 
transcription factors could be useful tools to treat cancer disease.  
Based on these considerations, the aim of the present thesis was the synthesis of different novel 
sets of sulfureted hybrid molecules, potentially candidates for the treatment of cancer. On one 
hand, we explored the potentialities of new sulfurated chemical scaffolds, such as 
dithiolethiones, methanethiosulfonates and allyldisulfides to evaluate their antiproliferative 
activity, as well as their ability to inhibit STAT3 and NfkB, and to design new anticancer agents. 
On the other hand, we evaluated the possibility of creating hybrid molecules, combining moieties 
with different mechanism of action, which could carry out a synergistic antitumor effect.  
In particular, the sulfurated compounds synthetized have been combined with different STAT3 
and/or NfkB inhibiting structures such as natural products (curcumin, phenolic acids and 
celastrol), semi-synthetic and synthetic systems (rosmaricine and heterocyclic compounds). 
Biological assays were in general quite encouraging and suggested that some of these new 
compounds could be considered as potential leads for the synthesis of new effective anticancer 
drugs. 
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1. INTRODUCTION 
1.1 Cancer: general aspects 
Cancer is a disease where abnormal cells grow with a potential to spread or invade different parts 
of the human body through blood and lymph system. Base of carcinogenesis process is a 
monoclonal genetic mutation, which depend on a single altered cell: under physiological 
conditions, this mutation is repaired by cellular systems and, if this is not possible, the cell 
undergoes apoptosis death. On the contrary, this mutation gives to the cell the ability to evade 
the body's control systems and therefore it begins to proliferate and accumulate mutations that 
confer a replication advantage over healthy cells. Moreover, cancer cells are able to evade the 
immune system which normally removes damaged or abnormal cells from the body. In this way, 
cancerous cells start growing independently and thus forming benign tumours, but by acquiring 
aggression, invasion and metastasis ability, they soon become malignant cancers. Indeed cancer 
disease are divided in benign and malignant based on their biological behaviours and 
morphological characteristics: usually the benign tumours are not fatal instead of malignant ones, 
which could be lethal because of the ability to penetrate the surrounding tissues and for the 
formation of metastasis in distant locations.1 
The possibility that a normal cell acquires the ability to proliferate in an uncontrolled way depends 
on a number of internal and external factors, which often act together or in sequence to provoke 
cancer in prolonged time, causing progressive genetic, morphological and functional alterations. 
The internal factors are generally not modifiable because of the characteristics of body cells, 
genetic mutations, hormones and functional aspects of the immune apparatus, which could be 
transmitted to offspring. On the contrary, the external factors, due to both life and work 
environments (i.e. infectious agents, chemical exposures, ionizing and non-ionizing radiations) 
and personal lifestyle (i.e. diet, smoking) can be modified by specific preventive interventions.2 
The fundamental characteristic of neoplastic proliferation is to be irreversible and autonomous, 
persisting even after the end of the trigger.  
This disease is a leading cause of death in industrialized countries and the second in the 
developing countries: this is due in part to the progressive aging of the population and of 
appropriate lifestyle involving smoking, sedentary lifestyle and a Western-style diet. 
Indeed, in 2012 there were 14 million3 new cases of cancer and 8.2 million deaths, numbers that 
are expected to increase in 2032 up to 22 million and 13 million respectively.4 
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In Italy, the number of new cases of cancer diagnosed in 2014 was almost 366,000: about 196,000 
(54%) in men and about 169,000 (46%) in women.5 During 2016, 1,685,210 new cancer cases and 
595,3690 cancer deaths are expected to occur in the United States, even if the cancer death rate 
has dropped by 23% since 1991. Despite this progress, cancer is now the leading cause of death 
in United States, primarily due to exceptionally large reductions in death from heart disease.6 
These data underline that it is necessary to implement new preventive measures and treatments 
better than the existing ones7 (including surgery, radiation, chemotherapy, hormone therapy, 
immune therapy, and targeted therapy) and, on other hand, it is important to find novel and 
safer therapeutic strategies which aim to identify new molecular targets which could allow a 
more effective pharmacological treatment for cancer and with less side effects. 
One of these objectives is to reduce two features of the most aggressive tumours: invasiveness 
and metastasis. During the last years it has been demonstrated a correlation between these 
cancer properties and the activation of some transcription factors such as STAT3 (Signal 
Transducer and Activator of Transcription 3) and NFkB (nuclear factor kappa-light-chain-
enhancer of activated B cells). Therefore, these proteins can be elected to new potential target 
in the strategies for the prevention or treatment against tumour diseases (Figure 1).8 
 
Figure 1. Multilevel interaction between STAT3 and NFkB.8  
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1.2 STAT3 
1.2.1 Signal Transducer and Activator of Transcription proteins  
STAT proteins (Signal Transducer and Activator of Transcription) are a family of latent, 
cytoplasmic transcription factors, which are activated in response to extracellular signals. STATs 
directly transmit these signals from plasma membrane to the nucleus and regulate cell growth 
and survival by modulating the expression of specific target genes. So far, seven members of this 
family of proteins have been discovered (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and 
STAT6)9: even if they have a structural similarity, they display different physiological functions 
such as embryonic development, organogenesis, cell differentiation and regulation of the 
immune system. Such proteins are approximately constituted by 750-850 amino acids and they 
have a highly conserved tertiary structure (Figure 2). 
All of them are composed by: 10 
 N-terminal domain, involved in the dimerization process of STAT, thus forming the 
tetramer (the active form of the protein) that contributes to stabilize DNA binding;9 
 Coiled-coil domain, four α-alpha helices consisting of a hydrophilic surface. This is 
important for the interaction between the transcription factor and other regulator 
proteins;11 
 DNA-binding domain, region characterized by β-sheet structure; 
 Linker domain, that ensures the appropriate conformation of the DNA-binding domain; 
 SH2 domain (Src Homology 2), which is essential for the interaction with the 
phosphorylated receptors and to form the homodimers;12 
 Tyrosine activation domain, a residue that is located near the C-terminal domain (in STAT3 
is located in position 705): when it is phosphorylated, it leads to the activation of STAT 
proteins and its subsequent translocation into the nucleus. Interaction of the 
phosphorylated tyrosine with the SH2-domain of other monomer also leads to the 
stabilization of the dimer; 
 C-terminal transactivation domain, which promotes gene transcription.13 
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Figure 2. (a) Crystal structure of STAT linked to DNA; (b) STAT functional domains.14 
 
1.2.2 STATs signalling pathway 
Upon binding growth factors (such as EGF, PDGF etc.), cytokines (i.e. as IL-6), polypeptide ligands 
and oncogenic proteins (i.e. Src and Ras) with their transmembrane receptors, STAT proteins are 
recruited on the cytoplasmic portion of the receptor where they are phosphorylated on the 
tyrosine residue by Src, JAK (Janus kinase) and Abl (Abelson leukemia kinase) proteins.15 
After the cytoplasmic phosphorylation of Tyr-705 by these tyrosine kinases proteins, STAT can 
dimerize by forming homodimers or heterodimers through specific reciprocal SH2-
phosphotyrosine interaction. The formed dimers then translocate into the nucleus and bind to 
specific DNA-sequences regulating the transcription of several genes which encode for inhibitor 
proteins of apoptosis (Bcl-xL , Mcl-1 and survivin), cell cycle regulators (cyclin D1 and c-Myc) and 
inducers of angiogenesis (VEGF) and inflammation (Figure 3).16, 17  
N-terminal 
domain  
SH2-domain 
Tyr activation 
domain 
C-terminal 
domain 
Linker domain   
DNA-binding 
domain  Coiled-coli 
domain  
(a)
) 
(b) 
N-terminal 
domain  
Coiled-coli 
domain  
DNA-binding 
domain  
Linker 
domain 
Tyr activation 
domain 
SH2-
domain 
NH2  COOH  
134  317 
331
731
7 
488
317 
331
731
7 
576 683 
pY ps 
Chapter I: Introduction 
 
7 
Figure 3. STATs patways.18 
 
1.2.3 Negative regulators of STATs signalling 
Among the different STAT proteins, it was found that STAT3 plays an important role in 
carcinogenesis19: it is involved in more than half of breast and lung cancers, hepatocellular 
carcinomas, multiple myelomas and more than 95% of head and neck cancers.20 
STAT3 was identified in 1994 as a DNA-binding factor that selectively binds to the IL-6-responsive 
element in the promoter of acute-phase genes from IL-6-stimulated hepatocytes.15 
Indeed, STAT3 was found to be constitutively activated by aberrant upstream tyrosine kinase 
activity in a broad spectrum of cancer cell lines, and it is considered a promising target for cancer 
therapy. Under physiological conditions, the STAT proteins help to carry out important biological 
functions. In this case, STAT3 plays a key role in maintaining embryonic stem cells in a pluripotent 
stage and their subsequent differentiation into myoblasts, astrocytes, motoneurons, osteoblasts 
and osteoclasts, as well as in the differentiation of stratified squamous epithelium. Furthermore, 
the activity of STAT3 is important for the efficiency of the immune system because it helps the 
maturation of B-lymphocytes and dendritic cells.21 
All these functions are related to an intermittent activation of STAT3, which is negatively 
regulated by modulating proteins. These negative modulators are represented by SOCS-1 and 
SOCS-3 (Suppressor of Cytokine Signalling proteins) that bind and inactivate the JAKs and by PIAS-
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3 (Protein Inhibitor of Activated STAT3), which is a nuclear factor able to interact with 
phosphorylated STAT3 and to block gene transcription. Moreover, several tyrosine 
phosphatases, such as SHP-1 and SHP-2, inactivate the protein by dephosphorylation of the 
tyrosine 705. Furthermore, STAT3 is partially degraded by the proteasome system through the 
binding of ubiquitin to lysine residue (Figure 4).15 
 
Figure 4. Negative regulation of the JAK-STAT pathway.22 
 
1.2.4 Influence of STAT3 on biological functions 
The constant presence of phosphorylated STAT3 influences various biological functions, 
encouraging the initiation and progression of the tumour growth (Figure 5). Some of these 
functions promote the development of cancerous cells and the reduction of apoptosis, as STAT3 
negatively regulates the transcription of the gene for the p53 protein.23 Importantly, numerous 
published reports showed that blocking constitutively activated STAT3 signalling leads to 
apoptosis only in tumour cells, with little effects on normal cells.24, 25 
Furthermore, STAT3 increases cell proliferation, thus promoting the transition from G1 to S phase 
of the cell cycle, through overexpression of cycle regulators as cyclin D1, cdc2, c-Myc and 
downregulation of p21 and p27 (inhibitor of cyclin-dependent kinase).  
Moreover, STAT3 plays an important role also in inflammatory pathway of cancer cells because 
induces transcription of many genes which code for some crucial inflammation proteins such as 
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IL-6, IL-10, IL-11, IL-17, IL-23, CXCL 12 and COX-2; the pro-tumoral inflammation is promoted 
through the expression of NFkB (Figure 5).21  
The constitutive activation of STAT3 also leads to a decrease of immune defences through the 
break of dendritic cells maturation and the inhibition of the immune response by the activation 
of the T-helper 1 cells and neutrophils, thus forming the inflammatory microenvironment 
suitable for cancer growth.26 Moreover, STAT3 induces malignancy of the tumour by promoting 
cell invasion, following an increase in the transcription of genes for some matrix 
metalloproteinases MMP-1, MMP-2 and MMP-9, which also contribute to angiogenesis and 
metastasis. Recent studies have shown that STAT3 is also involved in the reorganization of the 
cytoskeleton and in the control of cell adhesion properties, increasing cell-cell contact and 
intracellular adhesion, thus leading to the overexpression of genes required for invasion and 
cellular migration.23 An additional property of cancer cells, which is correlated to their 
uncontrolled proliferation, is the ability to increase the growth of endothelial cells in the 
surrounding blood walls: the result is the outgrowth of new capillaries into the tumour, which 
supply oxygen and nutrients. Angiogenesis is stimulated by different growth factors, mainly VEGF 
(Vascular endothelial growth factor), and recent studies have shown a strictly relationship 
between STAT3 and the overexpression of VEGF. The new capillaries formed in response to 
angiogenic stimulation are penetrated easily by the tumour cells, providing a good opportunity 
for cancer cells to enter inside the circulatory system and begin the metastatic process.27  
Some of these functions are reported in Figure 5. 
 
Figure 5. Roles of JAK–STAT3 in cancer.28 
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1.2.5 STAT3 as a novel anticancer drug target 
From the association of constitutive STAT3 activation with malignant transformation,15 a large 
number of studies has been undertaken for the validation of STAT3 as an anticancer drug target, 
and for the discovery of novel STAT3 inhibitors. The abnormal activation has been described in a 
wide range of cancers, including breast, lung, pancreatic, prostate, ovarian cancers, melanoma, 
leukemia and lymphoma, and it is often correlated with ominous clinical outcome.16, 19, 21, 29  
Recently, targeted deletion of STAT3 in skin cells was shown to prevent epithelial cancer and a 
dependence on STAT3 was demonstrated in lymphomas and myelomas.30 
The critical role and the function of STAT3 in tumorigenesis qualify it as a valid target for the 
development of novel anticancer therapeutic strategies. Indeed, many works reported that the 
inhibition of STAT3 specifically suppresses cancer cell survival and induces tumour regression 
without any effects in normal cells. Therefore, the specificity of STAT3 inhibitors could be used 
in combination with existing chemotherapeutic agents to reduce the side effects that are 
associated with the conventional chemotherapy. For example, in the development of new 
therapies, it has been considered also the possibility to use STAT3 inhibitors in combination with 
other molecules with anticancer activity, as doxorubicin or EGFR inhibitors, which demonstrated 
to reduce the resistance of cancer cells, allowing the use of these drugs at lower doses and 
therefore limiting also the problems related to their toxicity.31, 32 
 
1.2.6 STAT3 inhibitors classification 
Two main approaches have been explored to inhibit STAT3 signaling:33, 34 
 indirect, based on the inhibition of the upstream tyrosine kinases that are responsible for 
STAT3 activation or blocking factors as JAK, Src, Bcr-Abl, FLT3 and EGFR that are involved 
in the activation of STAT3 signalling. This kind of inhibition induces tumour-cell apoptosis 
but is poor selective. Among the indirect inhibitors there are various polyphenolic 
compounds as epigallocatechin-3-gallate (EGCG),35 curcumin,36 rosmanol,15 caffeic acid, 
betulinic acid and celastrol37 (Figure 6); 
 direct, by interaction of small molecules with the protein. In this selective approach, the 
starting point is the crystallographic structure of STAT3-SH2 domain.38 
There is a large number of compounds with STAT3 direct inhibitory activity reported to date, 
which denotes an enhanced interest in this field. Their structures range from peptides (i.e. PY*L) 
initially developed in order to mimic the amino acid sequence of the surroundings of 
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phosphorylated 705-tyrosine, to peptidomimetics (i.e. IIS610), to small molecules (i.e. S3I-201 
and derivatives), to oligonucleotides and platinum-containing compounds.  
Many of them showed good activity in terms of inhibition of STAT3 biological functions and the 
associated antitumor cell effects in vitro, as well as the suppression of tumour growth in mouse 
models of human tumours. In addition, natural products as cryptotanshinone,39 a quinone 
extracted from Salvia miltiorrhiza Bunge, was shown to suppress STAT3 activation in tumour cells 
and diallyl trisulfide (DATS),40 a constituent of processed garlic, demonstrated to inhibit 
phosphorylation, dimerization and nuclear translocation of STAT3 in prostate cancer cells both 
in culture and in vivo (Figure 6). Moreover, cryptotanshinone and the fungal 
metabolite galiellalactone from Ascomycete A111-95, have been identified as natural 
compounds with a direct inhibition on STAT3 (Figure 6).41 
In addition to these compounds, some synthetic small molecules42 have been developed: as an 
example, S3I-201 and its analogues (Figure 6), which are able to directly inhibit the formation of 
the dimer.43 
However, the majority of the compounds are at the experimental stage and new selective drug 
candidates with high potency and in vivo activity are needed. 
In the direct approach, much of the efforts have been addressed at disrupting the STAT3:STAT3 
dimerization, which is a fundamental step in STAT3 activation. Indeed, direct inhibitors should be 
preferred because the nonspecific mechanism of action of indirect inhibitors could cause 
important adverse effects.44 The slow progress of obtaining suitable direct STAT3 inhibitors for 
preclinical investigation and for clinical development could be attributed to the challenge of 
targeting protein-protein interactions (PPIs), which are very different from those of more-
established targets such as enzymes and G-protein-coupled receptors. Nonetheless, a number of 
successful examples started to prove that it is possible to overcome these hurdles and develop 
PPI modulators as drugs.45 
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Figure 6. Structures of some natural and synthetic inhibitors of STAT3.37, 43 
  
Chapter I: Introduction 
 
13 
1.3 NfkB 
1.3.1 Nuclear factor kappa B  
Discovered in 1986, Nuclear factor kappa B was found to bind the enhancer element of the 
immunoglobulin kappa light-chain of activated B cells, thereby it was coined the “NfkB” 
abbreviation. This heterodimeric protein is composed by different combinations of five proteins, 
which belong to the Rel family (RelA, RelB and cRel), and the NFkB family (p50 and p52).46, 47  
NfkB proteins function as dimeric transcription factors that regulate the expression of genes 
influencing a broad range of biological processes including innate and adaptive immunity, 
inflammation, stress responses, B-cell development and lymphoid organogenesis.  
Until now, five members of NfkB family have been identified, including NfkB1 and NfkB2, which 
are synthesized as pro-forms (p105 and p100) and are proteolytically processed to p50 and p52 
respectively, RelA (p65), RelB and c-Rel.  
All proteins of the NFkB family share some structural features (Figure 7), including: 
 N-terminal or Rel homology domain (RHD), which it is essential to bind specific DNA 
sequences as well as for the dimerization process.48 
 C-terminal, responsible of the dimerization process and the nonspecific DNA-phospate 
contact.48 
Moreover, p105 and p100, in contrast with other members of NfkB family, do not contain any 
transactivation domain but only an Ankyrin repeats which are cleaved upon maturation: 
consequently, dimers of p50 and p52 act as transcriptional factor, binding specific DNA-binding 
sequences.46 
Furthermore, other phosphorylation sites occur in some NfkB subunit after post-translational 
modifications, which are important for activation and crosstalk with other signalling pathways.46 
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Figure 7. (a) Crystal Structure of NfkB; (b) NFkB functional domains. Adapted from49 
 
1.3.2 NfkB signalling pathway 
The proteins of Rel family are present in the cytosol as homodimers or heterodimers in their 
inactive form, since are complexed by IkB protein (Inhibitor of kB) which mask and inhibit their 
Nuclear Localization Signal (NLS); 50 whereas, for the family of NfkB, the precursors present in the 
cytosol are the proteins p100 and p105, which are transformed into p52 and p50 only after the 
proteolytic cleavage. Once activated, these dimers can translocate into the nucleus and act as 
transcription factors. This activation occurs as a result of different signals, both exogenous (i.e. 
lipopolysaccharide-LPS or antigens) and endogenous (i.e. proinflammatory cytokines and growth 
factors), following two different pathways (Figure 8):46 
 Classical pathway: in this pathway, the interaction of microbial products (such as LPS) or 
antigens of pro-inflammatory cytokines (such as TNF-α and IL-1) or growth factors with 
their respective receptors leads to the activation of IKK complex (composed by IKKα, IKKβ 
and IKKγ, inhibitors of kB Kinase) which phosphorylates IkB proteins. Phosphorylation of 
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IkB brings to its degradation by the proteosome, freeing NFkB complexes to translocate 
into the nucleus where, either alone or in combination with other transcription factors 
(including AP-1, Ets, or STAT), they bind to NFkB-DNA response elements, and induce the 
transcription of the target genes.51 
 Alternative Pathway: the stimulation of the respective receptors by leukotrienes, CD40L 
(CD40 Ligand) or BAFF (B-cell Activating Factor) drives to the activation of the NIK protein 
(NFkB Inducing Kinase). In this way NIK phosphorylates IKKα complexes which, through 
the phosphorylation of p100 portion of the p100/RelB dimer, leads to the proteolytic 
cleavage to p52. This creates 52/RelB complexes that pass into the nucleus and induce 
target gene expression.51 
 
Figure 8. NfkB pathways.52 
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Regardless of the followed pathway, the activated dimers translocate to the nucleus and they 
bind to DNA at specific sequences of 9-10 pairs of nitrogenous bases (the sequences are different 
depending on the dimer involved in the interaction).47 Thanks to the binding, they perform the 
activity of transcription factors, thus bringing to the expression of pro-inflammatory genes coding 
for cytokines, chemokines, and molecules that mediates cell adhesion.53 
 
1.3.3 Negative regulators of NfkB signalling 
A large number of different external stimuli leads to activation of NFkB, which play important 
and conserved roles in immune and stress responses, and impact processes such as apoptosis, 
proliferation, differentiation, and development. Due to the ability of NfkB to influence 
expression of numerous genes, the activity of this protein is tightly regulated at multiple levels. 
One of these mechanisms regards the regulation of NFkB through the inhibition of the IkB 
proteins (IkB, inhibitor of NFκB), and the kinase that phosphorylates IkBs, called IkB kinase 
complex (IKK). The mechanism of action of IkB proteins in NfkB signalling is still not fully 
understood but it has been demonstrated that Bcl3, atypical member of this class, provides a 
repression of p50 or p52 homodimers.49 However, there are also different types of post-
translational modifications that can also modulate the activity of the IkB and IKK proteins as 
well as NFkB molecules themselves.54 
 
1.3.4 Influence of NfkB on biological functions 
Over the last years, it has been discovered that there is a strictly correlation between the chronic 
inflammation and cancer development.55 Indeed, NFkB was found to be constitutively activated 
in many solid malignancies56 and its mutation has been found in several types of cancer such as 
those in the prostate, breast, colon, liver, lung, and melanoma.46  
NfkB activation is related to initiation and progression of the tumour, since it promotes cell 
proliferation and inhibits apoptosis, but also to its aggressiveness and invasiveness, promoting 
the development of metastases (increasing the expression of metalloproteinases matrix and 
VEGF) and inducing resistance to drugs and to radiation.57 
In particular, NFkB signalling is essential for estrogen receptor-negative (ER-) breast cancer 
tumorigenesis, progression and metastasis.58-60 Furthermore, the role of NFkB in expressing pro-
inflammatory cytokines and enzymes contribute to the strong correlation between inflammation 
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and breast cancer. Among the pro-inflammatory enzymes that are transcriptionally controlled by 
NFkB there are cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2).61  
COX-2 and NOS2 expression in ER- breast cancer is highly correlated with poor patient 
prognosis.62, 63 In support of these data, there are some observations that show how proteins 
that activate NFkB play a key role in tumorigenesis: the protein tyrosine kinase EGFR (epidermal 
growth factor receptor) is involved in ovarian cancer, ZNF300 (Zinc Finger Protein 300) in cervical 
cancer and S100A4 protein promotes squamous cell cancer of the larynx.64, 65 Also exogenous 
agents such as HCV (Hepatitis C Virus) and many other carcinogens exploit the activation of NFkB 
to establish the chronic inflammation that promotes the development of HCV.57 
 
1.3.5 NfkB as a novel anticancer drug target 
Since NfkB is involved in the initiation and progression of cancer, its pathway is a potent key point 
of pharmacological interference in the clinics. Therefore, a combination of classical 
chemotherapy with NfkB inhibitors could result in a promising strategy to solve the cancer 
diseases. Recently it has been demonstrated that the inhibition of NfkB could be beneficial in the 
treatment of metastatic prostate cancer in combination with androgen antagonists inducing the 
apoptosis of many prostate cancer cells. Finally, it is important to underline that NfkB might be a 
useful target not only directly by blocking anti-apoptosis mechanisms of cancer cells, but also 
indirectly by moving macrophages from the tumour-tolerating M2-polarization stage towards the 
tumour-attacking M1-stage.66 
 
1.3.6 NfkB inhibitors classification 
The inhibition of NfkB proteins can occur by three mechanisms: 
 blocking the incoming stimulating signals at an early stage (e.g., the binding of ligand to 
its receptor); 
 interfering with some specific components of NfkB pathway (e.g., the recruitment of an 
adaptor to the receptor complex, the activation of the IKK complex, or degradation of 
IkB); 
 stopping the nuclear activity with the inhibition of NfkB binding with DNA or with the 
nuclear modification of its activity or specificity. 
Generally speaking, each of these three major steps is not susceptible to the same types of 
inhibitors.47 For example, N-acetylcysteine (Figure 9), by interfering with NfkB, shows at the same 
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time to have activities against liver cancer cells by inducing apoptosis and to increase the 
sensitivity of the same to treatment with IFN-α.57 Moreover, recent studies indicate that the 
panepoxydone (a compound isolated from Lentinus critinus, Figure 9) and the ethanol extract of 
Saussurea lappa (a medicinal herb) reduce the invasiveness and migration in different cancer 
breast cell lines through the inhibition of NFkB.67 On the other hands, also dithiolethione 
compounds, which are found in dietary vegetables and are clinically available, have been 
reported to inhibit NFkB activity in multiple cell types and have been shown to improve the 
effects of LPS toxicity in mice.68 This class of compounds has well established chemopreventive 
effects in humans.69 As an example, 5-[p-methoxyphenyl]-1,2-dithiole-3-thione (anethole 
dithiolethione, ADT) is efficacious in limiting bronchial dysplasia in smokers. Besides NFkB 
inhibition, dithiolethiones exert their chemopreventive effects, in part, by activating the Nrf2 
transcription factor that binds to the antioxidant response element on the promoter region of 
target genes70, 71 in addition to inhibiting the xenobiotic response element, which is responsible 
for carcinogen activation.72 
This data strongly underline the possibility of exploiting the inhibition of this transcription factor 
as a potential new strategy to struggle cancer diseases, especially in combination with other 
chemotherapeutic agents.56 
 
Figure 9. Some inhibitors of NfkB. 
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1.4 Sulfurated compounds  
It is well known that natural compounds represent a great resource for research in the 
pharmaceutical field. Among the components that can be found as metabolites in the plant 
kingdom there are sulfur compounds: allyl disulfides, from Liliaceae family, methanethiosulfonate 
and dithiolethione compounds, from Brassicaceae family, have been recently isolated and studied 
for their antiproliferative and chemopreventive properties. 
From Liliaceae family, allycin, diallyl trisulfide and diallyl disulfide (DATS and DADS, Figure 10), 
components founded in the extract of Allium sativum (garlic), are notable of interest. DADS has 
been identified to have in vitro anti-cancer properties on various cell lines of colon, prostate, 
bladder, lung, liver cancers and leukemia and melanoma. DADS exerts such activity through the 
induction of apoptosis and the reduction of tumour invasiveness and angiogenesis. In addition, 
it stimulates the production of some detoxification enzymes able to digest carcinogens.73 
Other classes of sulfur molecules, are methanethiosulfonate and dithiolethione compounds.74,75 
Representative of the first class is S-methyl methanethiosulfonate (S-MMTS, Figure 10), isolated 
from cauliflower, which is able to reduce more than 80% of the incidence of colon cancer in rats 
when it is administered during the post-initiation phase of cancer.76 Moreover, when it is 
coadministered with sulindac (a non-steroidal anti-inflammatory drug), it inhibits carcinogenesis 
and the enzyme ornithine decarboxylase, one biomarker of cell proliferation.74  
Recently, a new methanethiosulfonate derivative of valproic acid (ACS33, Figure 10), synthesized 
in Prof. A. Sparatore’s laboratory, showed good in vitro antiproliferative activity on PC3 and DU-
145 prostate tumour cell lines and it also inhibited the growth of PC3 in subcutaneous xenografts 
mouse models in vivo.77 
Dithiolethione compounds, which are found in dietary vegetables and are clinically available, 
have been reported to inhibit NFkB activity in multiple cell types and have been shown to 
ameliorate the effects of LPS toxicity in mice.68 This class of compounds has well established 
chemopreventive effects in humans.69 Among them, there is the anethole dithiolethione (ADT), 
which is also used as a drug in the treatment of xerostomia and as hepatoprotective agent.78  
Indeed, not only the ADT, but also other molecules containing the dithiolethione ring possess 
important activities that confer anticancer properties to these compounds. For instance, they 
activate PP2A (Protein Phosphatase 2A), an enzyme able to inhibit pro-tumorals mechanisms 
mediated by Akt, c-myc and m-TOR.79 
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Another important property of dithiolethiones is the inhibition of NfkB activity, resulted in a 
reduction of IL-6, IL-8 and VEGF expression, as well as of the activity of the metalloproteinase 
MMP-9 matrix, which is involved in pathological process such as metastasis. Dithiolethiones exert 
this activity according to two mechanisms: the first is direct and provides the formation of 
covalent bonds with the p50 and p65 subunits of NFkB,79 while the second one is indirect, where 
NfkB is inhibited thanks to the hydrogen sulfide (H2S) released.68 ADT-OH, the demethylated 
derivative of ADT, has proved to release this gas both in vitro and in vivo, via metabolic type 
mechanism.80, 81 
Recently, hydrogen sulfide has been demonstrated to act as anti-inflammatory component if 
released in low and constant concentrations, probably inhibiting the transcription mechanisms 
involved in the inflammatory process.  
In support of this theory, there is the anti-inflammatory activity of the S-diclofenac (i.e. ACS15, 
compound resulting from the esterification of diclofenac with the ADT-OH) which was found to 
be more effective and potent than diclofenac in several inflammation models: this is, at least in 
part, due to the effect of H2S released.68 Finally, some studies carried out on oltipraz, a drug with 
dithiolethione structure used in the treatment of schistosomiasis, have shown the ability of this 
molecule to induce phase II enzymes such as glutathione-S-transferase, an enzyme involved in 
the detoxification of many carcinogens (as the aflatoxin B1) and to inhibit angiogenesis both in 
vitro and in vivo.82-84 During the last years, in Prof. A. Sparatore’s laboratory, beyond ACS15, other 
new dithiolethione derivatives (ACS2, ACS18) have been synthesized: these significantly inhibited 
in vitro and in vivo cell proliferation (NSCLC xenograft in nude mice), enhancing E-cadherin and 
the tumour suppressor PP2A and exhibited antiangiogenic properties.85, 86  
Moreover, these compounds inhibited the activity and expression of several carcinogen activating 
enzymes as well as induced the expression of several carcinogen detoxification enzymes of the 
glutathione cycle.72 In addition to these compounds, other methanethiosulfonate derivatives 
were synthesized by our research group, including ACS26 and ACS42 together with the 
corresponding conjugated derivatives of valproic acid (ACS33 and ACS43, Figure 10).87  
These products are able to inhibit histone deacetylases (HDAC), a family of enzymes involved in 
the rearrangement of the chromatin and in the regulation of gene transcription. The activity of 
HDAC is probably related to the ability of the sulfur compounds to chelate Zn2+ ion, the enzyme 
cofactor.87 
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Therefore, on the basis of the results obtained in our laboratory and of the data found in 
literature, compounds belonging to these classes of sulfurated molecules can be considered 
potential lead compounds worthy of further studies and it is also possible that conjugating them 
with other molecules (active on carcinogenic processes), could lead to the obtaining of new 
chemical hybrids useful as anticancer agents. 
 
Figure 10. Molecular structure of sulfurated compounds. 
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1.5 Natural compounds 
1.5.1 Curcumin and cinnamic acids 
Turmeric is a spice obtained from dried and ground rhizomes of Curcuma Longa plant. This 
yellow-orange powder is widespread in South Asia, especially in India, and it is commonly used 
in cooking as curry powder and food coloring.88 Curcumin is the major active component of 
turmeric and it is a member of the curcuminoid family (composed by curcumin and its derivatives 
demethoxy and bisdemethoxy-curcumin, Figure 11).89 This diarylheptanoid phenol has been 
used for centuries in traditional Indian medicine to treat various respiratory disorders, such as 
asthma, allergy, cough, sinusitis, rhinitis, bronchial hyperactivity, as well as for other disorders, 
including anorexia and liver disease. Thanks to all these properties, curcumin is marketed in many 
countries, including the United States, India, Japan, Korea, Thailand, China, South Africa, Nepal 
and Pakistan, in different formats (i.e. capsules, tablets, ointments, energy drinks, soaps and 
cosmetics).88 
  
Figure 11. Curcuminoid structures. 
Several studies performed in the last thirty years have shown the ability of curcumin to inhibit in 
vitro the growth of some cancer cells and also to increase the potency of some chemotherapic 
drugs.88 Moreover, the pharmacological activity of curcumin does not involve only a single target, 
but it is the result of a synergistic effect involving several proteins. 
As a matter of fact, it is able to suppress the activity of some pharmacological targets involved in 
carcinogenesis and tumour progression, as STAT3 and NFkB,90 and to limit the functions of several 
enzymes that participate in the inflammatory process, such as COX-2 and iNOS. This anti-
inflammatory profile for the prevention and treatment of pathological conditions triggered by 
chronic inflammatory conditions, such as cancer, diabetes and Alzheimer's syndrome is 
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particularly relevant. Furthermore, it has been observed that curcumin interacts with many other 
biological targets, some of which are engaged in the replication of HIV virus.  
Moreover, the antiproliferative activity of curcumin is quite clear because it induces apoptosis in 
cancer cells through the generation of reactive oxygen radicals, mainly superoxide anions.91 
Because of this evidence, there is a great interest in the clinical development of this compound 
as a chemopreventive and/or chemotherapeutic agent.88 
The pro-apoptotic effect of curcumin is shown in different cell lines and it is correlated with the 
inhibition of the transcriptional activity of NFkB. In particular, recent studies demonstrate that 
curcumin is able to inhibit the p65 subunit of NFkB in time-dependent manner, but not the p50 
subunit.90, 92 
Moreover, curcumin has been classified as one of the natural compounds that indirectly inhibit 
STAT3, although its mechanism of action is not yet fully understood.90  
In particular, a recent study on the treatment of multiple myeloma reported that this phenol 
interact with JAK-STAT3 phosphorylation, blocking the translocation into the nucleus and DNA 
binding, and also to down-regulate the expression of Bcl-xL and cyclin D1, which are also 
regulated by STAT3 activation. Furthermore, curcumin does not inhibit the constitutive 
phosphorylation of STAT5 under the same conditions where STAT3 inhibition occurs and only at 
higher doses it is able to interact with STAT1 (transcription factor induced by IFN-α), thus showing 
a certain selectivity on STAT3 (Figure 12).36 
 
Figure 12. (a) Inhibition of the phosphorylation of STAT3, but not STAT5, in U266 cells. (b) STAT1 
inhibition induced by IFN-α in U266 cells.36 
  
(a) (b) 
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1.5.2 Phenolic acids 
Phenolic compounds, one of the most important classes of secondary metabolites from natural 
source, are a large group of phytochemicals derived from the amino acids phenylalanine and 
tyrosine. From a chemical point of view, the phenolic compounds own different structures 
between them, but can be generally defined as substances with an aromatic ring bearing one or 
more hydroxyl groups. They are classified as phenolic acids, monophenols and polyphenols, 
depending on the number of hydroxylated aromatic rings and the type of functional groups 
present on the molecule.93 During the last years, these compounds attracted the interest of many 
researchers because of their antioxidant properties including scavenging of free radicals, 
chelation of metals, modulation of enzymatic activity and alteration of signal transduction and 
gene expression.94 Therefore, they are considered potential therapeutic agents able to prevent 
and treat various diseases, such as cancer, diabetes, cardiovascular disorders, inflammatory 
diseases and aging. In particular, it was observed that caffeic acid and ferulic acid are involved in 
the inhibition of several transcription factors, including STAT3 and NFkB.  
Moreover, esters and amides of ferulic and caffeic acids (i.e. Caffeic Acid Phenethyl Ester-CAPE) 
have demonstrated to own an anticancer activity more potent than the equivalent acid (Figure 
13).95  
 
Figure 13. Phenolic acids and ester derivatives.  
Ferulic acid (Figure 13) belongs to the class of hydroxycinnamates and it is abundant in rice bran 
or germ, fruit and coffee seeds. Thanks to its particular structure, which contains a catechol group 
and an unsaturated chain, ferulic acid is able to terminate free radical chain reactions.94 
In literature it is reported that ferulic acid and its ester derivatives decrease the levels of some 
inflammatory mediators, such as COX-2 and iNOS, suggesting its potential use as an anti-
inflammatory drug.96 Since free radicals are involved in the etiology of tumours, it was observed 
that ferulic acid protects the cells from oxidative stress, which often induces malignant 
transformation.94 Furthermore, ferulic acid showed antitumor activity in colon97 and lung 
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cancer.98 A recent study on metastatic lung adenocarcinoma proved that ferulic acid, as far as 
caffeic acid which is a natural analogue, showed some anticancer properties due to its ability to 
inhibit the cancer invasion induced by PMA (phorbol-12-myristate-13-acetate). This phorbol 
ester is released during the activation of some transcription factors, including NFkB and STAT3.99  
In particular, caffeic and ferulic acids are able to decrease in a dose-dependent manner the levels 
of NFkB and STAT3 in the treated cells, if compared with untreated cells (Figure 14).99 
Figure 14. Effects of caffeic acid (CAA) and ferulic acid (FA) on NFkB and STAT3 levels A549 cells treated 
with PMA.99 
 
Caffeic acid (Figure 13) is a catechol derivative of cinnamic acid and it occurs as secondary 
metabolite in many plant species such as fruits, vegetables and coffee, as well as in wine and 
olive oil.99 In addition to its antioxidant activity, it can be useful also in the prevention of cancer 
and in particular the formation of metastases.100 Many studies demonstrate its ability to reduce 
tumour invasiveness in cell lines of rat hepatoma and human lung adenocarcinoma. In this latter, 
caffeic acid is able to decrease the motility of cancer cells and their adhesion to the matrix. At 
the base of these effects, there is the inhibition of the pathway of some transcription factors, 
among them NFkB and STAT3.93 As previously mentioned, CAPE (Figure 13) is an excellent 
antioxidant because it modulates the immune response, it reduces the expression of the genes 
encoding for iNOS, COX2 and vascular endothelial growth factor, (VEGF) and it is also able to 
inhibit NfkB. 95-101 Through these multiple mechanisms, CAPE is able to induce apoptosis in 
prostate and lung cancers cells and melanoma.102 Moreover, CAUE (Caffeic Acid Undecyl Ester, 
Figure 13), has been found to reduce the expression of telomerase and to cause apoptosis in a 
human leukemia cell line through NFkB inhibition.103  
Cinnamic acid (Figure 13) is commonly found in nature and belongs to the class of auxins, natural 
hormones that regulate the growth of plants, and it has been isolated from coffee, vegetable oil, 
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wine and propolis.104, 105 Thanks to the presence of an α,β-unsaturated carboxylic acid bearing a 
phenyl group in β position, this compound is also used in the treatment of various form of cancer 
since this electrophilic system is able to react with thiol groups and, therefore, hypothetically 
with cysteines of biologically important peptides and proteins.105 Indeed, it has been observed 
that cinnamic acid inhibits the proliferation of cell lines of glioblastoma, melanoma, prostate and 
lung cancers; furthermore, it reduces the invasiveness in different cell lines of melanoma and 
interferes with the DNA proliferation and synthesis in adenocarcinoma of colon cells. Despite 
these interesting activities, its molecular mechanism is not fully understood yet.104, 105 However, 
in literature are reported many cinnamic acid derivatives which show anti-tumour properties. 
Among them, artepillin C, baccarin and drupanin (Figure 15), which are isoprene derivatives of 
cinnamic acid isolated from propolis, induce apoptosis both in vivo and in vitro. Moreover, 
cinnamoyl reserpine (Figure 15) is able to induce cell death and howiinolo A (Figure 15) is capable 
to arrest the cell cycle in the G1 phase, preventing the passage in the S phase where the 
duplication of DNA occurs, necessary for the development of cancer.105 Therefore, the synthesis 
of new derivatives of cinnamic, caffeic and ferulic acid represents a promising strategy for the 
development of new anticancer agents with innovative mechanisms of action or with reduced 
toxicity. 
 
Figure 15. Some derivatives of cinnamic acid.  
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1.5.3 Celastrol 
Celastrol, mainly extracted from the Chinese roots of Tripterygium Wilfordii or also called 
"Thunder of God Vine”, is a pentacyclic triterpenoid which belongs to the family of quinine 
methides (Figure 16).  
 
Figure 16. Mainly pentacyclic triterpenes (PCTT) of Celastraceae family. 
During the last years, celastrol has been widely investigated for its anti-inflammatory and 
anticancer activity106, 107 and many studies suggest that it can modulates multiple molecular 
targets.108 In particular, this triterpene suppresses the production of proinflammatory cytokines, 
as IL-1, IL-6 and TNF-α mainly involved in the initiation, proliferation and progression of 
carcinogenesis, inhibits NfKB activation, disrupts protein Hsp90 and also arrests the cell cycle.109 
Indeed, it has been reported in literature that celastrol has beneficial effects on a variety of 
cancer in vitro and in vivo (i.e. pancreatic cancer and prostate cancer) suggesting that it could be 
developed as a potential cancer treatment.106, 107 Recent studies showed that celastrol treatment 
suppresses NFkB expression in multiple myeloma cells (U266), demonstrating its ability to block 
IKK phosphorylation in a time-dependent manner (Figure 17a). Furthermore, this triterpene is 
able to inhibit the phospho-STAT3 (Figure 17b), which plays a critical role in the proliferation and 
survival of tumour cells. Lastly, celastrol hindered the proliferation of multiple myeloma cells 
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rising up the number of cells in the sub-G1 phase and also stimulating the expression of pro-
apoptotic protein as BAX and BAK.110 
Figure 17. (a) Celastrol suppressed NFkB and (b) phospho-STAT3.110  
Above all, celastrol is active against a protein class called heat shot protein (Hsp), a molecular 
chaperone which can assist other proteins in correcting folding and assembly. The most common 
is Hsp90 (homodimer of 90 kDa) which is overexpressed in tumour cells and it is able to regulate 
numerous cancer markers such as the oncogene Bcr/Abl, p53 and PI3K and AKT.111, 112 
 
1.5.4 Folic Acid 
In the field of anti-cancer treatments, it is very interesting the study of natural endocytosis 
mechanisms for the active targeting of drugs. In particular, many studies are focused on binding 
active molecules such as hormones, vitamins or growth factors whose receptors are known to 
be expressed or overexpressed in tumour tissues, to polymeric carrier molecules with the aim 
to improve target selectivity. Recently, folic acid receptors (FR) have attracted particular 
interest as high affinity membrane proteins and many studies reported that they are often 
overexpressed in several tumours as ovarian cancer (90% of cases), epithelial cancers as well as 
endometrial, brain, lung and kidney cancers.113 In humans, three isoforms have been identified, 
known as α, β and γ/γ’: the isoform FR-α is overexpressed in epithelial malign cancer instead of 
FR-β, which is expressed in sarcoma and myeloid leukemia.114 The causes of the FR 
overexpression in cancer tissues are not completely clear, however folate are essential for the 
survival and proliferation of cancer cells. In physiological conditions folic acid, after its reduction 
to tetrahydrofolate, is required for many biochemical processes, including the synthesis of DNA, 
RNA and transmethylation reactions, which are very important for high-rate division cells. Once 
the folic acid binds its receptor, it gets inside the cell by endocytosis with a non-clathrin-coated 
vesicle, then the contents of the vesicle is rapidly acidified with consequent dissociation of folic 
(a) (b) 
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acid from FR, thus allowing the vitamin to pass through the membrane into the cytoplasm 
through a carrier protein. Finally, the FR is exposed back to the extracellular space.115  
Recently, many studies demonstrated that an elevated level of FR induces cell proliferation by 
mediating the uptake of folate and also by generating regulatory signals, because these 
receptors seems to participate in a macromolecular complex able to generates intracellular 
signals causing cell survival and proliferation.116  In this context, two different strategies have 
been developed for targeting drugs to FR: the first one is to bind monoclonal antibodies for FR 
to an active molecule (i.e. doxorubicin), and the second regards the synthesis of new molecules 
where the folic acid and an anticancer compound are bound together through a chemical link 
(or spacer). The first approach has two great disadvantages: antibody has a low capacity to 
spread through biological barriers because of its size and the immunogenicity does not allow 
subsequent administrations. Instead of that, folic acid is stable, not expensive, has a very high 
affinity for its receptor and it is endocytosed very effectively.117 
 Therefore, it is more promising the use of the endogenous binding compared to that of a 
monoclonal antibody. For instance, to improve the efficacy of doxorubicin (DOX), Folate-
aminocaproic acid-doxorubicin (FA–AMA–DOX, Figure 18) was synthesized and studied in the 
laboratory of Prof. Si-Yuan Zhou. Results showed that the cytotoxicity of this new FA-conjugate 
toward KB and HepG2 cancer cells was greater than that of DOX at the same concentrations, 
and the antiproliferative activity could be attenuated by FA in a dose-dependent manner.118 
Figure 18. FA-AMA-DOX structure and schematic representation of its mechanism of action. Adapted 
from118  
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1.6 Semi-synthetic compounds: rosmaricine and derivatives 
Rosemary (Rosmarinus officinalis, Lamiaceae family)119 is a plant that grows in many parts of the 
world, and its leaves are commonly used as a spice or flavouring agent in food.120 In traditional 
Chinese medicine its extract has been used in the past to treat inflammation and in addition, 
because of its antioxidant properties, the rosemary extract was recently approved by the 
European Union as a food additive, as established by EU food additive legislation.121 
These properties are linked to the activities of many components (Figure 19) such as essential 
oils (i.e. borneol and pinene), phenolic acids (i.e. rosmarinic acid), diterpenes (i.e. carnosic acid, 
carnosol and rosmanol) and triterpenes (ursolic acid).122 Among them, rosmarinic acid, carnosic 
acid, carnosol and rosmanol, sharing a catechol group in their structure, have excellent 
antioxidant and free radical scavenging properties and also a good anti-inflammatory activity.122, 
123 During the last years, many studies have demonstrated that the rosemary extract, and 
specially the carnosic acid and its oxidation products (carnosol and rosmanol), possesses 
antiproliferative activity against various types of cancer.119  
Carnosic acid and carnosol show antiproliferative activity in cell lines from prostate, lung, breast, 
liver and colon cancers and leukemia. Indeed, they are able to induce apoptosis in tumour cells 
by inhibiting the AMP kinase (AMPK) and acting as inhibitors of the androgen receptor (AR) and 
the estrogen receptor α (ERα).121 Moreover, they reduce the angiogenesis and the metastatic 
processes through the inhibition of NFkB in cancer cells.124 Another important activity of 
rosemary derivatives is the inhibition of the p-glycoprotein (MDR1), an efflux pump that mediates 
resistance to a variety of chemically unrelated anticancer drugs.125 Even more, rosmanol has been 
classified as potent anticancer agent: it induces apoptosis in human colorectal adenocarcinoma 
cells (COLO205) and it has shown to inhibit STAT3 and NfkB pathways.122, 123  
By treating an ethanolic rosemary leaves extract with ammonia in presence of oxygen, 
rosmaricine (Figure 19) could be obtained. The structure of this diterpene alkaloid close 
resembles with rosmanol and it is connected with that one of other alkaloids having anticancer 
properties such as taxodone and taxodione.126 Nevertheless, the activity of rosmaricine on STAT3 
and NfkB has not yet been investigated. 
Moreover, some computational studies conducted in the research group of Prof. Yu-Chian Chen, 
have identified rosmaricine as a possible inhibitor of the epidermal growth factor receptor (EGFR) 
whose overexpression is often associated with cancer diseases.127 
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Figure 19. Structures of rosemary derivatives. 
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1.7 Synthetic systems 
1.6.1 S3I-201 derivatives 
Recently, a number of small molecule compounds which directly inhibit the activity and function 
of STAT3 has been discovered and studied for cancer treatment and prevention.42, 128  
Among them, S3I-201 (Figure 20) has been identified from the National Cancer Institute chemical 
libraries by using virtual screening as a selective STAT3-SH2 domain inhibitor. Indeed, it has been 
proved that S3I-201 blocks the formation of STAT3 homodimers (IC50=86 µM), STAT3 DNA-
binding and transcriptional activities. Moreover, it inhibits the expression of the STAT3-regulated 
genes (encoding for cyclin D1 and Bcl-xL) and also the proliferation of breast and hepatocellular 
cancer cells in mice.23, 129 Despite its cancer chemopreventive properties, further studies led to 
the synthesis of several analogues of S3I-201, able to bind the SH2 domain with higher affinity.43, 
130, 131 The STAT3-SH2 domain is composed of three pockets and S3I-201 occupies two of these, 
as seen through the molecular docking (Figure 20), since the salicylic acid is a well known mimetic 
group of p-Tyr-705. The binding between the protein and the molecule is stabilized through 
specific interactions: the salicylic acid moiety forms hydrogen bonds and salt bridges with Lys-
591, Ser-611 and Arg-609, while the O-tosyl group employs the hydrophobic pocket, which 
contains the side chain of Lys-591 and Arg-595. Moreover, it has been studied the effect of S3I-
201 in vitro as inhibitor of the pathway JAK/STAT3 in prostate cancer cells (CaP) and it was found 
to decrease the activation of STAT3.132 
 
 
 
 
 
 
                                                                                 
 
Figure 20. S3I-201 structure (green) and in silico study on STAT3-SH2 domain (pink = hydrophobic residues, 
blue = hydrophilic residues). The arrow indicates the potential interaction with the pocket.43 
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1.6.2 Heterocyclic compounds 
Among the numerous compounds able to inhibit the activity of STAT3, recently several molecules 
bearing the 1,2,5-oxadiazole moiety (Figure 21) have been synthesized by Prof. Barlocco’s 
research group of our department at the University of Milan which demonstrated to interfere 
with the STAT3 signalling pathway and also to exert antiproliferative activity.38, 133, 134  
Due to the considerable interest in the chemistry and bioactivity of 1,2,5-oxadiazoles, AVS-0288 
(Figure 21) and some related compounds substituted at positions 3 and 4 of the heterocycle have 
been discovered as potential anticancer agents thanks to their ability to interact with STAT3 
pathway.133 For example, AVS-0288 has been tested on a dual-luciferase assay system against 
cancer cell line and demonstrated significant inhibition towards STAT3 pathway (70% at 10 μm 
and 75% at 50 μm using HCT-116 cells), and these biological data have been also confirmed by 
modelling and crystallographic studies.134  
Therefore, supporting the hypothesis that conformational changes on these molecules have an 
important effect on the STAT3 inhibitory properties, 1,2,5-oxadiazole derivatives including MD77 
(Figure 21)135 which showed an interesting antiproliferative activity (IC50=1.8 μM on HCT-116 cell 
line) and other related molecules represent lead compounds worthy of further structural 
optimization. 
Figure 21. Compounds with 1,2,5-oxadiazole moiety. 
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2. AIMS OF THE RESEARCH PROJECT 
This research project deals with the design, synthesis, structural analysis, biological evaluation 
and the investigation of the mechanism of action of novel sulfurated compounds, with the aim 
to obtain anticancer agents acting through a multitarget mechanism.  
The strategies at the base of this project are the synthesis of new thiosulfonates, allyldisulfides 
and dithiolethione derivatives to investigate their ability to inhibit STAT3 and/or NFkB, 
considered promising targets for cancer therapy, because involved in the activation of pro-
inflammatory cytokines and antiapoptotic proteins, whose expression is generally increased in 
the early stages of cancer.9, 110, 136, 137, 138 Since drugs aimed at multiple targets can be more 
efficacious and less vulnerable to acquire resistance, molecules able to inhibit one or both 
transcription factors, by interfering with multiple approach to their activation pathway, could be 
useful tools to treat cancer disease. 
Therefore, my project mainly focuses on the syntheses of new hybrid molecules, obtained 
through the chemical linkage of a NFkB inhibitor (i.e. dithiolethiones, caffeic acid or ferulic acid, 
celastrol etc.) to a STAT3 inhibitor (such as curcumin, methanethiosulfonates, polyphenols or 
heterocyclic compounds) with the aim to achieve, at the same time, the inhibition of both 
transcription factors and where the two components of the new molecule should interact with a 
synergistic effect on cancer development.  
In this context, my research project is divided into several topics and involves the synthesis of 
different sets of compounds: 
2.1 Sulfurated intermediates 
It is well known from literature that S-methyl methanethiosulfonate (SMMTS), isolated from 
cauliflower, is able to inhibit colon tumour incidence when administered to rats during the post-
initiation phase of carcinogenesis.76 During the last few years in Prof. A. Sparatore’s laboratory a 
set of new methanethiosulfonate derivatives has been synthesized: as previously mentioned, one 
of them is ACS33 (Figure 10) that exhibited a good in vitro antiproliferative activity and in vivo 
inhibited the growth of PC3 in subcutaneous xenografts.77 Although SMMTS74 and other 
methanethiosulfonate derivatives139 exert their chemopreventive and anticancer activity 
through multiple mechanism, their hypothetical direct or indirect activity on STAT3 had not been 
previously studied. Indeed, small methanethiosulfonate derivatives have been previously used 
to examine the accessibility of cysteine residues in ion channel and receptor proteins,140, 141 
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because these reagents can react with the free thiol group of cysteine residues to form a mixed 
disulfide between the cysteine sulfur and the electrophilic moiety of the reagent. Of course, if 
the cysteine residue is in a critical region, the additional mass prevents normal function of the 
protein. 
For these reasons, first of all we decided to evaluate the ability of ACS33 and of few others 
methanethiosulfonate hybrids (Figure 10), previously synthesized in our lab, to interact with 
STAT3-SH2 domain. Therefore, we submitted them to the AlphaScreen based assay, an in vitro 
competitive binding test used to identify compounds able to directly inhibit the binding of SH2-
containing proteins to their correspondent phosphopeptides (the physiological ligands). 
Since all the above mentioned compounds resulted able to strongly inhibit STAT3,142 we 
designed and synthesized other new methanethiosulfonates (i.e. ACS71, compound 1, and 
compounds 3, 5 and 7, Figure 22) to better understand and confirm the behaviour of this moiety 
on STAT3 and, eventually, to use them as tools to synthesize new hybrid compounds. Since 5-
(methylsulfonylthio)pentanoic acid (1) resulted to be a direct inhibitor of STAT3,142, 143 we 
decided to prepare the corresponding sulfone (compound 8, Figure 22) in order to evaluate its 
behaviour with the protein and possibly to confirm the potentiality of the thiosulfonate moiety 
to interact with the STAT3-SH2 domain. At the same time, the methyl ester of 1 has been 
prepared (compound 2, Figure 22) to verify if its antiproliferative activity can be improved by 
masking the original carboxylic acid and therefore increasing its cell permeability.  
Moreover, taking inspiration by the structures of natural sulfurated compounds such as allicin 
and diallyl trisulfide, which are able to inhibit phosphorylation, dimerization and nuclear 
translocation of STAT3 in prostate cancer cells in culture and in vivo,40, 144 the allyldisulfides 11 
and 9 have been prepared in order to check their activity on STAT3 and NfkB and also to 
evaluate their cytotoxicity (Figure 22). In the same way and for the same reason of 2, the methyl 
ester 10 (Figure 22) has been prepared to verify if the antiproliferative activity can be improved 
by increasing its lipophilicity. Finally, even if the dithiolethiones were reported to exert 
chemopreventive and anticancer activities87 through multiple mechanisms, including NfkB 
inhibition,79 their direct or indirect activity on STAT3 had not been yet investigated.  
For this reason, we decided to use some dithiolethione derivatives such as the not commercial 
carboxylic acid 14, its ethyl ester 13 and 12 (ADTOH), as starting materials to synthesize new 
hybrid molecules to be tested as NfkB and STAT3 inhibitors (Figure 22).  
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Figure 22. Structures of thiosulfinates, allyldisulfides and dithiolethione compounds (1-14). 
 
2.2 S3I-201 and related compounds 
Compound S3I-201 (Figure 23) is a well known direct STAT3 inhibitor, often used as reference in 
biological experiments and recently it has been studied for cancer treatment and prevention.42, 
128 In detail, S3I-201 blocks the formation of STAT3 homodimers and it inhibits the proliferation 
of breast and hepatocellular cancer cells in mice.23, 129 However, the presence of an electrophilic 
tosylate leaving group in S3I-201, renders it highly susceptible to alkylate also other substrates 
and therefore it is not very stable in the biological medium. Therefore, we decided to modify the 
structure of compound S3I-201 through the replacement of the oxygen with a sulfur atom, thus 
obtaining compound 15 (Figure 23), or through the replacement of the tosylate group with the 
methanethiosulfonate (compound 16, Figure 23), with the idea to evaluate if the presence of the 
thiosulfonate moiety can modify the ability of S3I-201 to interact with STAT3 and its potency as 
antiproliferative agent. Actually, compound 16 was not obtained and compound 17 was instead 
isolated and tested.142 
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Figure 23. Structures of the studied thiosulfonate drug hybrids and of compound 17. 
 
2.3 Curcumin and cinnamic acids derivatives 
In addition to a large number of compounds with STAT3 inhibitory activity reported in literature 
(i.e. peptides, peptidomimetics, small molecules and platinum-containing compounds), natural 
products such as epigallocatechin-3-gallate (EGCG),35 resveratrol,145 curcumin,36 phenolic acids as 
ferulic/caffeic acid146 and celastrol37 have been shown to suppress STAT3 activation in tumour 
cells. It is also well known that natural sulfurated compounds (such as dithiolethiones,79 allicin, 
diallylpolysulfides40 and S-methylmethanethiosulfonate) are endowed with cancer 
chemopreventive properties, through multiple mechanisms (including NFkB and/or STAT3 
inhibition). On this basis, we firstly decided to synthesize a set of novel drug hybrids (compounds 
18-36, Figure 24 and Figure 25) obtained through the condensation of curcumin or ferulic/caffeic 
acids with some sulfurated compounds, such as thiosulfonates, dithiolethiones and 
allyldisulfides.  
In addition, searching for useful drug candidates in the development of chemotherapeutic 
agents, we thought that it would be interesting to change the phenolic groups of curcumin into 
thiol groups thus affording product 22 (Figure 24), in order to evaluate its potency as anticancer 
agent and to use it as a starting point to prepare other substituted thio-analogues. 
Finally, to investigate the eventual role of the substituents on the phenyl ring and mainly that of 
the hydroxyl moieties of caffeic acid on STAT3 inhibition, we synthesized the 
methanethiosulfonate hybrids of cinnamic acid (34, Figure 25) and of 3,4-dimethoxy and 3,4-
dichlorocinnamic acids (35 and 36, respectively; Figure 25).147 
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Figure 24. Structures of the synthesized curcumin derivatives (18-21) and thio-analogue (22). 
 
Figure 25. Structures of the synthesized cinnamic acid derivatives 23-36.  
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2.4 Celastrol hybrids 
In the search of new scaffolds with potential antiproliferative activity, we took into consideration 
the triterpene celastrol (Figure 26) which, during the last years, has been widely investigated for 
its anti-inflammatory and anticancer activity106, 107 and many studies suggest that it can 
modulates multiple molecular targets.108 Indeed, celastrol has been shown to have beneficial 
effects on a variety of in vitro and in vivo models of cancer diseases (i.e. pancreatic cancer and 
prostate cancer) suggesting that it could be developed as a potential anticancer agent.106  
As previously mentioned, some sulfurated derivatives exhibited an in vitro and in vivo 
antiproliferative activity. Therefore, with the aim to obtain novel antitumor agents, these 
molecules were coupled with celastrol (compounds 37-42, Figure 26). In particular, compounds 
37 and 38, which differ for only one methylene in the methanethiosulfonate alkyl chain, were 
synthesized to evaluate the contribution of the increased lipophilicity on the antiproliferative 
activity. Furthermore 39 (Figure 26) has been synthesized with the aim to explore if the allyl 
cysteine methyl ester could change and enhance the selectivity on NfkB and the antiproliferative 
activity of celastrol.148 
Moreover, it has been demonstrated that glucosamine has an inhibitory effect on the expression 
of protumor factors, and it could represent a potential anticancer compound.149 Therefore, to 
evaluate the effect of coupling it with celastrol, compound 40 (Figure 26) has also been prepared 
and tested.  
 
Figure 26. Structures of celastrol and derivatives 37-41. 
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Finally, considering the overexpression of the folic acid receptor in some cancer types,113 
compound 42 (Figure 27) was synthetized with the aim to improve the selectivity of celastrol 
against cancer cells which overexpress this receptor.  
 
Figure 27. Structures of hybrid 42. 
 
2.5 Rosmaricine and derivatives  
Rosmaricine (Figure 28) is a not commercially available diterpenoid aminocompound extracted 
from Rosmarinus officinalis L. leaves, which it does not exist as such in the plant but, as 
demonstrated by Wenkert et al.,150 it is formed through a complex reaction between some 
oxidation derivatives of carnosic acid and the ammonia used to liberate the bases supposed to 
be present.  
Since the structure of rosmaricine closely resembles that one of the natural polyphenol rosmanol, 
which has been described as a STAT3 inhibitor, we decided to prepare rosmaricine following with 
few modifications the procedure described by Boido et al. 126 in order to test its activity on STAT3 
and NfkB and to use it as starting material to synthesize new derivatives. 
Indeed, rosmaricine demonstrated to be a good inhibitor of both STAT3 and NFkB transcription 
factors, also endowed with antiproliferative activity. For these reasons, in view of the growing 
interest on terpenoid compounds as potential antitumoral drugs and following our recent studies 
on sulfurated drug-hybrids as multitarget anticancer agents, we thought interesting to synthesize 
three new derivatives through the condensation of the amino group of rosmaricine with some 
sulfurated carboxylic acids, containing a thiosulfonate or an allyldisulfide or a dithiolethione 
moiety, thus obtaining 43, 44 and 45, respectively (Figure 28). Then we investigated their ability 
to inhibit STAT3 and NFkB transcription factors as well as their antiproliferative activity on a 
human cancer cell line.151 
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Figure 28. Structures of rosmaricine and new hybrids. 
 
2.6 Heterocyclic derivatives 
Another idea took the cue from recent results obtained from Prof. Barlocco’s research group 
concerning 1,2,5-oxadiazoles, among which MD77 (Figure 29) has been selected as a lead 
compound because of its significant antiproliferative activity (IC50=1.8 μM on HCT-116 cell line).15, 
135 Since dithiolethione and methanethiosulfonate compounds were reported to exert 
chemopreventive and anticancer activities,72, 74, 77, 141 as well as to be able to react with thiol 
groups, and therefore, hypothetically, with cysteines of biologically important peptides and 
proteins,152, 153 we considered that the introduction of these moieties on a suitable scaffold could 
be useful to obtain new inhibitors able to covalently link the active site of several transcription 
factors. Indeed, a similar behaviour was observed between a dithiolethione derivative and 
NfkB.79 On this basis, and within the existing collaboration with our two research groups, we 
decided to couple different oxadiazole scaffolds in some way related to the MD77 structure, with 
two representative sulfurated compounds (1 and 14), with the aim to obtain new STAT3 and NfkB 
inhibitors, useful as anticancer agents. The synthesized new hybrid compounds have the 
dithiolethione and the methanethiosulfonate systems linked to a differently substituted 1,2,5-
oxadiazole ring through an ester (48, 50 and 51, Figure 29) or an amidic bond (46, 47 and 49, 
Figure 29). In addition, the bioisosteric analogues of 50 and 51 have been synthesized, by 
replacing the oxadiazole with a substituted N-methylimidazole (52 and 53, Figure 29).154 
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Figure 29. Structures of new 1,2,5-oxadiazole and N-methylimidazole hybrids (46-53). 
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3. CHEMISTRY 
3.1 Sulfurated intermediates 
For the preparation of the new hybrid compounds, it has been necessary to start from the 
synthesis of some different sulfurated intermediates, which are not commercially available. In 
particular the methanethiosulfonates 5-(methylsulfonylthio)pentanoic acid (ACS71, compound 
1)155, S-4-hydroxybutyl methanesulfonothioate (compound 5), 2-((methylsulfonyl)thio)acetic 
acid (compound 3)156, 157 and S-(3-aminopropyl)methanesulfonothioate hydrobromide (7) with S-
(2-aminoethyl) methanesulfonothioate hydrobromide (compound 6),155 the allyldisulfides 3-
(allyldisulfanyl)propanoic acid (compound 9)71 and 2-(allyldisulfanyl)ethanol (compound 11) and 
the dithiolethione 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (ACS48, compound 14)71 have 
been prepared following with few modifications the methods described in literature. 
The acid 1 and 3 were synthesized with the following procedure: initially sodium 
methanesulfinate (54), obtained by a reaction between sodium sulfite and methanesulfonyl 
chloride in H2O, was warmed up with elemental sulfur in methanol to yield sodium 
methanethiosulfonate (55); the intermediate 55 was than reacted with 5-bromovaleric acid, at 
60 °C, to give compound 1 or with 2-bromoacetic acid, at room temperature, to provide 3 
(Scheme 1). We observed that with a temperature higher than 60 °C the final yield of the reaction 
got lower, probably due to the instability of the thiosulfonate group at high temperature. 
 
Scheme 1. Reagents and conditions: (a) Na2SO3, NaHCO3, H2O, 50 °C, 4 h, 99%; (b) S, MeOH, reflux, 30-45 
min, 97%; (c) dry DMF, 60 °C, 5 h, 70%; (d) acetone, rt, overnight, 80%. 
Similarly to 1, the alcohol S-(3-hydroxybutyl) methanesulfonothioate (5) has been prepared 
reacting 4-bromobutanol with 55. Moreover, the amines S-(3-aminopropyl) 
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methanesulfonothioate hydrobromide (7) and S-(2-aminoethyl) methanesulfonothioate 
hydrobromide (6) were provided by a nucleophilic reaction from intermediate 55 with 3-
bromopropanamine hydrobromide or 2-bromoethanamine hydrobromide, respectively (Scheme 
2).  
 
Scheme 2. Reagents and conditions: (a) dry DMF, 60 °C, 5 h, 19%; (b) EtOH, 60 °C, 6 h, 34-36%. 
Furthermore, acid 9 has been obtained reacting 1,2-diallyldisulfane with 3-mercaptopropanoic 
acid in a basic methanolic solution and the respective alcohol 11 was synthesized reacting 2-
mercaptoethanol with 1,2-diallyldisulfane at 50 °C (Scheme 3). 
 
Scheme 3. Reagents and conditions: (a) diethyl ether/MeOH (1:2), 10M NaOH, N2, rt, 24 h, 66%; (b) DMSO, 
N2, 50 °C, 5h, 50%. 
To prepare 14, first of all the carboxylic group of 4-isopropyl benzoic acid was protected through 
a Fisher esterification in ethanol, in order to obtain the corresponding ethyl ester 56. After 
treatment with melted sulfur at 220 °C, the obtained ethyl 4-(3-thioxo-3H-1,2-dithiol-4-
yl)benzoate (13) was converted, through acidic hydrolysis, into the corresponding acid 14 
(ACS48), as reported in Scheme 4.  
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Scheme 4. Reagents and conditions: (a) H2SO4, EtOH, reflux, 7h, 92%; (b) S, 220 °C, 5 h; toluene/acetone, 
110 °C; rt, 15 h, 40%; (c) acetic acid, H2SO4, reflux, 5 h, 86%. 
Moreover, the methyl esters of 1 and 9, methyl 5-((methylsulfonyl)thio)pentanoate (2) and 
methyl 3-(allyldisulfanyl)propanoate (10), have been synthesized in good yields through the 
condensation of the corresponding carboxylic acid with methanol, using N,N'-
dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) as coupling reagents 
(Scheme 5). 
 
Scheme 5. Reagents and conditions: (a) DCC, DMAP, MeOH, dry CH2Cl2, N2, rt, 2-4 h, 80-89%. 
 
Similarly to compound 1, the sulfone 5-(methylsulfonyl)pentanoic acid (8) was reached by using 
54 and 5-bromovaleric acid (Scheme 6). 
 
Scheme 6. Reagents and conditions: (a) dry DMF, 60 °C, 5 h, 27%. 
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3.2 S3I-201 and related compounds 
First of all we decided to synthesize the reference compound 2-hydroxy-4-(2-
(tosyloxy)acetamido)benzoic acid (S3I-201) following the procedure, with few modifications, 
described by Turkson et al.158 The synthesis required the intermediate methyl 2-(tosyloxy)acetate 
(57), prepared through the tosylation of methyl glycolate, which was hydrolyzed with a basic 
aqueous solution thus obtaining the corresponding 2-(tosyloxy)acetic acid (58) and then 
converted into the acyl chloride 59. The reaction between 59 and p-aminosalicylic acid (PAS) lead 
to the formation of the final compound S3I-201 (Scheme 7). 
 
Scheme 7. Reagents and conditions: (a) TsCl, TEA, dry diethyl ether, N2, 0 °C, 3 h, 73%; (b) 5% NaOH 
aqueous solution, rt, 3 h, 86%; (c) SOCl2, reflux, 2 h; (d) Na2CO3, 0.1M NaOH/THF, 0 °C to rt, 3 h, 45%. 
 
Differently from S3I-201, compound 15 has been obtained by reacting 61, prepared accordingly 
to Wang et al.,159 with 4-(2-chloroacetamido)-2-hydroxybenzoic acid 60 (Scheme 8). This latter 
was prepared from the reaction of PAS with chloroacetyl chloride as described by Harte et al.160 
  
Scheme 8. Reagents and conditions: (a) dry DMF, N2, 60 °C, 4 h, 60%. 
 
Since the analogous reaction of sodium methanethiosulfonate with 4-(2-chloroacetamido)-2-
hydroxybenzoic acid did not afford the desired 2-hydroxy-4-(2-
((methylsulfonyl)thio)acetamido)benzoic acid, we tried to obtain it through a coupling between 
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p-aminosalicylic acid and 2-((methylsulfonyl)thio)acetic acid (3, Scheme 9), prepared as 
previously described.156, 157 Surprisingly, instead of the methanethiosulfonate derivative (16), S-
((methylsulfonyl)methyl) 4-amino-2-hydroxybenzothioate (17) was obtained in low yield through 
an, at the present, undefined mechanism possibly involving a concerted decarboxylation and 
rearrangement of the methanesulfonylthioacetic acid (3).142 
 
Scheme 9. Reagents and conditions: (a) HOBt, EDAC, DIPEA, dry DMF, Ar, 0 °C to rt, 5 h, 5%. 
 
In order to unambiguously assess the molecular structure, we performed on compound 17 the 
X-ray crystallographic and the ORTEP161 drawing is shown in Figure 30. In the molecule, the 
central -S–C=O moiety is approximately coplanar with respect to the p-aminosalicylic system, 
which presents a strong intramolecular O-H…O hydrogen bond. The conformation of the lateral 
chain is characterized by a torsion angle C7-S2-C8-S1 of 36(1)°. In the crystal, molecules are linked 
by N-H…O hydrogen-bonding interactions, forming chains parallel to the b-axis direction. 
Figure 30. Left: ORTEP161 drawing of 17, showing the arbitrary atomic numbering (displacement ellipsoids 
at 40% probability). Right: Intermolecular interactions viewed about along a axis.  
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3.3 Curcumin and cinnamic acids 
3.3.1 Curcumin derivatives and thio-analogue 
Curcumin esters were prepared by condensing the phenol groups of curcumin with 14,71 1155 and 
9,71 prepared in our laboratory as previously mentioned. The coupling between curcumin with 
2.5 equivalents of dithiolthione 14, using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDAC) in presence of DMAP, led to the formation of the diester ((1E, 4Z, 6E)-3-
hydroxy-5-oxo-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-phenylen)bis(4-(3-tioxo-3H-1,2-dithiol-4-
yl)benzoate (20) in good yield whereas the same reaction performed with 0.7 equivalents of 14 
allowed the formation of the monoester 4-((1E, 4Z, 6E)-5-Hydroxy-7-(4-hydroxy-3-
methoxyphenyl)-3-oxo-1,4,6-triene-1-yl)-2-methoxyphenyl 4-(3-tioxo-3H-1,2-dithiol-4-
yl)benzoate (21) in very poor yield (Scheme 10). For the preparation of 4,4'-((1E,4Z,6E)-3-
hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-phenylene)bis(5-
(methylsulfonylthio)pentanoate) (18) and ((1E,4Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-
diyl)bis(2-methoxy-4,1-phenylene)bis(2-(allyldisulfanyl)acetate) (19), the thiosulfonate 1 and the 
allyldisulfide 9 were reacted with curcumin in presence of DCC and DMAP, providing the final 
compounds 18 and 19 respectively, as reported in Scheme 10. Analogous attempts to obtain the 
curcumin monoester of 18 and 19 failed because both monoester compounds were unstable 
during the purification process and thus proving the impossibility to isolate the final pure 
products: we obtained them only in trace with a mixture of other degradation compounds. 
Scheme 10. Reagents and conditions: (a) R’OH (1, 9, 14), EDAC or DCC, DMAP, dry solvent (THF for 18; 
CHCl3 for 19; DMF for 20 and 21), 3-20 h, rt, 85-6%. 
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Moreover the curcumin derivative (1E,4Z,6E)-5-hydroxy-1,7-bis(4-mercapto-3-
methoxyphenyl)hepta-1,4,6-trien-3-one (22), was prepared following with some modifications 
the method described by Pedersen et al., as reported in Scheme 11.162 To protect the phenol 
group, vanillin was firstly reacted with dimethylthiocarbamoyl chloride in presence of 1,4-
diazabicyclo[2.2.2]octane (DABCO)163 and then, after the thermal Newman-Kwart rearrangement 
of O-(4-formyl-2-methoxyphenyl) dimethylcarbamothioate (62),164, 165 the intermediate 64 was 
obtained by reacting the methene protected acetyl acetone with the aromatic aldehyde S-(4-
formyl-2-methoxyphenyl) dimethylcarbamothioate (63) and triisopropyl borate in presence of N-
butylamine.166, 167 Lastly, 64 was converted into the corresponding thiophenol in a basic 
methanolic solution to get the final compound 22.165, 168 
 
Scheme 11. Reagents and conditions: (a) dimethylthiocarbamoyl chloride, DABCO, dry DMF, 60 °C, 3 h, 
80%; (b) dry DMF, MW 340W (250 °C), 15 min, 90%; (c) 2,4-pentanedione, boric anhydride, 70 °C, 3 h; (d) 
triisopropyl borate, N-butylamine, dry THF, reflux, 24 h, 49%; (e) 5.3M KOH, MeOH/1,4-dioxane (1.6:4), 
rt, 7 h, 54%. 
 
3.3.2 Ferulic acid derivatives 
For the synthesis of ferulic acid derivatives, previously it has been necessary to prepare the key 
intermediate (E)-3-(3-methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylic acid (66). First of 
all, ferulic acid has been reacted with an excess of 2-methoxyethoxymethyl chloride (MEM-Cl) in 
presence of N,N-diisopropylethylamine (DIPEA)169 and then, after the selective hydrolysis with 
lithium hydroxide of (E)-(2-methoxyethoxy)methyl 3-(3-methoxy-4-((2-
methoxyethoxy)methoxy)phenyl) acrylate (65), the desired 66 was obtained (Scheme 12). Ferulic 
acid hybrids have been prepared by coupling the MEM-protected acid (66) with different 
sulfurated alcohols: S-2-hydroxyethyl methanesulfonothioate (4),170 S-4-hydroxybutyl 
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methanesulfonothioate (5) and 2-(allyldisulfanyl)ethanol (11), with the amine derivative S-2-
aminoethyl methanesulfonothioate (6)171 and with 4-(4-hydroxyphenyl)-1,2-dithiol-3-thione 
(12), prepared by demethylation of anetholetrithione (ADT) as previously described by Bottcher 
et al.172 After deprotection of intermediates 67-71 with trifluoroacetic acid (TFA) at rt, the 
corresponding amide (26) or esters (24, 25, 27 and 28) have been obtained with moderate yields 
(Scheme 12). 
 
Scheme 12. Reagents and conditions: (a) MEM-Cl, DIPEA, dry CH2Cl2, 0 °C to rt, 5 h, 99%; (b) LiOH*H2O, 
THF/H2O (2:1), rt, 24 h, 84%; (c) RH (4-6, 11 and 12), DCC (EDAC for 69), DMAP, dry CH2Cl2 (CHCl3 for 69), 
rt, 3-20 h, 68-96%; (d) TFA, dry CH2Cl2, rt, 4-7 h, 35-72%. 
 
3.3.3 Caffeic acid derivatives 
Caffeic acid hybrids were obtained through a similar synthetic route as previously described for 
the ferulic acid derivatives. However, in this case the protection of the catechol group was better 
achieved by treating caffeic acid methyl ester (29) with NaH and MEM-Cl.173 After 5N NaOH 
hydrolysis,174 the obtained (E)-3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylic acid (73) 
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was coupled with 4 or 6 or 11 or 12 and finally, treatment of intermediates 74-77 with TFA at rt 
allowed the obtainment of the desired hybrids 30-33 (Scheme 13).  
 
Scheme 13. Reagents and conditions: (a) H2SO4 (cat.), MeOH, reflux, 2h, 99%; (b) NaH, MEM-Cl, dry THF, 
0 °C, 5 h, 75%; (c) 5N NaOH, THF/MeOH (4:1), 40 °C, 3 h, 98%; (d) RH (4, 6, 11 and 12) DCC or EDAC, DMAP, 
dry THF or CH2Cl2, rt, 4-20 h, 40-80%; (e) TFA, dry CH2Cl2 or CHCl3, rt, 5-8 h, 9-64%. 
To be noted that, during the coupling reaction between compound 76 and 11 and in a lower 
extent using 4, the formation of the N-acylurea of the acid (78) was observed (Figure 31). 
 
Figure 31. Structure of N-acilurea compound. 
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3.3.4 Cinnamic acid derivatives 
The cinnamic acid derivatives 2-(methylsulfonylthio)ethyl cinnamate (34) and (E)-2-
((methylsulfonyl)thio)ethyl 3-(3,4-dimethoxyphenyl)acrylate (35) have been synthesized by 
coupling S-2-hydroxyethyl methanesulfonothioate (4) with cinnamic (79) or dimethoxycinnamic 
(80) acid, previously prepared as described in literature,175 whereas (E)-2-
(methylsulfonylthio)ethyl 3-(3,4-dichlorophenyl)acrylate (36) has been obtained using the 
commercially available dichlorocinnamic acid in presence of coupling reagents (Scheme 14). 
 
Scheme 14. Reagents and conditions: (a) DCC, DMAP, dry CH2Cl2 or THF, rt, 1-4 h, 38-62%. 
 
3.4 Celastrol hybrids 
The amides S-(2-((2R,4αS,6αS,12βR,14αS)-10-hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-oxo-
1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-carboxamido)ethyl) methane 
sulfonothioate (37), S-(3-((2R,4αS,6αS,12βR,14αS)-10-hydroxy-2,4α,6α,9,12β,14α-hexamethyl-
11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-carboxamido) propyl) 
methane sulfonothioate (38), methyl 3-(allylthio)-2-((2R,4αS,6αS,12βR,14αS)-10-hydroxy-2,4α,6 
α,9,12β,14α-hexamethyl-11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropice 
ne-2-carboxamido)propanoate (39) and (2R,4αS,6αS,12βR,14αS)-10-hydroxy-
2,4α,6α,9,12β,14α-hexamethyl-11-oxo-N-((2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl) 
tetrahydro-2H-pyran-3-yl)-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-
carboxamide (40) have been obtained through coupling of celastrol with intermediates 6 or 7, 
methyl 3-(allylthio)-2-hydroxypropanoate, previously prepared in our laboratory, or with D-(+)-
glucosamine hydrochloride in presence of coupling reagents (Scheme 15). The synthesis of the 
ester (2R,4αS,6αS,12βR,14αS)-4-(3-thioxo-3H-1,2-dithiol-4-yl)phenyl10-hydroxy-
2,4α,6α,9,12β,14α-hexamethyl-11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradeca 
hydropicene-2-carboxylate (41) was achieved in the same way using 4-(4-hydroxyphenyl)-3H-1,2-
dithiole-3-thione (12) and DCC with DMAP as coupling reagents (Scheme 15).  
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Scheme 15. Reagents and conditions: (a) 6 or 7 or methyl 3-(allylthio)-2-hydroxypropanoate or D-(+)-
glucosamine hydrochloride, HOBt, EDAC, TEA, dry DMF or THF, rt, 5-20 h, 22-64%; (b) 12, DCC, DMAP, dry 
THF, rt, 16 h, 50%. 
Compound 2-(4-(((2-amino-4-hydroxypteridin-6-yl)methyl)amino)benzamido)-5-((2-((2R, 
4αS,6αS,12βR,14αS)-10-hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-oxo-1,2,3,4,4α,5,6,6α,11, 
12β,13,14,14α,14β-tetradecahydropicene-2-carboxamido)ethyl)amino)-5-oxopentanoic acid 
(42), has been obtained with two different synthetic strategies and both of them lead to the 
isolation of final product in moderate yields. The first one, required the preparation of the 
intermediates 2-(4-(((2-amino-4-hydroxypteridin-6-yl)methyl)amino)benzamido)-5-((2-
aminoethyl)amino)-5-oxopentanoic acid (83) and the activated celastrol 84. Folic acid was 
activated to NHS-folate using N-hydroxsuccinimide (NHS) in presence of two equivalents DCC 
because in these conditions, as described by Trindade et al.,176 the γ-conjugate was prevalent 
obtained. The activated folate (81) was then reacted with tert-butyl(2-amino ethyl)carbamate 
giving 82 and, after the cleavage of the tert-butyloxycarbonyl protecting group (Boc) with TFA, 
compound 83 was isolated in moderate yield (Scheme 16).176  
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Scheme 16. Reagents and conditions: (a) NHS, DCC, dry DMSO, rt, 20 h; (b) tert-butyl (2-
aminoethyl)carbamate, TEA, dry DMSO, rt, 20 h, 76%; (c) TFA, rt, 1 h, 50%. 
Moreover, the activation of the carboxylic group of celastrol was achieved in presence of EDAC 
and HOBt (1-hydroxybenzotriazole), obtaining the intermediate (2R,4αS,6αS,12βR,14αS)-1H-
benzo[d][1,2,3]triazol-1-yl-10-hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-oxo-
1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-carboxylate (84). Finally, 
compound 42 was attempted by reacting intermediates 83 and 84 in presence of DIPEA, as 
reported in Scheme 17.   
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Scheme 17. Reagents and conditions: (a) HOBt, DCC, DMAP, dry CH2Cl2, rt, 2 h, 65%; (b) DIPEA, dry DMF, 
rt, 15 h, 45%. 
The second synthetic route required the preliminary preparation of intermediate 2-((((9H-
fluoren-9-yl)methoxy)carbonyl)amino)ethanaminium 2,2,2-trifluoroacetate (85), which was 
carried out starting from Boc-ethylenediamine, as previously described by Watzke et al.177 
Intermediate (2R,4αS,6αS,12βR,14αS)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)ethyl 10-
hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-
tetradecahydropicene-2-carboxylate (86), obtained through the coupling of 85 and celastrol, was 
treated with piperidine, thus affording (2R,4αS,6αS,12βR,14αS)-2-aminoethyl10-hydroxy-
2,4α,6α,9,12β,14α-hexamethyl-11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydro 
-picene-2-carboxylate (87). The final product 42 has been achieved condensing 81, prepared as 
previously described, and 87 using DIPEA as a base (Scheme 18). 
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Scheme 18. Reagents and conditions: (a) HOBt, EDAC, TEA, dry CH2Cl2, rt, 4 h, 75%; (b) piperidine, dry 
DMF, 0 °C to rt, 1 h, 84%; (c) 81, DIPEA, dry DMF, rt, 15 h, 50%. 
 
3.5 Rosmaricine and derivatives 
Rosmaricine was obtained following the procedure described by Barteselli178 which slightly 
modified the method of Boido et al.126, 150 Rosmaricine amides 43, 44 and 45 have been achieved 
through the condensation of the amino group of rosmaricine and the carboxylic group of 1, 9 and 
14 respectively (Scheme 20), using EDAC and HOBt as coupling reagents.151 
 
Scheme 20. Reagents and conditions: (a) ROH (1, 9 and 14), EDAC, HOBt, DIPEA, dry DMF, rt, 2-6 h, 19-
38%.  
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3.6 Heterocyclic derivatives 
3.6.1 Synthesis of dithiolethione hybrids 
The hybrids 4-(3-thioxo-3H-1,2-dithiol-4-yl)-N-(4-(4-(4-(trifluoromethyl)benzamido) 1,2,5-
oxadiazol-3-yl)benzyl)benzamide (46), (4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)methyl 4-(3-
thioxo-3H-1,2-dithiol-4-yl)benzoate (50) and (5-(4-chlorophenyl)-1-methyl-1H-imidazol-4-
yl)methyl 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoate (52) were obtained through the coupling of 14 
respectively with: (4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-
yl)phenyl)methanaminium chloride (89), obtained by deprotection of Boc group with 4N HCl in 
1,4-dioxane of tert-butyl 4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-
yl)benzylcarbamate (88) kindly provided by Prof. Romeo’s research group (Scheme 21); 
compound (4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)methanol (90), synthesized in collaboration 
with Prof. Barlocco’s research group,179 and (5-(4-chlorophenyl)-1-methyl-1H-imidazol-4-
yl)methanol (91) synthesized by Dr. Rimoldi’s research group (Scheme 22). 
 
Scheme 21. Reagents and conditions: (a) 4N HCl, dry 1,4-dioxane, rt, 30 min. 
 
Scheme 22. Reagents and conditions: (a) 89 TBTU, NMM, dry DMF, rt, 20 h; (b) 90 or 91, EDAC, DMAP, 
dry DMF, rt, 20 or 24 h, 59-78%. 
Chapter I: Chemistry 
 
58 
The amide 46 was obtained using TBTU (O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
tetrafluoroborate) as a coupling regent in presence of NMM. Whereas, the ester compounds 50 
and 52 were obtained with the same method using EDAC and DMAP. 
 
3.6.2 Synthesis of 5-(methylsulfonylthio)pentanoic acid hybrids 
In analogy with above mentioned dithiolethiones derivatives, the hybrids S-(5-oxo-5-((4-(4-(4-
(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-yl)benzyl)amino)pentyl) methanesulfonothioate 
(47), 4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-yl)phenyl 5-
((methylsulfonyl)thio)pentanoate (48) (4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)methyl 5-
((methylsulfonyl)thio)pentanoate (51), (5-(4-chlorophenyl)-1-methyl-1H-imidazol-4-yl)methyl 5-
((methylsulfonyl)thio)pentanoate (53) and S-(5-((4-((4-(4-chlorophenyl)-1,2,5-oxadiazol-3-
yl)carbamoyl)phenyl)amino)-5-oxopentyl) methanesulfonothioate (49) have been obtained 
through coupling reactions between compound 1 and compounds 90, N-(4-(4-hydroxyphenyl)-
1,2,5-oxadiazol-3-yl)-4-(trifluoromethyl)benzamide (92), 4-amino-N-(4-(4-chlorophenyl)-1,2,5-
oxadiazol-3-yl)benzamide (93) all of them kindly provided by Prof. Barlocco’s research group),178 
91 and 89, as reported in Scheme 23. Compared to dithiolethione products, which were obtained 
in good yields (59-78%) and were easily isolated and purified thanks to their stability and low 
solubility, the methylsulfonylthiosulfonate derivatives were obtained with moderate (28-48%) or 
lower yields (6-7%), probably due to the instability of the methanethiosulfonate group during the 
purification process.154 
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Scheme 23. Reagents and conditions: (a) 89, TBTU, NMM, dry DMF, rt, 20 h, 42%; (b) 92 or 90 or 91, DCC, 
DMAP, dry THF or dry CH2Cl2 or dry DMF, rt, 4-20 h, 28-48%; (c) 93, EDAC, DMAP, dry DMF, rt, 24 h, 7%. 
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4. EXPERIMENTAL 
4.1 General  
All commercially available solvents and reagents were used without further purification, unless 
otherwise stated. Reactions were monitored by thin layer chromatography analysis on 
aluminum-backed Silica Gel 60 plates (70-230 mesh, Merck), using an ultraviolet fluorescent lamp 
(254-365 nm). Purification of intermediates and final compounds was performed by CC= flash 
column chromatography using Geduran® Si 60 (40-63 µm, Merck). 1H and 13C NMR spectra: 
recorded in CDCl3, CD3OD, D2O, DMSO-d6 or acetone-d6 on Bruker DRX Avance 200 MHz or on a 
Varian 300 MHz Oxford equipped with a non-reverse probe at 25° C; chemical shifts are 
expressed as δ (ppm) and J in Hertz. Multiplicity is reported as s (singlet), br s (broad singlet), d 
(double), t (triplet), q (quartet), m (multiplet), dd (double of doublets), dt (doublet of triplets). 
High-resolution mass spectra (HRMS): FT-Orbitrap mass spectrometer in positive or negative 
electro spray ionization (ESI). UPLC-MS analysis: X-Bridge Oligonucleotide BEH C18 2.1 x 50 mm 
column and Xevo G2-XS Q-TOF with electrospray ionization source. MaxEnt 1 software: used to 
deconvolute the multiple charge states. Ultrasound sonicator: Eurosonic MU-2.5 l. Centrifuge: 
HERMLE Z206A. Microwave reactor: Biotage® initiator classic. The melting points were 
determined on a Büchi apparatus (M-560 instrument) and are uncorrected. Single Crystal X-Ray 
Analysis: Bruker Apex II CCD diffractometer, using graphite-monochromatized Mo-K radiation 
(=0.71073 Å). 
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4.2 Sulfurated intermediates 
Sodium methanesulfinate (54) 
 
 
 
A solution of sodium sulfite (10 g, 79.3 mmol) in water (38 ml) was vigorously stirred for 15 
minutes at room temperature. NaHCO3 (13.3 g, 158.6 mmol) was added and the mixture was 
stirred for 1 h at 50° C. After this time, methanesulfonyl chloride (6 ml, 79.3 mmol) was added 
dropwise and then the mixture was vigorously stirred at 50 °C for 4 h. After cooling at room 
temperature, the water was evaporated in vacuo. The obtained white residue was taken up with 
methanol (40 ml) in order to separate the sodium methanesulfinate from methanol-insoluble 
salts, and the mixture was stirred overnight. After filtration of inorganic salts, the solution was 
evaporated under reduced pressure to obtain the title compound as a white solid. Yield: 99%. 
Mp 208.7-211.2 °C. 1H NMR (300 MHz, D2O): δ 2.25 (s, 3H, CH3) ppm.  
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Sodium methanethiosulfonate (55) 
 
 
 
A mixture of sodium methanesulfinate (compound 54, 2 g, 19.6 mmol) and sulfur (0.63 g, 19.6 
mmol) in methanol (120 ml) was heated under reflux for 30-45 minutes, until all of the sulfur had 
dissolved. The reaction was conducted with a system of three traps (one empty, the second filled 
up with 2N NaOH and the third with NaClO) because of H2S releasing. After the completion of 
reaction, unreacted sulfur was filtrated and the solution was evaporated under reduced pressure. 
The obtained residue was recrystallized with methanol affording in sodium 
methanethiosulfonate (55) as a white solid. Yield: 97%. Mp 272.8-274.2 °C. 1H NMR (300 MHz, 
D2O): δ 3.25 (s, 3H, CH3) ppm.  
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5-(Methylsulfonylthio)pentanoic acid (ACS71) (1) 
 
 
 
To a solution of sodium methanethiosulfonate (compound 55, 2.50 g, 18.64 mmol) in anhydrous 
N,N-dimethylformamide (12 ml), 5-bromovaleric acid (1.74 g, 9.32 mmol) was added. The 
mixture was stirred at 60 °C for 5 h. The reaction was monitored by thin layer chromatography 
(eluent phase dichloromethane:methanol/9.6:0.4). After cooling at room temperature, the 
solution was evaporated under reduced pressure and the obtained residue was taken up with 
iced-water and acidified with a cold solution of 2 M KHSO4. The aqueous phase was extracted 
with ethyl acetate for four times and the organic layer was washed firstly with a cold solution of 
2 M KHSO4, then with iced-water and brine. The combined organic extracts were dried with 
anhydrous Na2SO4, filtered and evaporated to dryness to obtain a yellow pale oil which 
crystallized spontaneously in the fridge over 6 h. The solid was rinsed firstly three times with a 
solution of diethyl ether/petroleum ether (1:1) and then two times with diethyl ether to give 
white crystals. Yield: 70%. Mp 65.3-67.6 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.06 (s, 1H, COOH 
collapsed with D2O), 3.50 (s, 3H, CH3), 3.20 (t, 2H, J=7.4 Hz, CH2), 2.24 (t, 2H, J=7.4 Hz, CH2), 1.74-
1.54 (m, 4H, CH2) ppm. 
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2-((Methylsulfonyl)thio)acetic acid (3) 
 
 
 
Sodium methanethiosulfonate (compound 55, 500 mg, 3.73 mmol) and 2-bromoacetic acid (470 
mg, 3.38 mmol) were mixed together in acetone (8 ml). The reaction was stirred at room 
temperature for 20 h and was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/9:1). After the completion of reaction, inorganic salts were filtered 
and the solution was evaporated under reduced pressure. The resulting yellow pale oil was 
crystallized with dichloromethane to provide the final product as a white crystal solid. Yield: 80%. 
Mp 80.1-81.5 °C. 1H NMR (300 MHz, DMSO-d6): δ 13.18 (br s, 1H, COOH collapsed with D2O), 4.07 
(s, 2H, CH2), 3.53 (s, 3H, CH3) ppm.  
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S-4-Hydroxybutyl methanesulfonothioate (5) 
 
 
 
Sodium methanethiosulfonate (compound 55, 1.9 g, 14.37 mmol) and 4-bromobutanol (2.0 g, 
13.07 mmol) were mixed together in anhydrous N,N-dimethylformamide (7 ml) under inert 
atmosphere. The reaction was stirred at 60 °C for 5 h and was monitored by thin layer 
chromatography (eluent phase dichloromethane:methanol/9.4:0.6). After this time, inorganic 
salts were filtered and the solution was evaporated under reduced pressure. The resulting dark-
yellow oil was purified by CC (silica gel; dichloromethane/methanol; in gradient up to 99.7:0.3). 
A light brown oil was obtained. Yield: 19%. 1H NMR (300 MHz, DMSO-d6): δ 4.45 (br s, 1H, OH 
collapsed with D2O), 3.48 (s, 3H, CH3), 3.42 (t, 2H, J=6.7 Hz, CH2O), 3.19 (t, 2H, J=6.9 Hz, SCH2), 
1.76-1.66 (m, 2H, CH2), 1.52-1.43 (m, 2H, CH2) ppm. 13C NMR (75 MHz, CDCl3): δ 62.04, 50.92, 
36.45, 31.39, 26.37. HRMS (ESI): m/z calculated for C5H13O3S2 [M+H]+: 185.03061; found: 
185.03010.  
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S-(ω-Aminoalkyl) methanesulfonothioates (6 and 7) 
 
 
 
General method. Compound 55 (1 g, 7.35 mmol) and 3-bromopropyl-1-amine hydrobromide 
(1.61 g, 7.35 mmol) or 2-bromoetyl-1-amine hydrobromide (1.72 g, 7.35 mmol) were mixed 
together in 15 ml of ethanol and the solution was stirred for 6 h at 60 °C: the progress of the 
reaction was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/9:0.1). 
After that, sodium bromide was filtered off and the filtrate was evaporated under reduced 
pressure to obtain an oil, which crystallized after treatment with ethanol/diethyl ether (1:1) 
yielding in both cases a pale yellow solid.  
 
S-(2-aminoethyl) methanesulfonothioate hydrobromide (6). Yield: 36%. Mp: 101.2-107.0 °C. 1H 
NMR (300 MHz, DMSO-d6): δ 7.97 (br s, 2H, NH2 collapsed with D2O), 3.59 (s, 3H, CH3), 3.41 (t, 
2H, J=6.9 Hz, CH2), 3.17 (t, 2H, J=7.8 Hz, CH2) ppm. 
 
S-(3-Aminopropyl) methanesulfonothioate hydrobromide (7). Yield: 34%. Mp: 127.9-129.8 °C. 
1H NMR (300 MHz, DMSO-d6): δ 7.69 (br s, 2H, NH2 collapsed with D2O), 3.53 (s, 3H, CH3), 3.26 (t, 
2H, J=7.5 Hz, CH2), 2.88 (t, 2H, J=7.5 Hz, CH2), 1.99 (m, 2H, CH2) ppm.  
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3-(Allyldisulfanyl)propanoic acid (9) 
 
 
 
To a solution of diallyl disulfide (4.13 g, 28.26 mmol) in a mixture of diethyl ether (21 ml) and 
methanol (41 ml), 3-mercaptopropanoic acid (1 g, 9.42 mmol) dissolved in diethyl ether (10.2 ml) 
was added, followed by a solution of 10M NaOH (0.94 ml). The reaction mixture was stirred at 
room temperature, under inert atmosphere for 24 h and monitored by thin layer 
chromatography (eluent phase dichloromethane:ethylacetate/7:3). The solution was then 
evaporated under reduced pressure and the oily residue was taken up with diethyl ether and 
washed with 1M HCl. The organic layer was dried with anhydrous Na2SO4, filtered and 
evaporated to dryness to obtain a residue that was purified by CC (silica gel; 
dichloromethane/methanol; in gradient up to 98:2). A yellow pale oil was obtained. Yield: 66%. 
1H NMR (300 MHz, CDCl3): δ 5.91-5.77 (m, 1H, CH=CH2), 5.24-5.13 (m, 2H, CH=CH2), 3.33 (d, 2H, 
J=7.5 Hz, CH2), 2.92 (t, 2H, J=7.2 Hz, CH2), 2.80 (t, 2H, J=7.2 Hz, CH2) ppm. 
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2-(Allyldisulfanyl)ethanol (11) 
 
 
 
2-Mercaptoethanol (1.24 g, 0.016 mol) was added to a solution of diallyl disulfide (0.803 g, 0.0055 
mol) in DMSO (5 ml) and the mixture was stirred at 50 °C for 5 h under inert atmosphere. The 
solution was purified by flash chromatography on silica gel, using cyclohexane/ethyl acetate 
(68:32) as eluent. A colourless oil was obtained. Yield: 50%. 1H NMR (300 Mz; CDCl3):  5.92-5.78 
(m, 1H, CH=CH2), 5.26-5.16 (m, 2H, CH=CH2), 3.87 (t, J=5.86 Hz, 2H, CH2), 3.34 (d, J=7.33 Hz, 2H, 
CH2), 2.85 (t, J=5.86 Hz, 2H, CH2), 1.88 (s, 1H, OH collapsed with D2O). 13C NMR (75 MHz, CDCl3): 
133.27, 118.73, 60.26, 42.09, 41.20 ppm. 
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Ethyl 4-isopropylbenzoate (56) 
 
 
 
To a solution of 4-isopropyl benzoic acid (2 g, 12.18 mmol) dissolved in ethanol (50 ml), 
concentrated H2SO4 (0.29 ml, 6.58 mmol) was added dropwise at room temperature. The reaction 
was stirred at reflux for 7 h. 
The solution was stripped off and the obtained residue was taken up with dichloromethane and 
washed four times with a solution of 5% NaHCO3 and then with brine. The organic layer was dried 
with anhydrous Na2SO4, filtered and evaporated to dryness to obtain a residue that was purified 
by CC (silica gel; dichloromethane; isocratic), using the Flash Chromatography Purification System 
Biotage SP-1. The fractions containing the purified product were gathered up to provide the 
product (11) as a pale yellow oil. Yield: 92%. 1H NMR (300 MHz, CDCl3): δ 7.97 (d, 2H, J=8.6 Hz, 
ArH), 7.28 (d, 2H, J=8.6 Hz, ArH), 4.38 (q, 2H, J=7 Hz, CH2CH3), 3.05-2.96 (m, 1H, J=6.7 Hz, CH), 
1.39 (t, 3H, J=7 Hz, CH2CH3), 1.27 (d, 6H, J=6.7 Hz, CH3) ppm.  
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Ethyl 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoate (13) 
 
 
 
To sulfur (2.30 g, 70.6 mmol) heated at 145 °C, ethyl 4-isopropylbenzoate (compound 56, 1.76 g, 
9.17 mmol) was added dropwise over 5 minutes. The reaction was stirred for 5 h at 210 °C, 
connecting the reaction flask to a system of three traps (one empty, the second filled up with 2N 
NaOH and the third with NaClO) because of H2S releasing. After cooling at 110 °C, toluene (5.5 
ml) and acetone (12.6 ml) were added and the mixture was stirred overnight at room 
temperature and monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/9.5:0.5). After the completion of reaction, unreacted sulfur was 
filtered and the solution was evaporated under reduced pressure: the resulting crude product 
was purified by CC (silica gel; dichloromethane/cyclohexane; in gradient up to 30:20). The 
fractions containing the purified product were gathered up to provide the final product as an 
orange solid. Yield: 40%. NMR (300 MHz, CDCl3): δ 8.47 (s, 1H, SCH=), 8.12 (d, 2H, J=8 Hz, ArH), 
7.63 (d, 2H, J=8 Hz, ArH), 4.39 (q, 2H, J=7.1 Hz, CH2CH3), 1.40 (t, 3H, J=7.1 Hz, CH2CH3) ppm.  
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4-(3-Thioxo-3H-1,2-dithiol-4-yl)benzoic acid (14) 
 
 
 
Ethyl 4-(-thioxo-3H-1,2-dithiol-4-yl)benzoate (compound 13, 1 g, 3.52 mmol) dissolved in glacial 
acetic acid (45 ml), was treated with 50% (v/v) H2SO4 (7 ml). The resulting mixture was stirred at 
100 °C for 5 h and monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/9.5:0.5). After cooling, the orange precipitate formed was collected 
and isolated by filtration. The product cake was washed several times with iced water and then 
with diethyl ether, dried under vacuum providing an orange solid corresponding to the desired 
product. Mp 258.4-261.2 °C. Yield: 86%. 1H NMR (300 MHz, DMSO-d6): δ 13.03 (s, 1H, COOH 
collapsed with D2O), 9.23 (s, 1H, SCH=), 7.98 (d, 2H, J=8.2 Hz, ArH), 7.69 (d, 2H, J=8.2 Hz, ArH) 
ppm.  
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Methyl 5-((methylsulfonyl)thio)pentanoate (2) 
 
 
 
To a solution of 5-(methylsulfonylthio)pentanoic acid (ACS71, 250 mg, 1.18 mmol), DCC (243 mg, 
1.18 mmol) and DMAP (13.2 mg, 0.12 mmol) dissolved in anhydrous dichloromethane (1.5 ml), 
methanol (0.3 ml, 7.40 mmol) was added under nitrogen atmosphere. The reaction was 
monitored by thin layer chromatography (eluent phase dichloromethane:methanol/9.7:0.3) and 
was complete within 4 h at room temperature. After the filtration of the obtained N,N’-
dicyclohexylurea (DCU), the solvent was evaporated and the residue was taken up with 
dichloromethane and washed firstly with a cold solution of 0.5N HCl, then with a cold solution of 
5% NaHCO3, finally with iced water and brine. The organic layer was dried with anhydrous 
Na2SO4, filtered and evaporated to dryness to obtain the pure product as a yellow pale oil. Yield: 
89%. 1H NMR (300 MHz, CDCl3): δ 3.67 (s, 3H, OCH3), 3.32 (s, 3H, CH3), 3.18 (t, 2H, J=7.2 Hz, CH2), 
2.37 (t, 2H, J=7.2 Hz, CH2), 1.83-1.76 (m, 4H, CH2) ppm. 
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Methyl 3-(allyldisulfanyl)propanoate (10) 
 
 
 
Methanol (0.45 ml, 10.43 mmol) was added to a stirring solution of 3-(allyldisulfanyl)propaonic 
acid (ACS81, 300 mg, 1.68 mmol), DCC (379.1 mg, 1.84 mmol) and DMAP (17.9 mg, 0.16 mmol) 
in anhydrous dichloromethane (1.5 ml) under inert atmosphere. The reaction was monitored by 
thin layer chromatography (eluent phase cyclohexane:ethylacetate/1:1) and was completed 
within 2 h, stirring at room temperature. After the filtration of DCU, the solvent was evaporated 
and the residue was taken up with dichloromethane and washed firstly with a cold solution of 
0.5N HCl, then with a cold solution of 5% NaHCO3, finally with iced water and brine. The organic 
layer was dried with anhydrous Na2SO4, filtered and evaporated to dryness to obtain the final 
product as a yellow pale oil. Yield: 80%. 1H NMR (300 MHz, CDCl3): δ 5.91-5.77 (m, 1H, CH=CH2), 
5.24-5.13 (m, 2H, CH=CH2), 3.70 (s, 3H, CH3), 3.33 (d, 2H, J=7.5 Hz, CH2), 2.93 (t, 2H, J=7.2 Hz, 
CH2), 2.74 (t, 2H, J=7.2 Hz, CH2) ppm. 
  
Chapter I: Experimental 
 
74 
5-(Methylsulfonyl)pentanoic acid (8) 
 
 
 
To a solution of sodium methanesulfinate (compound 54, 2 g, 19.03 mmol) in anhydrous N,N-
dimethylformamide (12 ml), 5-bromovaleric acid (1.73 g, 9.51 mmol) was added. The mixture 
was stirred at 60 °C for 5 h. The reaction was monitored by thin layer chromatography (eluent 
phase dichloromethane:methanol/9.5:0.5). The solution was evaporated under reduced 
pressure and the obtained residue was taken up with iced-water and acidified with a cold solution 
of 2 M KHSO4. The aqueous phase was extracted with ethyl acetate (four times) and the 
combined organic extracts were washed firstly with a cold solution of 2M KHSO4, then with iced-
water and brine. Then the organic phase was dried with anhydrous Na2SO4, filtered and 
evaporated to dryness to obtain a yellow pale oil which crystallized spontaneously in the fridge. 
The solid was rinsed with a solution of diethyl ether/petroleum ether (1:1) to give white crystals. 
Yield: 27%. Mp 111.3-112.8 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.01 (s, 1H, COOH collapsed with 
D2O), 3.13 (t, 2H, J=7.4 Hz, CH2), 2.92 (s, 3H, CH3), 2.23 (t, 2H, J=7.4 Hz, CH2), 1.72-1.53 (m, 4H, 
CH2) ppm.  
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4.3 S3I-201 and related compounds 
Methyl 2-(tosyloxy)acetate (57) 
 
 
 
A solution of methyl glycolate (1 g, 11.1 mmol) and tosyl chloride (2.1 g, 11.1 mmol) in anhydrous 
diethyl ether (5 ml) at 0 °C, was treated dropwise with triethylamine (3.09 ml, 22.2 mmol). The 
temperature was maintained at 0 °C with stirring for 3 h. After this time, water was added and 
the phases separated. The aqueous phase was extracted with cold diethyl ether. The combined 
organic extracts were dried with anhydrous Na2SO4, filtered and evaporated to dryness to obtain 
a residue that was purified by CC (silica gel; ethyl acetate/cyclohexane; in gradient up to 35:65), 
using the Flash Chromatography Purification System Biotage SP-1. The fractions containing the 
purified product were gathered up to provide a colourless oil which solidified on standing as 
white solid. Mp 65.0-66.1 °C. Yield: 73%. 1H NMR (300 MHz, CDCl3): δ 7.83 (d, 2H, J=8.2 Hz, ArH), 
7.36 (d, 2H, J=8.2 Hz, ArH), 4.61 (s, 2H, OCH2), 3.74 (s, 3H, OCH3), 2.46 (s, 3H, ArCH3) ppm.  
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2-(Tosyloxy)acetic acid (58) 
 
 
 
A solution of methyl 2-(tosyloxy)acetate (compound 57, 1.5 g, 6.14 mmol) in ethanol (5 ml) was 
treated at room temperature with 5% NaOH aqueous solution (4 ml). The resulting mixture was 
stirred at room temperature for 3 h. After the completion of reaction, ethanol was evaporated 
under reduced pressure and the basic aqueous phase was extracted with diethyl ether in order 
to remove the unreacted ester. The aqueous mixture was then acidified with a solution 5% HCl 
(5.5 ml) and was extracted three times with chloroform. The combined organic extracts were 
dried with anhydrous Na2SO4, filtered and evaporated to dryness to obtain white crystal solid. 
Mp 138.8-139.1 °C. Yield: 86%. 1H NMR (300 MHz, CD3OD): δ 7.82 (d, 2H, J=8.2 Hz, ArH), 7.41 (d, 
2H, J=8.2 Hz, ArH), 4.60 (s, 2H, OCH2), 2.43 (s, 3H, ArCH3) ppm.  
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2-Chloro-2-oxoethyl 4-methylbenzenesulfonate (59) 
 
 
 
A mixture of 2-(tosyloxy)acetic acid (compound 58, 600 mg, 2.6 mmol) and thionyl chloride (1.5 
ml, 15.6 mmol) was heated at reflux for 2 h. The excess thionyl chloride was removed in vacuo 
and the resulting grey oil dried under vacuum at 50 °C for 1.5 h. The obtained acyl chloride was 
used without further purification. 
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2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid (S3I-201) 
 
 
 
A mixture p-amino salicylic acid (307 mg, 2.01 mmol) and NaOH (80 mg, 2.01 mmol) in water (18 
ml) was stirred at room temperature for 10 minutes until complete dissolution and Na2CO3 (176 
mg, 1.67 mmol) was then added and the mixture cooled to 0 °C. A solution of 2-chloro-2-oxoethyl 
4-methylbenzenesulfonate (compound 59, 600 mg, 2.41 mmol) in tetrahydrofuran (4 ml) was 
added and the resulting solution allowed to warm to room temperature and stirred for 3 h. The 
reaction was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/7.5:2.5). The mixture was poured into a separating funnel containing 
iced-diethyl ether (10 ml) and the aqueous phase was washed with a further portion of iced-
diethyl ether. Then the aqueous phase was acidified by addition of 1N HCl solution and the 
product extracted into ethyl acetate. The combined organic extracts were washed twice with 1N 
HCl solution, dried with anhydrous Na2SO4, filtered and the evaporated under vacuum. The 
resulting salmon-orange solid was rinsed with chloroform to provide the title compound as a 
white powder. The diethyl ether previously used to wash the basic aqueous phase, was dried 
with anhydrous Na2SO4, filtered and evaporated to dryness obtaining a residue that was 
recrystallized with diethyl ether and the white powder was rinsed with chloroform to give 2-
hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid (S3I-201) as a white solid. Mp 218.4-221.3 °C. 
Yield: 45%. 1H NMR (300 MHz, DMSO-d6): δ 11.40 (br s, 1H, OH collapsed with D2O), 10.32 (s, 1H, 
NH collapsed with D2O), 7.81 (d, 2H, J=7.8 Hz, ArH), 7.69 (d, 1H, J=8.8 Hz, ArH), 7.46 (d, 2H, J=7.8 
Hz, ArH), 7.17 (d, 1H, J=1.8 Hz ArH), 6.93 (dd, 1H, J=8.8 and 1.8 Hz, ArH), 4.68 (s, 2H, CH2), 2.37 
(s, 3H, ArCH3) ppm. 
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4-(2-Chloroacetamido)-2-hydroxybenzoic acid (60) 
 
 
 
p-Amino salicylic acid (1 g, 6.52 mmol) was dissolved in water (80 ml) along with NaOH (0.26 g, 
6.52 mmol). The solution was placed in an ice bath at 0 °C and choroacetyl chloride (3.31 g, 29.3 
mmol) was then added dropwise over 15 minutes. The reaction mixture was stirred overnight at 
room temperature and it was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/7.5:2.5). The solution was then filtered and the resulting solid 
residue was washed with cold water for three times and then with diethyl ether to provide white 
crystals. Yield: 87%. Mp 235.5.-236.9 °C. 1H NMR (300 MHz, DMSO-d6): δ 11.40 (br s, 1H, OH 
collapsed with D2O), 10.58 (s, 1H, NH collapsed with D2O), 7.76 (d, 1H, J=9.3 Hz, ArH), 7.35 (d, 1H, 
J=1.6 Hz, ArH), 7.06 (dd, 1H, J=1.6 Hz and 9.3 Hz, ArH), 4.28 (s, 2H, CH2Cl). 
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Sodium toluenethiosulfonate (61) 
 
 
 
A mixture of sodium sulfite (3.3 g, 26.2 mmol) in water (25 ml) was vigorously stirred for 15 
minutes at room temperature until complete dissolution. NaHCO3 (4.4 g, 52.45 mmol) was added 
and the mixture was stirred for 1 h at 50 °C. Then 4-toluenesulfonyl chloride (5 g, 26.2 mmol) was 
carefully added and, after the addition, the mixture was vigorously stirred at 50 °C for 4 h. After 
cooling at room temperature, the water was evaporated under reduced pressure. The obtained 
white residue was taken up with methanol (40 ml) in order to separate the sodium 
methanesulfinate from methanol-insoluble salts; then, the mixture was stirred overnight. After 
filtration of inorganic salts, the solution was evaporated under reduced pressure to obtain the 
sodium toluenesulfinate as a white solid.  
Sodium toluenesulfinate (1 g, 5.61 mmol) and sulfur (0.180 g, 5.61 mmol) were mixed together 
in methanol (100 ml) and the reaction mixture was heated under reflux for 30 minutes, until all 
of the sulfur had dissolved. The reaction was conducted in a round bottom flask connected with 
a system of three traps (one empty, the second filled up with 2N NaOH and the third with NaClO) 
because of H2S releasing. After the completion of reaction, unreacted sulfur was filtered and the 
solution was evaporated under reduced pressure to obtain the title compound as a white solid. 
Yield: 99%. Mp >300 °C (dec.). 1H NMR (300 MHz, D2O): δ 7.64 (d, 2H, J=8.1 Hz, ArH), 7.23 (d, 2H, 
J=8.1 Hz, ArH), 2.30 (s, 3H, CH3) ppm. 
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2-Hydroxy-4-(2-(tosylthio)acetamido)benzoic acid (15) 
 
 
 
Sodium toluenethiosulfonate (compound 61, 812 mg, 3.83 mmol) and 4-(2-chloroacetamido)-2-
hydroxybenzoic acid (compound 60, 805 mg, 3.48 mmol) were dissolved in anhydrous N,N-
dimethylformamide (7.5 ml) under nitrogen. The reaction mixture was stirred at 60 °C for 4 h and 
was monitored by thin layer chromatography (eluent phase dichloromethane:methanol/7:3). 
After cooling at room temperature, inorganic salts were filtered and the solution was evaporated 
under reduced pressure. The obtained residue was taken up with dichloromethane and washed 
with cold water (three times) and then with iced brine. The organic layer was dried with 
anhydrous Na2SO4, filtered and evaporated to dryness to provide a residue that was purified by 
CC (silica gel; dichloromethane/methanol; in gradient up to 98.7:1.3), using the Flash 
Chromatography Purification System Biotage SP-1. A salmon pink solid was obtained. The solid 
was rinsed firstly with diethyl ether/petroleum ether (2:1) and then with diethyl ether/methanol 
(1:0.2) to give white crystal solid. Yield: 60%. Mp 170.0-171.9 °C. 1H NMR (300 MHz, DMSO-d6): 
δ 11.41 (br s, 1H, OH collapsed with D2O), 10.42 (s, 1H, NH collapsed with D2O), 7.80 (d, 2H, J=7.8 
Hz, ArH), 7.71 (d, 1H, J=8.7 Hz, ArH), 7.38 (d, 2H, J=7.8 Hz, ArH), 7.11 (d, 1H, J=1.6 Hz, ArH), 6.91 
(dd, 1H, J=1.6 and 8.7 Hz, ArH), 4.05 (s, 2H, CH2S), 2.31 (s, 3H, ArCH3) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ 171.93, 165.09, 162.41, 145.56, 145.01, 141.48, 131.47, 130.47, 127.31, 110.67, 
108.53, 106.59, 21.44 ppm. HRMS (ESI): m/z calculated for C16H16NO6S2 [M+H]+: 382.04190; 
found: 382.04130. 
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S-((Methylsulfonyl)methyl) 4-amino-2-hydroxybenzothioate (17) 
 
 
 
To a solution of 2-((methylsulfonyl)thio)acetic acid (compound 3, 366 mg, 2.15 mmol) in 
anhydrous N,N-dimethylformamide (2 ml) under argon and at 0 °C, HOBt (290 mg, 2.15 mmol), 
N,N-diisopropylethylamine (0.341 ml, 1.96 mmol) and EDAC (412 mg, 2.15 mmol) were added. 
After 5 minutes p-aminosalicylic acid (300 mg, 1.96 mmol) was added and the reaction was stirred 
at room temperature for 5 h. After the completion of reaction, the solution was evaporated 
under reduced pressure. The obtained residue was taken up with ethyl acetate and washed with 
a cold solution of 0.5N HCl and then with brine. The organic layer was dried with anhydrous 
Na2SO4, filtered and evaporated to dryness. The crude product was purified by CC (silica gel; 
dichloromethane/methanol; in gradient up to 99.7:0.3). After washing with diethyl ether, a white 
solid was obtained. Yield: 5%. Mp 149.9-152.0 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.67 (br s, 1H, 
OH collapsed with D2O), 7.51 (d, 1H, J=8.7 Hz, ArH), 6.43 (br s, 2H, NH2 collapsed with D2O), 6.17 
(dd, 1H, J=2.1 and 8.7 Hz, ArH), 6.01 (d, 1H, J=2.1 Hz, ArH), 4.66 (s, 2H, CH2), 2.98 (s, 3H, CH3) 
ppm. 13C NMR (75 MHz, DMSO-d6): δ 184.69, 161.68, 157.19, 131.72, 109.25, 107.76, 98.72, 
49.48, 39.86 ppm. HRMS (ESI): m/z calculated for C9H11NO4S2Na [M+Na]+: 284.0027; found: 
284.0024; calculated for C9H12NO4S2 [M+H]+: 262.0208; found 262.02044; calculated for 
C9H10NO4S2 [M-H+]-: 260.0057; found 260.0051.  
Crystal data for EG15: C9H11 N1O4S2, Mr = 261.3 g/mol, Triclinic, Space group P-1, a = 5.080(3) Å, 
b = 9.8552(6) Å, c = 11.4649(7) Å, α = 81.569(1), β = 88.232(1), γ = 77.41(1), V = 554.12(6) Å3, Z = 
2, Dcalc = 1.566 mg/m3, R = 0.033 (5853 reflections), wR2 = 0.0864, T = 293(2)K, GOF = 1.080. The 
reflections were collected in the range 1.8° ≤  ≤ 25.02° employing a 0.55 x 0.22 x 0.02 crystal.  
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4.5 Curcumin and cinnamic acids derivatives 
4.3.1 Curcumin derivatives and thio-analogue 
((1E,4Z,6E)-3-Hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-phenylene) bis(4-
(3-thioxo-3H-1,2-dithiol-4-yl)benzoate) (20) 
 
 
 
To a solution of 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (14, 346 mg, 1.36 mmol) in 
anhydrous N,N-dimethylformamide (12 ml) under inert atmosphere and at 0 °C, EDAC (310 mg, 
1.62 mmol), DMAP (13 mg, 0.1 mmol) and curcumin (200 mg, 0.54 mmol) were added. After 10 
minutes the ice-bath was removed and the mixture was stirred at room temperature for 20 h. 
The reaction was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/10:0.3). The solution was then evaporated under reduced pressure. 
The obtained residue was taken up with iced water and the brown precipitate isolated by 
filtration. The product cake was washed twice with iced water (20 ml each), then washed with 
cold methanol and dried under vacuum to give the title compound as an orange solid. Yield: 85%. 
Mp 167.8-171.1 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.30 (s, 2H, SCH=), 8.17 (d, 4H, J=7.9 Hz, ArH), 
7.81 (d, 4H, J=7.9 Hz, ArH), 7.69 (d, 2H, J=15.9 Hz, CH=CH), 7.59 (d, 2H, J=1.9 Hz, ArH), 7.37 (m, 
4H, ArH), 7.04 (d, 2H, J=15.9 Hz, CH=CH), 6.23 (s, 1H, CH), 3.84 (s, 6H, OCH3) ppm. 13C NMR (75 
MHz, DMSO-d6): δ 214.12, 183.90, 164.18, 161.17, 151.93, 147.39, 141.64, 140.53, 139.68, 
134.66, 130.42, 130.18, 128.89, 125.46, 124.16, 122.22, 112.86, 56.78. HRMS (ESI-TOF): m/z 
calculated for C41H29O8S6 [M+H]+: 841.01867; found: 841.0175. 
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4-((1E,4Z,6E)-3-Hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl)-2-
methoxyphenyl 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoate (21) 
 
 
 
To a solution of 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (14, 250 mg, 0.98 mmol) in 
anhydrous N,N-dimethylformamide (9 ml) under inert atmosphere and at 0 °C, EDAC (282 mg, 
1.47 mmol), DMAP (12 mg, 0.1 mmol) and curcumin (470 mg, 1.27 mmol) were added. After 10 
minutes the ice-bath was removed and the mixture was stirred at room temperature for 20 h. 
The reaction was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/10:0.3). After the completion of reaction, the solution was 
evaporated under reduced pressure. The obtained residue was taken up with iced water and the 
brown precipitate isolated by filtration. The product cake was washed twice with iced water (20 
ml each), then washed with cold methanol and dried in vacuo overnight. The crude was then 
purified by CC (silica gel; dichloromethane/methanol; in gradient up to 99.8:0.2), using the Flash 
Chromatography Purification System Biotage SP-1. After washing with diethyl ether and cold 
methanol, an orange solid was obtained. Yield: 6%. Mp 201.1-205.9 °C. 1H NMR (300 MHz, DMSO-
d6): δ 9.67 (br s, 1H, OH collapsed with D2O), 9.29 (s, 1H, SCH=), 8.17 (d, 2H, J=7.9 Hz, ArH), 7.81 
(d, 2H, J=7.9 Hz, ArH), 7.66-7.56 (m, 3H, ArH), 7.33 (m, 3H, ArH), 7.16 (d, 1H, J=8.5 Hz, CH=CH), 
6.98 (d, 1H, J=15.6 Hz, CH=CH), 6.83-6.76 (m, 2H, CH=CH), 6.14 (s, 1H, CH), 3.83 (s, 6H, OCH3) 
ppm.13C NMR (75 MHz, DMSO-d6): δ 213.88, 185.39, 181.82, 163.97, 160.95, 151.68, 150.00, 
148.44, 147.16, 142.03, 141.24, 139.44, 134.55, 130.18, 129.95, 128.67, 126.66, 125.16, 123.89, 
123.82, 121.80, 121.60, 116.15, 112.49, 111.89, 101.82, 56.52, 56.15 ppm. HRMS (ESI): m/z 
calculated for C31H25O7S3 [M+H]+: 605.07624; found: 605.07581. 
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((1E,4Z,6E)-3-Hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-phenylene) bis(5-
((methylsulfonyl)thio)pentanoate) (18) 
 
 
 
To a solution of 5-(methylsulfonylthio)pentanoic acid (1, 430 mg, 2.02 mmol) and curcumin (300 
mg, 0.81 mmol) in anhydrous tetrahydrofuran (10 ml) under nitrogen, DCC (417 mg, 2.02 mmol) 
and DMAP (19 mg, 0.2 mmol) were added. The reaction was monitored by thin layer 
chromatography (eluent phase dichloromethane:methanol/10:0.4) and was complete within 5 h 
at room temperature. After the filtration of the obtained DCU, the solvent was evaporated and 
the residue was taken up with ethyl acetate and washed firstly with a cold solution of 0.5N HCl, 
then with a cold solution of 5% NaHCO3, finally with iced water and brine. The organic layer was 
dried with anhydrous Na2SO4, filtered and evaporated to dryness to obtain a residue that was 
purified by CC (silica gel; ethyl acetate/cyclohexane; in gradient up to 40:60), using the Flash 
Chromatography Purification System Biotage SP-1. The fractions containing the purified product 
were gathered up and rinsed with diethyl ether/ethyl acetate (9:1) to provide a sticky brown oil. 
Yield: 24%. 1H NMR (300 MHz, CDCl3): δ 7.62 (d, 2H, J=15.6 Hz, CH=CH), 7.18-7.12 (m, 4H, ArH), 
7.06 (dd, 2H, J=8.1 and 1.7 Hz, ArH) 6.56 (d, 2H, J=15.6 Hz, CH=CH), 5.85 (s, 1H, CH), 3.88 (s, 6H, 
OCH3), 3.33 (s, 6H, CH3), 3.26-3.21 (m, 4H, CH2COO), 2.69-2.65 (m, 4H, CH2S), 1.93-1.90 (m, 8H, 
CH2) ppm. 13C NMR (75 MHz, CDCl3): δ 183.06, 170.81, 151.33, 141.18, 139.91, 134.03, 124.32, 
123.21, 121.10, 111.42, 101.81, 55.93, 50.76, 35.99, 33.12, 28.83, 23.70 ppm. HRMS (ESI): m/z 
calculated for C33H41O12S4 [M+H]+: 757.14808; found: 757.14763. 
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((1E,4Z,6E)-3-Hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-phenylene)bis(3-
(allyldisulfanyl)propanoate) (19) 
 
 
 
To a solution of 3-(allyldisulfanyl)propanoic acid (9, 127 mg, 0.67 mmol) in anhydrous chloroform 
(5 ml) under inert atmosphere and at 0 °C, EDAC (145 mg, 0.76 mmol), DMAP (3 mg, 0.03 mmol) 
and curcumin (100 mg, 0.27 mmol) were added. After 5 minutes the ice-bath was removed and 
the mixture was stirred at room temperature for 3 h. The reaction was monitored by thin layer 
chromatography (eluent phase cyclohexane:ethylacetate/3:7). After the completion of reaction, 
the solution was evaporated under reduced pressure. The obtained residue was taken up with 
dichloromethane and washed firstly with a cold solution of 0.5N HCl, then with a cold solution of 
5% NaHCO3, finally with iced water and brine. The organic layer was dried with anhydrous 
Na2SO4, filtered and evaporated to dryness to obtain a residue that was purified by CC (silica gel; 
ethyl acetate/cyclohexane; in gradient up to 11:89), using the Flash Chromatography Purification 
System Biotage SP-1. The fractions containing the purified product were gathered up and rinsed 
with diethyl ether to provide a sticky yellow oil. Yield: 65%. 1H NMR (300 MHz, CDCl3): δ 7.63 (d, 
2H, J=14.5 Hz, CH=CH), 7.21-7.02 (m, 6H, ArH), 6.59 (d, 2H, J=14.5 Hz, CH=CH), 5.96-5.81 (m, 3H, 
CH and CH=CH2), 5.22-5.13 (m, 4H, CH=CH2), 3.91 (s, 6H, OCH3), 3.39 (d, 4H, J=11.1 Hz, CH2), 3.11-
3.01 (m, 8H, CH2) ppm. 13C NMR (75 MHz, CDCl3): δ 183.06, 169.67, 151.30, 141.18, 139.89, 
134.03, 133.24, 124.31, 123.21, 121.04, 118.81, 111.51, 101.86, 55.92, 42.19, 34.03, 33.15 ppm. 
HRMS (ESI-TOF): m/z calculated for C33H37O8S4 [M+H]+: 689.13713; found: 689.1431. 
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(O)-4-Formyl-2-methoxyphenyl dimethylcarbamothioate (62) 
 
 
 
4-Hydroxy-3-methoxybenzaldehyde (3 g, 19.71 mmol) and DABCO (3.8 g, 34.49 mmol) were 
mixed together in anhydrous N,N-dimethylformamide (7 ml) under inert atmosphere to give a 
light yellow solution. Dimethylthiocarbamoyl chloride (3.6 g, 29.5 mmol) was added over 3 
minutes and the resulting orange mixture was heated to 60° C and monitored by thin layer 
chromatography (eluent phase dichloromethane:methanol/10:0.1). The reaction was complete 
within 3 h. The mixture was poured into crushed iced and acidified to pH 2-3 with 5.0N HCl (1.2 
ml). The precipitate formed was collected and isolated by filtration. The product cake was 
washed twice with iced water (25 ml each), then washed with iced diethyl ether/petroleum ether 
(1:1) and dried under vacuum to give a cream-coloured solid that recrystallized from ethanol 
providing white crystal solid corresponding to the desired product. Yield: 80%. Mp 115.4-115.9 
°C. 1H NMR (300 MHz, DMSO-d6): δ 9.95 (s, 1H, CHO collapsed with D2O), 7.59-7.52 (m, 2H, ArH), 
7.31 (dd, 1H, J=1.2 and 8.3 Hz, ArH), 3.89 (s, 3H, OCH3), 3.31 (s, 3H, CH3NCH3), 3.24 (s, 3H, 
CH3NCH3) ppm.  
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(S)-4-Formyl-2-methoxyphenyl dimethylcarbamothioate (63) 
 
 
 
(O)-4-Formyl-2-methoxyphenyl dimethylcarbamothioate (compound 62, 700 mg) was dissolved 
in anhydrous N,N-dimethylformamide (2 ml) and charged into a 2.0-5.0 ml microwave vial. The 
mixture was stirred in a microwave reactor at 250 °C (250-300 W) for 15 minutes and monitored 
by thin layer chromatography (eluent phase dichloromethane:methanol/10:0.2). The obtained 
residue was diluted with water and the precipitate formed was collected and isolated by 
filtration. The product cake was washed twice with iced water (15 ml each), then washed with 
cold diethyl ether/petroleum ether (1:1) and dried in vacuo to give a cream-coloured solid.  Yield: 
90%. Mp 125.3-125.9 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.95 (s, 1H, CHO collapsed with D2O), 
7.68 (dd, 1H, J=1.4 Hz and 8.8 Hz, ArH), 7.57 (d, 1H, J=1.4 Hz, ArH), 7.49 (d, 1H, J=8.8 Hz, ArH), 
3.89 (s, 3H,OCH3), 3.31 (s, 3H, CH3NCH3), 3.24 (s, 3H, CH3NCH3) ppm.  
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S,S'-4,4'-((1E,3Z,6E)-3-Hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-
phenylene) bis(dimethylcarbamothioate) (64) 
 
 
 
2,4-Pentanedione (0.32 ml, 3.13 mmol) and boric anhydride (109 mg, 1.56 mmol), dissolved in 
ethyl acetate (2.5 ml), were stirred for 3 h at 70° C. After removing the solvent under reduced 
pressure, the resultant white solid was washed with hexane and then, (S)-4-formyl-2-
methoxyphenyl dimethylcarbamothioate (compound 63, 1 g, 4.18 mmol), triisopropyl borate 
(0.96 ml, 4.18 mmol), and anhydrous tetrahydrofuran (7 ml) were added: the mixture was stirred 
for a further 30 minutes. N-Butylamine (0.041 ml, 0.418 mmol) dissolved in anhydrous 
tetrahydrofuran was added dropwise in 5 minutes and the mixture was stirred at reflux for 24 h 
under inert atmosphere. After cooling at room temperature, the formed solid was filtered and 
washed with iced tetrahydrofuran/petroleum ether (1:0.5) and dried under vacuum to give an 
orange solid. The obtained residue (918 mg) was taken up with chloroform (100 ml) and the boron 
complex was hydrolysed by adding 1.8M HCl (30 ml) and heating at 60° C for 1 h. The two layers 
were separated and the aqueous phase was extracted three times with chloroform. The 
combined organic layers were washed with iced water, dried with anhydrous Na2SO4 and the 
solvent was stripped off. The final product 64 was crystallized with diethyl ether and rinsed with 
a solution of petroleum ether/dichloromethane (2:0.5) to provide a pale orange solid. Yield: 49%. 
Mp 190.0-191.2 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.71 (d, 2H, J=16.5 Hz, CH=CH), 7.50-7.41 (m, 
3H, ArH), 7.38-7.29 (m, 3H, ArH), 7.11 (d, 2H, J=16.5 Hz, CH=CH), 6.28 (s, 1H, CH), 3.89 (s, 6H, 
OCH3), 3.08 (s, 6H, CH3NCH3), 3.81 (s, 6H, CH3NCH3) ppm. 
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(1E,4Z,6E)-5-Hydroxy-1,7-bis(4-mercapto-3-methoxyphenyl)hepta-1,4,6-trien-3-one (22) 
 
 
 
To a solution of compound 64 (425 mg, 0.79 mmol) in 1,4-dioxane (8 ml) under inert atmosphere, 
potassium hydroxide (154 mg, 1.90 mmol) dissolved in methanol (3.2 ml) was added. The 
reaction was stirred at room temperature for 7 h to completion of hydrolysis. After this time, the 
mixture was poured into crushed ice, acidified with 6N HCl and the precipitate was collected and 
isolated by filtration. The product cake was washed twice with cold water (20 ml each), then 
washed with iced diethyl ether and dried in vacuo to obtain an orange-yellow solid. Yield: 54%. 
Mp 147.9-150.1 °C. 1H NMR (300 MHz, CDCl3): δ 7.58 (d, 2H, J=15.9 Hz, CH=CH), 7.25 (d, 2H, J=1.4 
Hz, ArH), 7.07 (dd, 2H, J=8.5 Hz and 1.4 Hz, ArH), 7.01 (d, 2H, J=8.5 Hz, ArH), 6.55 (d, 2H, J=15.9 
Hz, CH=CH), 5.82 (s, 1H, CH), 3.98 (s, 2H, SH collapsed with D2O), 3.94 (s, 6H, OCH3) ppm. HRMS 
(ESI-TOF): m/z calculated for C21H21O4S2 [M+H]+: 401.0881; found: 401.0891. 
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4.3.2 Ferulic Acid derivatives 
 (E)-(2-Methoxyethoxy)methyl 3-(3-methoxy-4-((2-methoxyethoxy)methoxy)phenyl) acrylate 
(65) 
 
 
 
To a solution of ferulic acid (100 mg, 0.52 mmol) and DIPEA (0.27 ml, 1.03 mmol) in anhydrous 
chloroform (2 ml) at 0 °C, 2-methoxyethoxymethyl chloride (0.18 ml, 1.55 mmol) dissolved in 
anhydrous chloroform (1 ml) was added dropwise for 5 minutes. After 5 minutes the ice-bath 
was removed and the mixture was stirred at room temperature for 5 h under inert atmosphere. 
The reaction was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/10.5:0.5). After 3 h, 2-methoxyethoxymethyl chloride (0.03 ml, 0.22 
mmol) was added in order to speed up the reaction and it was monitored by thin layer 
chromatography (TLC). After the completion of reaction, the obtained residue was quenched 
with 0.5N HCl and the aqueous phase was extracted three times with dichloromethane. The 
combined organic layers were dried with anhydrous Na2SO4, filtered and evaporated to dryness 
to obtain a pale yellow oil. Yield: 99%. 1H NMR (300 MHz, DMSO-d6): δ 7.64 (d, 1H, J=15.9 Hz, 
CH=CH), 7.41 (d, 1H, J=1.6 Hz, ArH), 7.23 (dd, 1H, J=1.6 and 8.2 Hz, ArH), 7.09 (d, 1H, J=8.2 Hz, 
ArH), 6.60 (d, 1H, J=15.9 Hz, CH=CH), 5.36 (s, 2H, CH2), 5.26 (s, 2H, CH2), 3.81 (s, 3H, OCH3), 3.74-
3.70 (m, 4H, CH2), 3.48-3.43 (m, 4H, CH2), 3.23 (s, 3H, OCH3), 3.20 (s, 3H, OCH3) ppm. 
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(E)-3-(3-Methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylic acid (66) 
 
 
 
(E)-(2-Methoxyethoxy)methyl 3-(3-methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylate 
(compound 65, 1,4 g, 3.83 mmol) and lithium hydroxide monohydrate (1,45 g, 34.47 mmol) 
dissolved in 15 ml of tetrahydrofuran/water solution (2:1), were stirred for 24 h at room 
temperature. The reaction was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/10:0.1). After the completion of reaction, the tetrahydrofuran was 
evaporated under reduced pressure. The obtained residue was acidified with a solution of 0.5N 
HCl and the aqueous phase was extracted three times with ethyl acetate. The combined organic 
layers were washed with brine and dried with anhydrous Na2SO4, filtered and evaporated to 
dryness to obtain a pale pink oil which was crystallized with diethyl ether providing (E)-3-(3-
methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylic acid (66) as a white solid. Mp 78.4-79.8 
°C. Yield: 84%. 1H NMR (300 MHz, DMSO-d6): δ 12.24 (s, 1H, COOH collapsed with D2O), 7.51 (d, 
1H, J=15.9 Hz, CH=CH), 7.34 (d, 1H, J=1.6 Hz, ArH), 7.17 (dd, 1H, J=1.6 and 8.2 Hz, ArH), 7.08 (d, 
1H, J=8.2 Hz, ArH), 6.46 (d, 1H, J=15.9 Hz, CH=CH), 5.25 (s, 2H, CH2), 3.80 (s, 3H, OCH3), 3.74-3.70 
(m, 2H, CH2), 3.48-3.43 (m, 2H, CH2), 3.20 (s, 3H, OCH3) ppm. 
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3-(4-Hydroxy-3-methoxyphenyl)acrylic acid (23) 
 
 
 
To a solution of ferulic acid (500 mg, 2.57 mmol) dissolved in methanol (32 ml), concentrated 
H2SO4 (0.91 ml, 17.22 mmol) was added dropwise at room temperature. The reaction was stirred 
at reflux for 2 h and was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/10.8:0.2). The solution was stripped off and the obtained residue 
was taken up with ethyl acetate and washed three times with a solution of 5% NaHCO3 and then 
with brine. The organic layer was dried with anhydrous Na2SO4, filtered and evaporated to 
dryness and the crude was purified by CC (silica gel; ethyl acetate/cyclohexane; in gradient up to 
35:65), using the Flash Chromatography Purification System Biotage SP-1. The fractions 
containing the purified product were gathered up to provide the final product as a colourless oil. 
Yield: 71%. 1H NMR (300 MHz, DMSO-d6): δ 7.59 (d, 1H, J=15.9 Hz, CH=CH), 7.11 (d, 1H, J=1.6 Hz, 
ArH), 7.03 (dd, 1H, J=1.6 and 8.2 Hz, ArH), 6.95 (d, 1H, J=8.2 Hz, ArH), 6.36 (d, 1H, J=15.9 Hz, 
CH=CH), 3.93 (s, 3H, OCH3), 3.80 (s, 3H, OCH3) ppm.  
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3-(3-Methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylate esters (67, 68, 70, 71) 
 
General method. To a solution of (E)-3-(3-methoxy-4-((2-methoxyethoxy)methoxy) 
phenyl)acrylic acid (66, 109 mg, 0.53 mmol) and the appropriate ROH (4, 5, 12, 11, 1 or 1.1 eq) in 
anhydrous dichloromethane (2-5 ml) or tetrahydrofuran (5 ml), DCC (109 mg, 0.53 mmol) and 
DMAP (7 mg, 0.05 mmol) were added. The reaction mixture was stirred for 5-20 h at room 
temperature under inert atmosphere. After the filtration of DCU, the residue was diluted with 
dichloromethane and washed three times with a cold solution of 0.5N HCl and then with iced-
water and finally with brine. The organic layer was dried with anhydrous Na2SO4, filtered and the 
solvent was removed under reduced pressure. The resulting residue was purified by CC (silica gel; 
dichloromethane/methanol; in gradient as indicated for each compound). 
 
(E)-2-(Methylsulfonylthio)ethyl 3-(3-methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylate 
(67). CC (silica gel; dichloromethane/methanol; in gradient up to 99:1). The title compound was 
obtained as a pale yellow oil. Yield: 77%. 1H NMR (300 MHz, CDCl3): δ 7.67 (d, 1H, J=15.9 Hz, 
CH=CH), 7.22 (dd, 1H, J=1.9 and 8.2 Hz, ArH), 7.10 (d, 1H, J=8.2 Hz, ArH), 7.06 (d, 1H, J=1.9 Hz, 
ArH), 6.32 (d, 1H, J=15.9 Hz, CH=CH), 5.37 (s, 2H, CH2), 4.52 (t, 2H, J=6.6 Hz, CH2), 3.92 (s, 3H, 
OCH3), 3.83 (t, 2H, J=3.8, CH2), 3.55 (t, 2H, J=3.8, CH2), 3.50 (t, 2H, J=6.6 Hz, CH2S), 3.40 (s, 3H, 
CH3), 3.37 (s, 3H, OCH3) ppm. 
 
(E)-4-(Methylsulfonylthio)butyl 3-(3-methoxy-4-((2 methoxyethoxy)methoxy)phenyl)acrylate 
(68). CC (silica gel; dichloromethane/methanol; in gradient up to 99.6:0.4). The fractions 
containing the purified product were gathered up to provide a yellow oil. Yield: 70%. 1H NMR 
(300 MHz, DMSO-d6): δ 7.61 (d, 1H, J=15.6 Hz, CH=CH), 7.39 (d, 1H, J=1.5 Hz, ArH), 7.21 (dd, 1H, 
J=1.5 and 8.1 Hz, ArH), 7.09 (d, 1H, J=8.1 Hz, ArH), 6.59 (d, 1H, J=15.6 Hz, CH=CH), 5.25 (s, 2H, 
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CH2), 4.19-4.15 (m, 2H, CH2), 3.79 (s, 3H, OCH3), 3.73-3.68 (m, 2H, CH2), 3.51 (s, 3H, CH3), 3.48-
3.42 (m, 2H, CH2), 3.30-3.22 (m, 3H, CH2), 3.21 (s, 2H, OCH3), 1.80-1.72 (m, 4H, CH) ppm.   
 
(E)-2-(Allyldisulfanyl)ethyl 3-(3-methoxy-4-((methoxyethoxy)methoxy)phenyl)acrylate (70). CC 
(silica gel; dichloromethane/methanol; in gradient up to 99.9:0.1). The title compound was 
obtained as an old-rose oil. Yield: 80%. 1H NMR (300 MHz, CDCl3): δ 7.68 (d, 1H, J=15.9 Hz, 
CH=CH), 7.31 (d, 1H, J=1.3 Hz, ArH), 7.22 (d, 1H, J=8.2 Hz, ArH), 7.12 (dd, 1H, J=1.3 and 8.2 Hz, 
ArH), 6.38 (d, 1H, J=15.9 Hz, CH=CH), 5.96-5.90 (m, 1H, CH=CH2), 5.41 (s, 2H, CH2), 5.29-5.17 (m, 
2H, CH=CH2), 4.51-4.43 (m, 2H, CH2), 3.93 (s, 3H, OCH3), 3.88-3.84 (m, 2H, CH2), 3.59-3.56 (m, 2H, 
CH2), 3.39 (s, 3H, OCH3), 3.38-3.35 (m, 2H, CH2), 3.09-2.97 (m, 2H, CH2) ppm. 
 
(E)-4-(3-Thioxo-3H-1,2-dithiol-5-yl)phenyl 3-(3-methoxy-4-((2-
methoxyethoxy)methoxy)phenyl)acrylate (71). The solid residue was crystallized with a solution 
of CH2Cl2/MeOH (3:0.5) to give the title compound as an orange solid. Yield: 68%. Mp 105.7-108.2 
°C. 1H NMR (300 MHz, DMSO-d6): δ 7.99 (d, 2H, J=7.9 Hz, ArH), 7.84 (s, 1H, SCH=), 7.82 (d, 1H, 
J=15.9 Hz, CH=CH), 7.50 (d, 1H, J=1.6 Hz, ArH), 7.40 (d, 2H, J=7.9 Hz, ArH), 7.33 (d, 1H, J=8.2 Hz, 
ArH), 7.13 (dd, 1H, J=1.6 and 8.2 Hz, ArH), 6.84 (d, 1H, J=15.9 Hz, CH=CH), 5.29 (s, 2H, CH2), 3.83 
(s, 3H, OCH3), 3.73 (t, 2H, J= 5.8 Hz, CH2), 3.45 (t, 2H, J= 5.8 Hz, CH2), 3.21 (s, 3H, OCH3) ppm. 
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 (E)-S-2-(3-(3-Methoxy-4-((2-methoxyethoxy)methoxy)phenyl)acrylamido)ethyl 
methanesulfonothioate (69) 
 
 
 
S-2-Aminoethyl methanesulfonothioate hydrobromide (6, 230 mg, 0.97 mmol) and DIPEA (0.17 
ml, 0.97 mmol) were mixed together in anhydrous chloroform (8 ml) and (E)-3-(3-methoxy-4-((2-
methoxyethoxy)methoxy)phenyl)acrylic acid (compound 66, 250 mg, 0.89 mmol), EDAC (254 mg, 
1.34 mmol) and DMAP (11 mg, 0.09 mmol) were added. The reaction mixture was stirred for 3⅟2 
h under inert atmosphere at room temperature. After its completion, the reaction mixture 
poured into a separation funnel, firstly washed with a cold solution of 0.5N HCl, then with cold 
water and brine. The combined organic layers were dried with anhydrous Na2SO4, filtered and 
the solvent was stripped off to obtain the title compound as a pale yellow oil. Yield: 96%. 1H NMR 
(300 MHz, DMSO-d6): δ 8.85 (s, 1H, NH collapsed with D2O), 7.38 (d, 1H, J=15.6 Hz, CH=CH), 7.19 
(d, 1H, J=1.8 Hz, ArH), 7.11 (dd, 1H, J=1.8 and 8.5 Hz, ArH), 7.09 (d, 1H, J=8.5 Hz, ArH), 6.51 (d, 
1H, J=15.6 Hz, CH=CH), 5.23 (s, 2H, CH2), 3.79 (s, 3H, OCH3), 3.73-3.70 (m, 2H, CH2), 3.54 (s, 3H, 
CH3), 3.51 (t, 2H, J=6 Hz, CH2), 3.46-3.43 (m, 2H, CH2), 3.31 (t, 2H, J=6 Hz, CH2), 3.20 (s, 3H, OCH3) 
ppm. 
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3-(4-Hydroxy-3-methoxyphenyl)acrylate esters (24, 25, 27, 28) and amide (26)  
 
General procedure. To a solution of the appropriate 3-(3-methoxy-4-((2-
methoxyethoxy)methoxy)phenyl)acrylate derivative (67-71) (0.38 mmol) in anhydrous 
dichloromethane (2 ml), trifluoroacetic acid (0.16 ml, 2.12 mmol) was added and the mixture was 
stirred at room temperature for 5-7 h. After its completion, the solvent and the trifluoroacetic 
acid were evaporated in vacuo. The obtained residue was taken up with dichloromethane, 
washed twice with a cold solution of NaHCO3 at 5% (w/w) and then with iced-brine. The organic 
layer was dried with anhydrous Na2SO4, filtered and evaporated to dryness to obtain a residue 
that was purified by CC (silica gel; eluent as indicated for each compound). 
 
(E)-2-(Methylsulfonylthio)ethyl 3-(4-hydroxy-3-methoxyphenyl)acrylate (24). CC (silica gel; 
dichloromethane; isocratic). A colourless oil was obtained. Yield: 64%. 1H NMR (300 MHz, DMSO-
d6): δ 9.64 (br s, 1H, OH collapsed with D2O), 7.58 (d, 1H, J=15.9 Hz, CH=CH), 7.32 (d, 1H, J=1.9 
Hz, ArH), 7.12 (dd, 1H, J=1.9 and 8.2 Hz, ArH), 6.78 (d, 1H, J=8.2 Hz, ArH), 6.48 (d, 1H, J=15.9 Hz, 
CH=CH), 4.41 (t, 2H, J=6.1 Hz, CH2), 3.80 (s, 3H, OCH3), 3.58 (s, 3H, CH3), 3.53 (t, 2H, J=6.1 Hz, CH2) 
ppm. 13C NMR (75 MHz, CDCl3): δ 166.71, 148.32, 146.85, 146.12, 126.62, 123.27, 144.81, 114.20, 
109.56, 62.28, 55.99, 50.94, 35.19 ppm. HRMS (ESI): m/z calculated for C13H17O6S2 [M+H]+: 
333.04665; found: 333.04606. 
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(E)-4-(Methylsulfonylthio)butyl 3-(4-hydroxy-3-methoxyphenyl)acrylate (25). CC (silica gel; 
dichloromethane/methanol; in gradient up to 99.5:0.5). The title compound was obtained as a 
light-grey oil. Yield: 64%. 1H NMR (300 MHz, DMSO-d6): δ 9.60 (br s, 1H, OH collapsed with D2O), 
7.53 (d, 1H, J=15.7 Hz, CH=CH), 7.30 (d, 1H, J=1.4 Hz, ArH), 7.10 (dd, 1H, J=1.4 and 8.6 Hz, ArH), 
6.78 (d, 1H, J=8.6 Hz, ArH), 6.45 (d, 1H, J=15.7 Hz, CH=CH), 4.14 (t, 2H, J=6.15 Hz, CH2), 3.79 (s, 
3H, OCH3), 3.51 (s, 3H, CH3), 3.30-3.22 (m, 3H, CH2), 1.80-1.72 (m, 4H, CH2) ppm.13C NMR (75 
MHz, CDCl3): δ 167.19, 148.08, 146.83, 145.16, 126.84, 123.07, 115.08, 114.75, 109.43, 63.34, 
55.95, 50.67, 35.98, 27.63, 26.36 ppm. HRMS (ESI): m/z calculated for C15H21O6S2 [M+H]+: 
361.07795; found: 361.07734. 
 
(E)-S-2-(3-(4-Hydroxy-3-methoxyphenyl)acrylamido)ethyl methanesulfonothioate (26). CC 
(silica gel; dichloromethane/methanol; in gradient in gradient up to 99.5:0.5). A light-grey oil was 
obtained. Yield: 50%. 1H NMR (300 MHz, DMSO-d6): δ 9.46 (s, 1H, OH collapsed with D2O), 9.29 
(s, 1H, NH collapsed with D2O), 7.34 (d, 1H, J=15.6 Hz, CH=CH), 7.12 (d, 1H, J=1.8 Hz, ArH), 6.99 
(dd, 1H, J=1.8 and 7.9 Hz, ArH), 6.78 (d, 1H, J=7.9 Hz, ArH), 6.42 (d, 1H, J=15.6 Hz, CH=CH), 3.79 
(s, 3H, OCH3), 3.56-3.50 (m, 2H, CH2), 3.54 (s, 3H, CH3), 3.32-3.30 (m, 2H, CH2) ppm. 13C NMR (75 
MHz, DMSO-d6): δ 166.45, 149.08, 148.49, 140.29, 126.91, 122.33, 119.03, 116.33, 111.54, 56.22, 
50.95, 39.02, 36.09. HRMS (ESI): m/z calculated for C13H18NO5S2 [M+H]+: 332.06264; found: 
332.06205. 
 
(E)-2-(Allyldisulfanyl)ethyl 3-(4-hydroxy-3-methoxyphenyl)acrylate (27). CC (silica gel; 
dichloromethane/methanol; in gradient 99.9:0.1). The title compound was obtained as a 
colourless oil. Yield: 35%. 1H NMR (300 MHz, DMSO-d6): δ 9.62 (br s, 1H, OH collapsed with D2O), 
7.59 (d, 1H, J=15.9 Hz, CH=CH), 7.37 (d, 1H, J=1.1 Hz, ArH), 7.11 (d, 1H, J=8.2 Hz, ArH), 7.81 (dd, 
1H, J=1.1 and 8.2 Hz, ArH), 6.49 (d, 1H, J=15.9 Hz, CH=CH), 5.91-5.73 (m, 1H, CH=CH2), 5.29-5.08 
(m, 2H, CH=CH2), 4.48-4.31 (m, 2H, COOCH2), 3.82 (s, 3H, OCH3), 3.42-3.38 (m, 2H, CH2), 3.07-
2.96 (m, 2H, CH2) ppm. 13C NMR (75 MHz, CDCl3): δ 166.98, 148.08, 146.76, 145.40, 133.21, 
126.87, 123.21, 118.76, 114.95, 114.73, 109.34, 62.11, 55.95, 42.38, 37.37 ppm. HRMS (ESI): m/z 
calculated for C15H17O4S2 [M-H]-: 325.05683; found: 325.0549. 
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(E)-4-(3-Thioxo-3H-1,2-dithiol-5-yl)phenyl 3-(4-hydroxy-3-methoxyphenyl)acrylate (28). After 
the completion of reaction, the solution was filtered and the resulting solid residue was rinsed 
with a solution of ethyl ether/dichloromethane (4:1) for two times to provide orange crystals. 
Yield: 72%. Mp 204.5-206.8 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.75 (br s, 1H, OH collapsed with 
D2O), 7.99 (d, 2H, J=8.7 Hz, ArH), 7.80 (d, 1H, J=15.9 Hz, CH=CH), 7.44 (s, 1H, SCH=), 7.39 (m, 3H, 
ArH), 7.22 (dd, 1H, J=1.6 and 8.2 Hz, ArH), 6.28 (d, 1H, J=8.2 Hz, ArH), 6.74 (d, 1H, J=15.9 Hz, 
CH=CH), 3.83 (s, 3H, OCH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ 216.12, 173.47, 165.58, 154.37, 
150.70, 148.70, 148.42, 136.40, 129.32, 126.05, 124.54, 123.82, 116.28, 113.58, 112.27, 
56.45.HRMS (ESI): m/z calculated for C19H15O4S3 [M+H]+: 403.01325; found: 403.01282. 
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4.3.3 Caffeic acid derivatives 
 (E)-Methyl 3-(3,4-dihydroxyphenyl)acrylate (29) 
 
 
 
To a solution of caffeic acid (1 g, 5.51 mmol) dissolved in methanol (70 ml), concentrated H2SO4 
(2 ml, 37.53 mmol) was added dropwise at room temperature. The reaction was stirred at reflux 
for 2 h and was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/8.5:1.5). The solution was stripped off and the obtained residue was 
taken up with dichloromethane and washed three times with a solution of 5% NaHCO3 and then 
with brine. The organic layer was dried with anhydrous Na2SO4, filtered and evaporated to 
dryness to obtain the product (29) as a pale beige solid. Mp 156.9-160.4 °C. Yield: 99%. 1H NMR 
(300 MHz, DMSO-d6): δ 9.34 (br s, 2H, OH collapsed with D2O), 7.47 (d, 1H, J=15.9 Hz, CH=CH), 
7.04 (d, 1H, J=1.6 Hz, ArH), 6.99 (dd, 1H, J=1.6 and 8.2 Hz, ArH), 6.75 (d, 1H, J=8.2 Hz, ArH), 6.26 
(d, 1H, J=15.9 Hz, CH=CH), 3.68 (s, 3H, CH3) ppm.  
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(E)-Methyl 3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylate (72) 
 
 
 
To a solution of (E)-methyl 3-(3,4-dihydroxyphenyl)acrylate (compound 29, 500 mg, 2.58 mmol) 
in anhydrous tetrahydrofuran (6 ml) at 0 °C under nitrogen, 60% sodium hydride (w/v) in mineral 
oil (375 mg, 9.37 mmol) dissolved in anhydrous tetrahydrofuran (12 ml), was added dropwise. 
After 10 minutes 2-methoxyethoxymethyl chloride (1.30 g, 10.32 mmol) in anhydrous 
tetrahydrofuran (5 ml) was added slowly and the mixture was stirred at 0 °C for 5 h under inert 
atmosphere (TCL: eluent phase dichloromethane:methanol/9.5:0.5). After its completion a 
saturated solution of NH4Cl was added and the aqueous phase was extracted three times with 
dichloromethane. The combined organic extracts were dried with anhydrous Na2SO4, filtered and 
the solvent was evaporated under reduced pressure to provide a residue that was purified by CC 
(silica gel; ethyl acetate/cyclohexane in ratio 7:3; isocratic). The fractions containing the purified 
product were gathered up and the title compound was obtained as a yellow oil. Yield: 75%. 1H 
NMR (300 MHz, DMSO-d6): δ 7.56 (d, 1H, J=15.9 Hz, CH=CH), 7.48 (d, 1H, J=1.2 Hz, ArH), 7.31 (dd, 
1H, J=1.2 and 8.2 Hz, ArH), 7.12 (d, 1H, J=8.2 Hz, ArH), 6.49 (d, 1H, J=15.9 Hz, CH=CH), 5.27 (s, 4H, 
CH2), 3.85-3.62 (m, 7H, CH3 and CH2), 3.52-3.37 (m, 4H, CH2), 3.20 (s, 6H, CH3) ppm.  
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(E)-3-(3,4-Bis((2-methoxyethoxy)methoxy)phenyl)acrylic acid (73) 
 
 
 
(E)-Methyl 3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylate (compound 72, 1.33 g, 3.59 
mmol) dissolved in a mixture of tetrahydrofuran/methanol in ratio 4:1 (16 ml), was treated with 
a solution of 5N NaOH (4.3 ml). The resulting mixture was stirred at 40 °C for 3 h and it was 
monitored by thin layer chromatography (eluent phase dichloromethane:methanol/8:2). After 
the completion of reaction, the organic solvents were evaporated and the basic aqueous phase 
was washed with ethyl acetate in order to remove the unreacted ester. The aqueous solution 
was then acidified with 6N HCl and extracted three times with ethyl acetate. The combined 
organic extracts were dried with anhydrous Na2SO4, filtered and evaporated in vacuo to obtain a 
yellow oil which was crystallized with diethyl ether: (E)-3-(3,4-bis((2-
methoxyethoxy)methoxy)phenyl)acrylic acid (73) was obtained as white solid. Mp 56.6-58.3 °C. 
Yield: 98%. 1H NMR (300 MHz, DMSO-d6): δ 12.08 (s, 1H, COOH collapsed with D2O), 7.48 (d, 1H, 
J=15.9 Hz, CH=CH), 7.44 (d, 1H, J=1.5 Hz, ArH), 7.27 (dd, 1H, J=1.5 and 8.2 Hz, ArH), 7.12 (d, 1H, 
J=8.2 Hz, ArH), 6.38 (d, 1H, J=15.9 Hz, CH=CH), 5.26 (s, 4H, CH2O), 3.80-3.65 (m, 4H, CH2), 3.55-
3.38 (m, 4H, CH2), 3.21 (s, 6H, CH3) ppm.  
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3-(3,4-bis((2-Methoxyethoxy)methoxy)phenyl)acrylate esters (74, 76, 77) 
 
 
General procedure. (E)-3-(3,4-Bis((2-methoxyethoxy)methoxy)phenyl)acrylic acid (73, 355 mg, 1 
mmol) and the appropriate ROH (4, 11 and 12, 1 mmol) were mixed together in anhydrous 
dichloromethane or tetrahydrofuran (4 ml), and DCC (206 mg, 1 mmol) and a catalytic amount 
of DMAP were added. The reaction mixture was stirred for 5-20 h under inert atmosphere at 
room temperature. After the filtration of DCU, the solvent was evaporated under reduced 
pressure and the residue was taken up in ethyl acetate and washed three times first with a cold 
solution of 0.5N HCl, then with a cold solution of 5% (w/w) NaHCO3 and finally with cold brine. 
The organic layer was dried with anhydrous Na2SO4, filtered and the solvent was removed under 
reduced pressure. The resulting residue was purified by CC (silica gel; dichloromethane/methanol 
or ethyl acetate/cyclohexane in gradient as indicated for each compound). 
 
(E)-2-(Methylsulfonylthio)ethyl 3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylate (74). 
CC (silica gel; dichloromethane/methanol; in gradient up to 98.4:1.6). A yellow oil was obtained. 
Yield: 53%. 1H NMR (300 MHz, DMSO-d6): δ 7.59 (d, 1H, J=15.9 Hz, CH=CH), 7.50 (d, 1H, J=1.2 Hz, 
ArH), 7.32 (dd, 1H, J=1.2 and 8.2 Hz, ArH), 7.13 (d, 1H, J=8.2 Hz, ArH), 6.50 (d, 1H, J=15.9 Hz, 
CH=CH), 5.27 (s, 4H, CH2), 4.42 (t, 2H, J=6 Hz, CH2), 3.80-3.65 (m, 4H, CH2), 3.57 (s, 3H, CH3), 3.53 
(t, 2H, J=6 Hz, CH2), 3.50-3.38 (m, 4H, CH2), 3.21 (s, 6H, CH3) ppm. 
 
 
 
Chapter I: Experimental 
 
104 
(E)-2-(Allyldisulfanyl)ethyl 3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylate (76) and N-
acylurea by-product (78). (a) The raw yellow oil initially obtained partially crystallized in freezer; 
after dilution with ether and filtration, white crystals have been obtained, which resulted to be 
the N-acylurea (78). 
(b) The ethereal mothers, evaporated to dryness were purified through CC (silica gel; 
dichloromethane/methanol; in gradient up to 99:1) to achieve the title compound as a yellow oil 
(76).  
 
(E)-3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)-N-cyclohexyl-N-(cyclohexylcarbamoyl) 
acrylamide (78). Yield: 30%.1H NMR (300 MHz, CDCl3): δ = 7.58 (d, 1H, J=15.6 Hz, CH=CH), 7.34 
(d, 1H, J=1.4 Hz, ArH), 7.21 (d, 1H, J=8.2 Hz), 7.10 (dd, 1H, J=1.4 and 8.2 Hz, ArH), 7.05 (br s, 1H, 
NH collapsed with D2O), 6.61 (d, 1H, J=15.6 Hz, CH=CH), 5.33 (s, 2H, CH2), 5.30 (s, 2H, CH2) 4.10-
4.09 (m, 1H, CH), 3.87-3.83 (m, 4H, CH2), 3.75-3.73 (m, 1H, CH), 3.57-3.36 (s, 6H, OCH3), 1.99-1.58 
(m, 10H, CH), 1.41-1.14 (m, 10H, CH) ppm. 13C NMR (75 MHz, CDCl3): δ = 167.05, 154.09, 149.02, 
147.28, 143.10, 129.25, 122.93, 118.06, 116.31, 116.25, 94.63, 94.14, 77.01, 71.50, 71.47, 67.99, 
59.01, 56.28, 49.77, 32.78, 30.94, 26.29, 26.28, 25.45, 25.36, 24.66 ppm. 
 
(E)-2-(Allyldisulfanyl)ethyl 3-(3,4-bis((2-methoxyethoxy)methoxy)phenyl)acrylate (76). Yield: 
40%. 1H NMR (300 MHz, DMSO-d6): δ 7.56 (d, 1H, J=15.6 Hz, CH=CH), 7.48 (d, 1H, J=1.2 Hz, ArH), 
7.30 (dd, 1H, J=1.2 and 8.2 Hz, ArH), 7.11 (d, 1H, J=8.2 Hz, ArH), 6.49 (d, 1H, J=15.6 Hz, CH=CH), 
5.90-5.70 (m, 1H, CH=CH2), 5.40-5.00 (m, 6H, CH2 and CH=CH2), 4.35 (d, 2H, J=6.3 Hz, CH2), 3.85-
3.60 (m, 4H, CH2), 3.52-3.35 (m, 6H, CH2), 3.20 (s, 6H, OCH3), 3.01 (d, 2H,  J=6.3 Hz, CH2) ppm. 
 
(E)-4-(3-Thioxo-3H-1,2-dithiol-5-yl)phenyl 3-(3,4-bis((2-
methoxyethoxy)methoxy)phenyl)acrylate (77). CC (silica gel; ethyl acetate/cyclohexane; in 
gradient up to 37:63). A red oil was obtained which crystallized spontaneously in the fridge during 
the night. The solid was rinsed with petroleum ether to give orange crystals. Yield: 60%. Mp 81.4-
84.0 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.98 (d, 2H, J=8.8 Hz, ArH), 7.84-7.76 (m, 2H, CH=CH and 
SCH=), 7.59 (d, 1H, J=1.2 Hz, ArH), 7.47-7.32 (m, 3H, ArH), 7.17 (d, 1H, J=8.8, ArH), 6.76 (d, 1H, 
J=15.9 Hz, CH=CH), 5.30 (s, 4H, CH2), 3.78-3.70 (m, 4H, CH2), 3.50-3.41 (m, 4H, CH2), 3.21 (s, 6H, 
OCH3) ppm.  
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(E)-S-2-(3-(3,4-Bis((2-methoxyethoxy)methoxy)phenyl)acrylamido)ethyl 
methanesulfonothioate (75) 
 
 
 
S-2-Aminoethyl methanesulfonothioate hydrobromide (6, 101 mg, 0.65 mmol) and DIPEA (0.11 
ml, 0.65 mmol) were mixed together in anhydrous chloroform (4 ml) and (E)-3-(3,4-bis((2-
methoxyethoxy)methoxy)phenyl)acrylic acid (compound 73, 212 mg, 0.59 mmol), EDAC (107 mg, 
0.89 mmol) and DMAP (7.3 mg, 0.06 mmol) were added. The reaction mixture was stirred for 4 
h under argon at room temperature. The obtained residue was poured into a separation funnel, 
firstly washed with a cold solution of 0.5N HCl, then with a cold solution of 5% NaHCO3, finally 
with cold water and brine. The organic layer was dried with anhydrous Na2SO4, filtered and the 
solvent was removed under reduced pressure to obtain a yellow oil which crystallized 
spontaneously in the fridge during the night. The solid was rinsed with diethyl ether to give ash 
grey crystals. Yield: 80%. Mp 62.3-64.6 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.38 (s, 1H, NH 
collapsed with D2O), 7.38-7.30 (m, 2H, ArH and CH=CH), 7.17 (m, 2H, ArH), 6.46 (d, 1H, J=15.6 Hz, 
CH=CH), 5.26 (s, 4H, CH2O), 3.78-3.69 (m, 4H, CH2), 3.60-3.39 (m, 9H, CH3 and CH2), 3.32 (t, 2H, 
J=6.3 Hz, CH2), 3.20 (s, 6H, OCH3) ppm. 
  
Chapter I: Experimental 
 
106 
3-(3,4-Dihydroxyphenyl)acrylate esters (30, 32, 33) and amide (31) 
 
 
General procedure. To a solution of the appropriate 3-(3,4-dihydroxyphenyl)acrylate derivative 
(74-77, 0.42 mmol) in anhydrous dichloromethane or chloroform (2 ml), trifluoroacetic acid (0.32 
ml, 4.21 mmol) was added and the reaction mixture was stirred, under argon, at room 
temperature for 5-8 h. After the completion of reaction, the solvent and the trifluoroacetic acid 
were evaporated to dryness. The residue was washed with the solvents indicated for each 
compounds or purified by CC (silica gel, eluent as indicated for each compound). 
 
(E)-2-(Methylsulfonylthio)ethyl 3-(3,4-dihydroxyphenyl)acrylate (30). The solid residue washed 
with dichloromethane/petroleum ether (1:1) and dried in vacuo to afford the title compound as 
a white solid. Yield: 64%. Mp 133.1-134.8 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.61 (br s, 1H, OH 
collapsed with D2O), 9.13 (br s, 1H, OH collapsed with D2O), 7.50 (d, 1H, J=15.9 Hz, CH=CH), 7.04-
7.00 (m, 2H, ArH), 6.47 (d, 1H, J=8.9 Hz, ArH), 6.25 (d, 1H, J=15.9 Hz, CH=CH), 4.39 (t, 2H, J=6.3 
Hz, CH2), 3.56 (s, 3H, CH3), 3.51 (t, 2H, J=6.3 Hz, CH2) ppm. 13C NMR (75 MHz, d6-DMSO): δ 166.90, 
149.36, 146.59, 146.26, 126.07, 122.23, 116.43, 115.62, 113.90, 62.81, 50.89, 35.14. HRMS (ESI): 
m/z calculated for C12H15O6S2 [M+H]+: 319.03100; found: 319.03052. 
 
(E)-S-2-(3-(3,4-Dihydroxyphenyl)acrylamido)ethyl methanesulfonothioate (31). CC (silica gel; 
dichloromethane/methanol; in gradient up to 99:1). The purified product was obtained as a tan 
oil. Yield: 9%. 1H NMR (300 MHz, DMSO-d6): δ 8.25 (s, 2H, OH collapsed with D2O), 7.54 (s, 1H, 
NH collapsed with D2O), 7.42 (d, 1H, J=15.6 Hz, CH=CH), 7.08 (d, 1H, J=1.1 Hz, ArH), 6.95 (dd, 1H, 
J=1.1 and 8.2 Hz, ArH), 6.84 (d, 1H, J=8.2 Hz, ArH), 6.44 (d, 1H, J=15.6 Hz, CH=CH), 3.78-3.60 (m, 
2H, CH2), 3.49 (s, 3H, CH3), 3.41 (t, 2H, J=6.3 Hz, CH2) ppm. 13C NMR (75 MHz, DMSO-d6): δ 166.23, 
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147.91, 145.98, 140.18, 126.64, 120.99, 118.29, 116.19, 114.29, 50.69, 38.80, 35.81 ppm. HRMS 
(ESI): m/z calculated for C12H16NO5S2 [M+H]+: 318.04699; found: 318.04643.  
 
(E)-2-(Allyldisulfanyl)ethyl 3-(3,4-dihydroxyphenyl)acrylate (32). The obtained residue was 
taken up with dichloromethane and washed twice with iced-brine. The combined organic layers 
were dried with anhydrous Na2SO4, filtered and evaporated to dryness to obtain a residue that 
was purified by preparative TLC (silica gel; dichloromethane/methanol 10:0.4). The title 
compound was obtained as a green-grey oil. Yield: 42%. 1H NMR (300 MHz, acetone-d6): δ 8.45 
(s, 1H, OH collapsed with D2O), 8.17 (s, 1H, OH collapsed with D2O), 7.55 (d, 1H, J=15.2 Hz, 
CH=CH), 7.16 (s, 1H, ArH), 7.05 (dd, 1H, J=1.8 and 7.9 Hz, ArH), 6.86 (d, 1H, J=7.9 Hz, ArH), 6.28 
(d, 1H, J=15.2 Hz, CH=CH), 5.92-5.82 (m, 1H, CH=CH2), 5.25-5.11 (m, 2H, CH=CH2), 4.40 (t, 1H, 
J=6.6 Hz, CH2)*, 4.28 (t, 1H, J=6.6 Hz, CH2)*, 3.42 (d, 1H, J=7.1 Hz, CH2)*, 3.26 (d, 1H, J=7.1 Hz, 
CH2)*, 3.03 (t, 1H, J=6.3 Hz, CH2)*, 2.75 (t, 1H, J=6.3 Hz, CH2)* ppm. 13C NMR (75 MHz, acetone-
d6): δ 166.32, 147.95, 145.40, 145.28, 133.54, 126.63, 121.73, 118.00, 115.49, 114.37, 124.29, 
61.97, 41.67, 36.99 ppm. * The 1H NMR showed split signals for the enantiotropic hydrogens. 
HRMS (ESI): m/z calculated for C14H15O4S2 [M-H]-: 311.04118; found: 311.0395.  
 
(E)-4-(3-Thioxo-3H-1,2-dithiol-5-yl)phenyl 3-(3,4-dihydroxyphenyl)acrylate (33). The residue 
was dissolved in dichloromethane (1 ml) and crystallized with diethyl ether/methanol (9:1). The 
orange crystals were filtered and washed with the same bland (ethyl ether/methanol; 9:1) to 
provide the title compound as an orange solid. Yield: 54%. Mp 199.5-201.5 °C. 1H NMR (300 MHz, 
DMSO-d6): δ 9.72 (br s, 1H, OH collapsed with D2O), 9.18 (br s, 1H, OH collapsed with D2O), 7.97 
(d, 2H, J=8.5 Hz, ArH), 7.82 (s, 1H, SCH=), 7.71 (d, 1H, J=15.9 Hz, CH=CH), 7.37 (d, 2H, J=8.5, ArH), 
7.13-7.11 (m, 2H, ArH), 6.79 (d, 1H, J=8.2, ArH), 6.50 (d, 1H, J=15.9 Hz, CH=CH) ppm. 13C NMR (75 
MHz, DMSO-d6): δ 215.83, 173.20, 165.25, 154.11, 149.51, 148.24, 146.09, 136.12, 129.04, 
125.71, 123.60, 122.51, 116.23, 115.63, 112.79 ppm. HRMS (ESI-TOF): m/z calculated for 
C18H13O4S3 [M+H]+: 388.9976; found: 388.9972. 
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4.3.4 Cinnamic acid derivatives 
3-Phenylacrylic acids (79 and 80) 
 
 
 
General procedure. Benzaldehyde or 3,4-dimethoxybenzaldehyde (2.4 mmol) and malonic acid 
(375 mg, 3.6 mmol) were dissolved in piperidin (0.5 ml, 5.07 mmol) and charged into a 0.5-2 ml 
microwave vial. The mixture was stirred in a microwave reactor at 150 °C for 3 minutes. After 
cooling at room temperature, the mixture was slowly poured into water and crushed ice, acidified 
with 6N HCl and the precipitate was collected and isolated by filtration. The product cake was 
washed twice with cold water (15 ml each), then washed with petroleum ether and dried in 
vacuo.  
 
Cinnamic acid (79). A white-cream solid was obtained. Yield: 46%. Mp 132.0-134.2 °C. 1H NMR 
(300 MHz, DMSO-d6): δ 12.40 (s, 1H, COOH collapsed with D2O), 7.70-7.62 (m, 2H, ArH ), 7.57 (d, 
1H, J=15.9 Hz, CH=CH), 7.40-7.35 (m, 3H, ArH), 6.51 (d, 1H, J=15.9 Hz, CH=CH) ppm. 
 
(E)-3-(3,4-Dimethoxyphenyl)acrylic acid (80). A white solid was obtained. Yield: 63%. Mp 180.8-
183.2 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.16 (s, 1H, COOH collapsed with D2O), 7.50 (d, 1H, 
J=15.9 Hz, CH=CH), 7.29 (d, 1H, J=1.1 Hz, ArH), 7.18 (dd, 1H, J=1.1 and 8.2 Hz, ArH), 6.95 (d, 1H, 
J=8.2 Hz, ArH), 6.41 (d, 1H, J=15.9 Hz, CH=CH), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3) ppm. 
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2-(Methylsulfonylthio)ethyl 3,4-substitutedcinnamate (34-36) 
 
 
 
General procedure. To a solution of S-2-hydroxyethyl methanesulfonothioate (4, 200 mg, 1.28 
mmol) dissolved in anhydrous dichloromethane or tetrahydrofuran (5 ml), cinnamic acid (79) or 
(E)-3-(3,4-dimethoxyphenyl)acrylic acid (80), or (E)-3-(3,4-dichlorophenyl)acrylic acid (1.16 
mmol), DCC (264 mg, 1.28 mmol) and DMAP (12 mg, 0.1 mmol) were added. The reaction mixture 
was stirred for 1-4 h, at room temperature under inert atmosphere. After the completion of 
reaction, the DCU was filtered and the solution was evaporated under reduced pressure. The 
obtained residue was taken up with iced ethyl acetate and the residual DCU filtered. The organic 
solution was washed firstly with a cold solution of 0.5N HCl, then with a cold solution of 5% (w/w) 
NaHCO3 and finally with cold water and brine. The organic layer was dried with anhydrous 
Na2SO4, filtered and evaporated to dryness to get a residue that was purified as indicated for 
each compound. 
 
2-(Methylsulfonylthio)ethyl cinnamate (34). CC (silica gel; ethyl acetate/cyclohexane; in 
gradient up to 33:67). A yellow oil was obtained which crystallized spontaneously in the fridge 
during the night. The solid was rinsed with ethyl ether to give white-cream crystals. Yield: 62%. 
Mp 76.8-78.5 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.73 (d, 1H, J=15.9 Hz, CH=CH), 7.60-7.45 (m, 
2H, ArH), 7.45-7.35 (m, 3H, ArH), 6.43 (d, 1H, J=15.9 Hz, CH=CH), 4.52 (t, 2H, J=6 Hz, CH2), 3.50 (t, 
2H, J=6 Hz, CH2), 3.39 (s, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ 166.34, 145.71, 134.32, 
131.05, 129.39, 128.90, 117.86, 62.88, 50.67, 34.83 ppm. HRMS (ESI): m/z calculated for 
C12H15O4S2 [M+H]+: 287.04118; found: 287.04078. 
 
(E)-2-((Methylsulfonyl)thio)ethyl 3-(3,4-dimethoxyphenyl)acrylate (35). A colourless oily 
residue was crystallized from diethyl ether into cream-white crystals. Yield: 45%. Mp 99.8-102.7 
°C. 1H NMR (300 MHz, CDCl3): δ 7.67 (d, 1H, J=15.9 Hz, CH=CH), 7.12 (dd, 1H, J=1.2 and 8.4 Hz, 
ArH), 7.05 (d, 1H, J=1.2 Hz, ArH), 6.88 (dd, 1H, J=8.4 Hz, ArH), 6.30 (d, 1H, J=15.9 Hz, CH=CH), 4.51 
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(t, 2H, J=6.3 Hz, CH2), 3.92 (s, 6H, OCH3), 3.50 (t, 2H, J=6.3 Hz, CH2), 3.39 (s, 3H, CH3) ppm 13C NMR 
(75 MHz, CDCl3): δ 166.52, 151.33, 149.15, 145.80, 126.96, 122.84, 114.52, 111.04, 109.71, 62.23, 
55.90, 50.80, 35.11 ppm. HRMS (ESI): m/z calculated for C14H19O6S2 [M+H]+: 347.0623; found: 
347.06169. 
 
(E)-2-(Methylsulfonylthio)ethyl 3-(3,4-dichlorophenyl)acrylate (36). Yellow oily residue that 
was purified by CC (silica gel; cyclohexane/ethyl acetate in gradient up to 65:35). The obtained 
residue was crystallized with cold ethyl acetate and the solid was rinsed with petroleum ether to 
give white crystals. Yield: 38%. Mp 69.6-71.2 °C. 1H NMR (300 MHz, CDCl3): δ 7.67-7.55 (m, 2H, 
ArH and CH=CH), 7.48 (d, 1H, J=8.2 Hz, ArH), 7.53 (dd, 1H, J=1.6 and 8.2 Hz, ArH), 6.42 (d, 1H, 
J=15.9 Hz, CH=CH), 4.52 (t, 2H, J=6.3 Hz, CH2), 3.49 (t, 2H, J=6.3 Hz, CH2), 3.39 (s, 3H, CH3) ppm. 
13C NMR (75 MHz, CDCl3): δ 165.79, 143.19, 134.55, 134.09, 133.31, 130.96, 129.71, 127.14, 
118.88, 62.64, 50.95, 35.00 ppm. HRMS (ESI): m/z calculated for C12H13Cl2O4S2 [M+H]+: 
354.96323; found: 354.96278. 
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4.6 Celastrol hybrids 
Celastrol amides (37-40) 
 
 
General procedure. The appropriate amine (6 or 7 or methyl 3-(allylthio)-2-hydroxypropanoate 
or D-(+)-glucosamine hydrochloride, 0.12 mmol) and DIPEA or TEA (0.13 mmol) were dissolved 
in anhydrous N,N-dimethylformamide (1.5 ml) at 0 °C and celastrol (50 mg, 0.11 mmol), HOBt 
(15.9 mg, 0.12 mmol) and EDAC (23.40 mg, 0.12 mmol) were added. After ice bath removal, the 
reaction mixture was stirred at room temperature under nitrogen for 5-20 h. After the 
completion of reaction, the solution was evaporated under vacuum and the obtained residue 
was taken up dichloromethane or chloroform and washed two times with cold water. The organic 
layer was dried with anhydrous Na2SO4, filtered and evaporated to dryness. The crude mixture 
was purified as indicated for each compound.  
 
S-(2-((2R,4αS,6αS,12βR,14αS)-10-Hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-oxo-
1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-carboxamido)ethyl) 
methanesulfonothioate (37). CC (silica gel; cyclohexane/ethyl acetate; in gradient up to 43:57). 
The residue was washed several times with diethyl ether and petroleum ether: a red solid was 
obtained. Yield:  58%. Mp: 188.1-191.8 °C. 1H NMR (300 MHz, CDCl3): δ 7.05 (d, 1H, J=6.3 Hz, 
ArH), 6.57 (s, 1H, ArH), 6.37 (m, 2H, ArH and NH collapsed with D2O), 3.52-3.44 (m, 2H, CH2), 3.34 
(s, 3H, CH3), 3.26-3.22 (m, 2H, CH2), 2.45 (d, 2H, J=15.6 Hz, CH2), 2.22 (s, 3H, CH3), 2.15-1.48 (m, 
12H, CH2), 1.44 (s, 3H, CH3), 1.26 (s, 3H, CH3), 1.16 (s, 3H, CH3), 1.12 (s, 3H, CH3), 0.98-0.91 (m, 
1H, CH), 0.60 (s, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 178.74, 164.90, 145.97, 134.50, 
127.34, 119.40, 118.14, 117.40, 77.21, 65.83, 50.37, 45.09, 44.32, 43.12, 40.45, 39.42, 38.22, 
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36.29, 35.42, 34.94, 33.76, 33.52, 31.58, 31.03, 30.75, 29.94, 29.42, 28.63, 21.69, 18.48, 15.26, 
10.30 ppm. 
 
(2R,4αS,6αS,12βR,14αS)-10-Hydroxy-2,4α,6α,9,12β,14α-hexamethyl-N-(3-
(methylsulfonyl)propyl)-11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-
tetradecahydropicene-2-carboxamide (38). CC (silica gel; cyclohexane/ethyl acetate; in gradient 
up to 35:65). The solid was washed three times with a mixture of diethyl ether/ether petroleum 
(4:6) to get the final product as an orange solid. Yield: 61%. Mp: 178.4-181.9 °C. 1H NMR (300 
MHz, DMSO-d6): δ 8.66 (s, 1H, OH, collapsed with D2O), 7.64 (br s, 1H, NH, collapsed with D2O), 
7.05 (d, 1H, J=6.9 Hz, ArH), 6.39 (s, 1H, ArH), 6.33 (d, 1H, J=7.2 Hz, ArH), 3.42 (s, 3H, CH3), 3.11 (t, 
2H, J=7.1 Hz, CH2), 2.96 (t, 2H, J=7.1 Hz, CH2), 2.43 (d, 2H, J=15.6 Hz, CH2), 2.09-2.06 (m, 2H, CH2), 
2.07 (s, 3H, CH3), 2.01-1.47 (m, 12H, CH2), 1.37 (s, 3H, CH3), 1.20 (s, 3H, CH3), 1.06 (s, 3H, CH3), 
1.03 (s, 3H, CH3), 0.98-0.91 (m, 1H, CH), 0.51 (s, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 178.43, 
164.81, 146.00, 134.27, 127.39, 119.45, 118.09, 117.27, 77.19, 65.80, 50.54, 45.06, 44.34, 43.07, 
40.42, 39.39, 38.17, 37.41, 36.31, 34.99, 33.80, 33.73, 33.52, 31.58, 30.98, 30.80, 30.02, 29.43, 
29.36, 28.69, 21.73, 18.42, 15.23 ppm. 
 
Methyl 3-(allylthio)-2-((2R,4αS,6αS,12βR,14αS)-10-hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-
oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-
carboxamido)propanoate (39). CC (silica gel; dichloromethane/methanol; in gradient up to 95:5 
of methanol). The fractions containing the purified product were gathered up to provide a sticky 
orange solid which was crystallized with ethyl ether/petrol ether/cyclohexane (1:1:1). Yield: 64%. 
Mp 62.8-64.7 °C. 1H-NMR (300 MHz, DMSO-d6): δ 7.53 (s, 1H, OH, collapsed with D2O), 7.22 (d, 
1H, J=7.2 Hz, NH, collapsed with D2O), 7.10 (d, 1H, J=7.2 Hz, ArH), 6.44 (s, 1H, ArH), 6.43 (s, 1H, 
ArH), 5.80-5.60 (m, 1H, CH=CH2), 5.03 (dd, 2H, J=29.1 and 16.8 Hz, CH=CH2), 4.41 (t, 1H, J=6.75 
Hz, CH), 3.60 (s, 3H, OCH3), 3.10 (d, 2H, J=6.9 Hz, CH2), 2.90-2.82 (m, 2H, CH2), 2.28 (d, 2H, J=15.6 
Hz, CH2), 2.19 (s, 3H, CH3), 1.98-1.58 (m, 12H, CH2), 1.59 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.21 (s, 3H, 
CH3), 1.18 (s, 3H, CH3), 0.98-0.91 (m, 1H, CH), 0.70 (s, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 
177.87, 177.60, 171.45, 168.45, 164.29, 146.12, 133.89, 133.17, 127.24, 119.45, 118.05, 117.01, 
116.41, 52.15, 51.41, 44.84, 44.51, 42.49, 39.86, 39.30, 37.76, 36.45, 34.89, 34.28, 33.56, 32.77, 
31.74, 31.50, 31.09, 30.51, 30.45, 29.71, 22.43, 21.29, 18.07, 9.37 ppm. 
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(2R,4αS,6αS,12βR,14αS)-10-Hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-oxo-N-
((2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)-
1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-carboxamide (40). CC (silica 
gel; dichloromethane/methanol; in gradient up to 96.7:3.3). The fractions containing the purified 
compound were collected and washed with diethyl ether to obtain a red-orange solid. Yield: 22%. 
Mp: 185.4-187.8 °C. 1H NMR (300 MHz, acetone-d6): δ 7.54 (s, 1H, OH, collapsed with D2O), 7.13 
(d, 1H, J=6.3 Hz, ArH), 6.58 (br s, 1H, NH collapsed with D2O), 6.44 (s, 1H, ArH), 6.42 (s, 1H, ArH), 
5.66 (d, 1H, OH, collapsed with D2O), 5.12 (s, 1H, CH), 4.11 (d, 1H, OH, collapsed with D2O), 3.88 
(s, 1H, CH), 3.76-3.69 (m, 3H, CH2 and CH), 3.63-3.55 (m, 1H, CH), 3.42-3.27 (m, 2H, CH and OH 
collapsed with D2O), 2.76 (s, 1H, OH, collapsed with D2O), 2.53 (d, 1H, J=15.3 Hz, CH), 2.23 (s, 1H, 
CH), 2.17 (s, 3H, CH3), 1.99-1.53 (m, 12H, CH2), 1.43 (s, 3H, CH3), 1.29 (s, 3H, CH3), 1.21 (s, 3H, 
CH3), 1.14 (s, 3H, CH3), 0.98-0.91 (m, 1H, CH), 0.78 (s, 3H, CH3) ppm. 13C NMR (75 MHz, acetone-
d6): δ 178.24, 177.60, 178.06, 169.40, 164.33, 133.60, 127.16, 119.49, 118.02, 116.61, 91.37, 
72.03, 71.92, 71.88, 62.49, 61.99, 54.71, 44.85, 44.51, 42.63, 40.01, 39.33, 37.67, 36.43, 34.96, 
33.38, 33.30, 31.06, 30.95, 30.51, 29.91, 21.32, 21.23, 18.49, 9.36 ppm.  
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Celastrol esters (41 and 84) 
 
 
 
General procedure. 4-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (12) or HOBt (0.24 mmol) were 
added to a solution of celastrol (100 mg, 0.22 mmol), DCC (49.5 mg, 0.24 mmol) and DMAP (2.7 
mg, 0.02 mmol) previously dissolved in anhydrous dichloromethane or tetrahydrofuran (2.5-3 
ml). The reaction was stirred at room temperature for 2-20 h under inert atmosphere and it was 
monitored by thin layer chromatography (eluent phase dichloromethane:methanol/9.8:0.2). 
After its completion, the formed DCU was filtered and the solvent was stripped off in vacuo. The 
crude mixture was purified as indicated for each compound.  
 
(2R,4αS,6αS,12βR,14αS)-4-(3-Thioxo-3H-1,2-dithiol-5-yl)phenyl 10-hydroxy-2,4α,6α,9,12β,14α 
-hexamethyl-11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-
carboxylate (41). CC (silica gel; dichloromethane/methanol; in gradient up to 95.5:0.5). The 
fractions containing the purified product were gathered up and the final residue was washed 
with diethyl ether to obtain an orange crystal powder. Yield: 50%. Mp: 159.1-161.8 °C. 1H-NMR 
(300 MHz, DMSO-d6): δ 9.71 (s, 1H, OH, collapsed with D2O), 7.92 (d, J=8.7 Hz, 2H, ArH), 7.85 (s, 
1H, SCH=), 7.16 (d, J=8.7 Hz, 2H, ArH), 7.07 (d, J=6.6 Hz, 1H, ArH), 6.38 (s, 1H, ArH), 6.35 (d, J=6.6 
Hz, 1H, ArH), 2.25-2.09 (m, 2H, CH2), 2.07 (s, 3H, CH3), 1.91-1.43 (m, 12H, CH2), 1.39 (s, 3H, CH3), 
1.35 (s, 3H, CH3), 1.24 (s, 3H, CH3), 1.12 (s, 3H, CH3), 0.98-0.91 (m, 1H, CH), 0.65 (s, 3H, CH3) ppm. 
13C NMR (75 MHz, DMSO-d6): δ 215.84, 178.42, 176.41, 173.05, 167.78, 163.21, 153.95, 146387, 
136.18, 133.51, 129.22, 129.10, 127.34, 122.98, 120.64, 118.55, 117.59, 65.36, 44.87, 44.04, 
42.42, 40.94, 38.20, 36.43, 34.81, 33.36, 32.66, 31.78, 30.56, 29.76, 28.48, 24.63, 21.90, 19.24, 
15.61, 10.51 ppm 
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(2R,4αS,6αS,12βR,14αS)-1H-Benzo[d][1,2,3]triazol-1-yl 10-hydroxy-2,4α,6α,9,12β,14α-
hexamethyl-11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-
carboxylate (84). CC (silica gel; dichloromethane/methanol; in gradient up to 99.8:0.2). The 
fractions containing the product were gathered up and the final residue was washed with diethyl 
ether to obtain a red-orange crystal solid. Yield: 65%. Mp: 208.1-209.6 °C. 1H NMR (300 MHz, 
DMSO-d6): δ 8.74 (s, 1H, OH, collapsed with D2O), 8.09 (d, 1H J=8.4 Hz, ArH), 7.72-7.45 (m, 3H, 
ArH), 7.09 (d, 1H, J=7.2 Hz, ArH), 6.49-6.35 (m, 2H, ArH), 2.25-2.09 (m, 2H, CH2), 2.09 (s, 3H, CH3), 
1.93-1.43 (m, 12H, CH2),1.63 (s, 3H, CH3), 1.41 (s, 3H, CH3), 1.27 (s, 3H, CH3), 1.15 (s, 3H, CH3), 
1.05-0.91 (m, 1H, CH), 0.80 (s, 3H, CH3) ppm.  
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2-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-((2-((tert-
butoxycarbonyl)amino)ethyl)amino)-5-oxopentanoic acid (82) 
 
 
 
To a solution of folic acid (320 mg, 0.67 mmol) in dry dimethyl sulfoxide (12 ml), DCC (276.5 mg, 
1.34 mmol) and N-hydroxysuccinimide (NHS, 154.2 mg, 1.34 mmol) were added. The reaction 
mixture was stirred for 20 h in the dark at room temperature under inert atmosphere and its 
progress was monitored by thin layer chromatography (eluent phase chloroform:methanol:15% 
ammonia/4:4:1). After that, the precipitated DCU was filtered off, TEA (0.19 ml, 1.34 mmol) and 
N-Boc-ethylendiamine (0.21 ml, 1.34 mmol) were added to the filtrate containing the NHS-folate. 
The mixture has been stirred for 20 h in the dark under inert atmosphere. The product was 
precipitated by addition of a mixture of acetone/diethyl ether (1:4) and the thin yellow precipitate 
was carefully centrifuged and washed four times with acetone and two times with diethyl ether 
and finally dried under vacuum. A yellow solid was obtained. As previously described,176 the folic 
acid was conjugated with N-Boc-ethylendiamine almost exclusively in the terminal carboxylic acid 
(one main spot on TLC).  Yield: 76%. Mp: 183.1-191.3 °C. 1H NMR (300 MHz, DMSO-d6): δ 11.41 
(br s, 1H, OH), 10.56 (br s, 1H, NH), 8.64 (s, 1H, ArH), 8.02 (br s, 1H, NH), 7.78-7.28 (m, 2H, ArH), 
7.12 (br s, 1H, NH), 6.69-6.41 (m, 3H, ArH and NH), 4.48 (s, 3H, CH2 and CH), 3.06-2.72 (m, 4H, 
CH2), 2.30-1.70 (m, 6H, CH2 and NH2), 1.31 (s, 9H, CH3) ppm.  
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2-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-((2-
aminoethyl)amino)-5-oxopentanoic acid (83) 
 
 
 
Compound 82 (150 mg, 0.31 mmol) was dissolved in trifluoroacetic acid (TFA, 1 ml) at 0 °C and 
the reaction mixture was stirred for 1 h at room temperature. After that, TFA was removed under 
reduced pressure with the aid of dichloromethane and the red-dark residue was dissolved in a 
minimal amount of dry N,N-dimethylformamide. The addition of TEA resulted in the precipitation 
of a yellow powder which was washed and centrifuged and washed three times with acetone and 
three times with diethyl ether. A yellow solid was obtained. Yield: 50%. 1H NMR (300 MHz, DMSO-
d6): δ 10.55 (br s, 1H, OH), 8.62 (br s, 1H, NH), 8.02 (s, 1H, ArH), 8.02 (br s, 1H, NH), 7.66-7.31 (m, 
2H, ArH), 7.12 (br s, 1H, NH), 6.99-6.88 (m, 3H, ArH and NH), 6.64 (m, 2H, NH2), 4.48 (s, 2H, CH2), 
4.32 (s, 1H, CH), 2.91-2.80 (m, 4H, CH2), 2.43-2.10 (m, 6H, CH2 and NH2) ppm.  
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2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)ethanaminium 2,2,2-trifluoroacetate (85) 
 
 
(9H-fluoren-9-yl)methyl tert-butyl ethane-1,2-diyldicarbamate (528 mg, 1.38 mmol) was 
dissolved into a solution of 50% TFA in dichloromethane (12 ml): the reaction mixture was stirred 
at room temperature for 30 minutes and its progress was monitored by thin layer 
chromatography (eluent phase cyclohexane:ethylacetate/1:1). After that, the solvent and the 
acid were evaporated in vacuo and the obtained sticky oil was crystallized with dichloromethane 
and rinsed two times with diethyl ether providing a white crystal solid. Yield: 99%. Mp: 108.8-
113.5 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.88 (d, 2H J=7.5 Hz, ArH), 7.71 (br s, 2H, NH2 collapsed 
with D2O), 7.66 (d, 2H J=7.5 Hz, ArH), 7.43-7.29 (m, 5H, ArH and NH collapsed with D2O), 4.35 (d, 
2H J=6.6 Hz, CH2), 4.23-4.20 (m, 1H, CH), 3.20-3.18 (m, 2H, CH2), 2.83-2.80 (m, 2H, CH2) ppm.   
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(2R,4αS,6αS,12βR,14αS)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)ethyl 10-hydroxy-
2,4α,6α,9,12β,14α-hexamethyl-11-oxo-1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-
tetradecahydropicene-2-carboxylate (86) 
 
 
Celastrol (100 mg, 0.22 mmol), HOBt (44.6 mg, 0.33 mmol), EDAC (63.3 mg, 0.33 mmol) were 
dissolved in anhydrous dichloromethane (5 ml) and after cooling the solution to 0 °C, TEA (85 μl, 
0.61 mmol) and compound 85 (110.9 mg, 0.28 mmol) were added. The mixture was stirred for 4 
h at room temperature under argon atmosphere and the reaction was monitored by thin layer 
chromatography (eluent phase dichloromethane:methanol/10.2:0.8). After that, the residue was 
purified with a CC (silica gel; dichloromethane/methanol; in gradient up to 98:2). The fractions 
containing the product were gathered up and the final residue was washed with diethyl ether to 
obtain a red-orange crystal solid. Yield: 75%. Mp: 198.3.1-199.6 °C. 1H NMR (300 MHz, acetone-
d6): δ 8.61 (br s, 1H, OH collapsed with D2O), 7.91 (d, 2H J=7.8 Hz, ArH), 7.63 (d, 2H J=6.9 Hz, ArH), 
7.55 (br s, 1H, NH2 collapsed with D2O), 7.41-7.26 (m, 4H, ArH), 7.19 (br s, 1H, NH2 collapsed with 
D2O), 6.90 (d, 1H J=6.6 Hz, ArH), 6.35 (s, 1H, ArH), 6.19 (d, 1H J=6.6 Hz, ArH), 4.26-4.15 (m, 3H, 
CH and CH2), 3.03-2.48 (m, 4H, CH2), 2.38 (d, 2H, J=14.1 Hz, CH2), 2.10 (s, 3H, CH3), 1.74-1.45 (m, 
12H, CH2), 1.41 (s, 3H, CH3), 1.16 (s, 3H, CH3), 1.04 (s, 3H, CH3), 1.01 (s, 3H, CH3), 0.87-0.82 (m, 
1H, CH), 0.48 (s, 3H, CH3) ppm.   
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(2R,4αS,6αS,12βR,14αS)-2-aminoethyl 10-hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-oxo-
1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-carboxylate (87) 
 
 
Compound 86 (35 mg, 0.048 mmol) was dissolved in N,N-dimethylformamide (1 ml) and 
piperidine (15 μl, 0.12 mmol) was added at 0 °C. The reaction mixture was stirred for 1 h at room 
temperature and its progress was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/9:1). After that, the solvent was stripped off and the red residue was 
taken up in ethyl acetate and washed (two times) with water. The organic layer was dried with 
anhydrous Na2SO4, filtered and evaporated to dryness to obtain an oil which was rinsed with 
plentiful diethyl ether. An orange solid was obtained. Yield: 84%. 1H NMR (300 MHz, acetone-d6): 
δ 7.59 (br s, 1H, OH collapsed with D2O), 7.10 (d, 1H J=7.1 Hz, ArH), 7.05 (br s, 1H, NH2 collapsed 
with D2O), 3.03-3.21 (m, 4H, CH2), 2.50 (d, 2H, J=14.1 Hz, CH2), 2.19 (s, 3H, CH3), 2.01-1.52 (m, 
12H, CH2), 1.62 (s, 3H, CH3), 1.30 (s, 3H, CH3), 1.08 (s, 3H, CH3), 1.06 (s, 3H, CH3), 0.98-0.91 (m, 
1H, CH), 0.81 (s, 3H, CH3) ppm.   
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2-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-((2-
((2R,4αS,6αS,12βR,14αS)-10-hydroxy-2,4α,6α,9,12β,14α-hexamethyl-11-oxo-
1,2,3,4,4α,5,6,6α,11,12β,13,14,14α,14β-tetradecahydropicene-2-carboxamido)ethyl)amino)-
5-oxopentanoic acid (42) 
 
Procedure (a). To a solution of compound 84 (75 mg, 0.13 mmol) and DIPEA (0.057 ml, 0.32 mmol) 
in dry N,N-dimethylformamide (3.2 ml), compound 83 (63 mg, 0.13 mmol) was added. The 
reaction mixture was stirred for 15 h at room temperature under inert atmosphere and its 
progress was monitored by thin layer chromatography (eluent phase chloroform:methanol:15% 
ammonia/4:4:1). The mixture was filtered and the solid was rinsed firstly with acetone, then with 
a solution of methanol/acetone (1:5) and finally with ethyl ether obtaining a red solid. Yield: 45%.  
Procedure (b). To a solution of compound 87 (20 mg. 0.04 mmol) and DIPEA (0.057 ml, 0.32 mmol) 
in dry N,N-dimethylformamide (1.5 ml), 81 (21.8 mg, 0.04 mmol) was added. The reaction 
mixture was stirred for 16 h at room temperature under inert atmosphere and its progress was 
monitored by thin layer chromatography (eluent phase chloroform:methanol:15% 
ammonia/4:4:1). The mixture was filtered and the solid was rinsed firstly with acetone, then with 
a solution of methanol/acetone (1:5) and finally with ethyl ether obtaining a red solid. Yield: 50%.  
Mp: 229.0-236.1°C. 1H NMR (300 MHz, DMSO-d6): δ 11.43 (br s, 1H, OH collapsed in D2O), 10.56 
(br s, 1H, NH), 8.65 (s, 1H, OH, collapsed with D2O), 8.64 (s, 1H, ArH), 8.01-7.79 (m, 3H, NH), 7.68-
7.30 (m, 3H, ArH and NH), 7.05 (s, 1H, ArH), 6.91 (br s, 2H, NH2), 6.63 (s, 2H, ArH), 6.38-6.21 (m, 
2H, ArH), 4.46 (s, 2H, CH2), 4.28 (s, 1H, CH), 2.96 (s, 6H, CH2), 2.78 (s, 2H, CH2), 2.25-2.09 (m, 2H, 
CH2), 2.06 (s, 3H, CH3), 1.89-1.41 (m, 12H, CH2), 1.33 (s, 3H, CH3), 1.18 (s, 3H, CH3), 1.09 (s, 3H, 
CH3), 1.01 (s, 3H, CH3), 0.95-0.91 (m, 1H, CH), 0.47 (s, 3H, CH3). HRMS (ESI): m/z calculated for 
C50H61N9O8 [M+H]+: 915.46431; found 916.47158.  
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4.7 Rosmaricine and derivatives 
2H-10,4α-(Epoxymethano)phenanthren-12-one, 9-amino-1,3,4,9,10,10α-hexahydro-5,6-
dihydroxy-1,1-dimethyl-7-(1-methylethyl)-(4αR-(4α,9α,10α,10β))- 
 amides (43, 44, 45) 
 
 
 
General procedure. To a solution of the appropriate sulfurated acid (14, 1, 9, 0.29 mmol) in 
anhydrous N,N-dimethylformamide (1 ml) under argon and at 0 °C, HOBt (39.2 mg, 0.29 mmol), 
N,N-diisopropylethylamine (0.05 ml, 0.29 mmol) and EDAC (55.6 mg, 0.29 mmol) were added. 
After 5 minutes, rosmaricine (100 mg, 0.29 mmol) was added. The temperature was maintained 
at 0 °C with stirring for 2.5-6 h. After the completion of reaction, the solution was evaporated 
under reduced pressure. The obtained residue was taken up with ethyl acetate and washed firstly 
with a cold solution of 0.5N HCl, then with a cold solution of 5% NaHCO3, finally with cold brine. 
The organic layer was dried with anhydrous Na2SO4, filtered and evaporated to dryness. The 
crude mixture was purified as indicated for each compound.  
 
Compound 43. The green oil obtained was crystallized with a solution of diethyl ether, ethyl 
acetate and dichloromethane (in ratio 1:1:1) and rinsed with diethyl ether for several times to 
obtain a white solid. Yield: 38%. Mp 121.1-124.2 °C (dec.). 1H NMR (300 MHz, DMSO-d6): δ 8.44 
(br s, 2H, NH collapsed with D2O), 8.22 (br s, 2H, OH collapsed with D2O), 6.46 (s, 1H, ArH), 4.83 
(d, 1H, J=5.1 Hz, CH), 4.33 (s, 1H), 3.47 (s, 3H), 3.23-3.15 (m, 5H), 2.18-2.12 (m, 3H), 1.76-1.51 (m, 
6H), 1.37-1.28 (m, 2H), 1.14-1.05 (m, 6H), 0.88 (s, 3H), 0.76 (s, 3H) ppm. 13C NMR (75 MHz, 
acetone-d6): 176.89, 171.57, 144.35, 141.62, 136.06, 126.58, 124.26, 118.59, 75.60, 50.69, 50.50, 
49.83, 46.55, 38.15, 35.58, 34.89, 31.09, 30.89, 28.60, 27.55, 26.60, 24.47, 22.22, 21.98, 21.29, 
18.91 ppm. HRMS (ESI): m/z calculated for C26H38NO7S2 [M+H]+: 540.2090; found 540.2080. 
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Compound 44. The green oil was crystallized with diethyl ether and rinsed with the same solvent 
for three times to provide 15 mg of pure product. Moreover the liquid filtrate was purified by CC 
(silica gel; dichloromethane/methanol; in gradient up to 99.6:0.4). The fractions containing the 
purified product were gathered up to provide the final product as a light green-olive solid. Yield: 
24%. Mp 206.9.-209.2 °C. 1H NMR (300 MHz, acetone-d6): δ 8.57 (br s, 1H, NH collapsed with 
D2O), 8.26 (br s, 2H, OH collapsed with D2O), 6.74 (s, 1H, ArH), 5.92-5.83 (m, 1H), 5.21-5.10 (m, 
2H), 5.04 (t, 1H, J=3.6 Hz), 4.57 (d, 1H, J=3.6 Hz), 3.40 (d, 2H, J=7.2 Hz) 3.33-3.10 (m, 3H), 3.03 (t, 
2H, J=6.3 Hz), 2.67 (t, 2H, J=6.2 Hz), 2.08 (s, 1H), 2.03-1.87 (m, 1H), 1.57-1.43 (m, 3H), 1.22-1.14 
(m, 6H), 1.00 (s, 3H), 0.88 (s, 3H) ppm. 13C NMR (75 MHz, acetone-d6): δ 176.87, 169.96, 144.32, 
141.65, 136.05, 133.68, 126.42, 124.26, 118.70, 117.89, 75.61, 50.73, 50.59, 46.53, 41.49, 38.18, 
35.17, 34.01, 31.11, 30.88, 27.55, 26.60, 22.25, 21.93, 21.32, 18.91 ppm. HRMS (ESI): m/z 
calculated for C26H36NO5S2 [M+H]+: 506.2035; found 506.2026. 
 
Compound 45. The crude residue was crystallized with a solution of ethyl acetate/diethyl ether 
(1:3). The resulting orange solid was purified by CC (silica gel; dichloromethane/methanol; in 
gradient up to 99:1). The fractions containing the purified product were rounded up and firstly 
crystallized with few drops of ethyl acetate and a solution of diethyl ether/petroleum ether (1:1). 
The solid was rinsed with diethyl ether/petroleum ether (1:1) to get orange crystals 
corresponding to the desired product. Yield: 19%. Mp 243.2-249.7 °C. 1H NMR (300 MHz, 
acetone-d6)*: δ 9.12 (s, 1H), 8.04 (d, 2H, J=7.4 Hz), 7.72 (d, 2H, J=7.4 Hz), 6.82 (s, 1H), 5.28 (s, 1H), 
4.72 (s, 1H), 3.50-3.20 (m, 2H), 1.70-1.35 (m, 4H), 1.35-1.05 (m, 8H), 0.99 (s, 3H), 0.92 (s, 3H) ppm. 
13C NMR (75 MHz, DMSO-d6): 214.00, 177.83, 166.26, 160.35, 156.14, 147.62, 145.25, 142.57, 
136.87, 129.22, 128.23, 127.84, 127.56, 126.06, 124.49, 118.41, 76.27, 60.19, 50.93, 49.92, 46.65, 
38.25, 31.40, 26.63, 23.18, 22.82, 21.95, 19.23 ppm. HRMS (ESI): m/z calculated for C30H32NO5S3 
[M+H]+: 582.1443; found 582.1447. 
 
* The 1H NMR didn’t show the catecolic group maybe because of its interaction with the 
deuterate solvent. 
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4.9 Heterocyclic derivatives 
(4-(4-(4-(Trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-yl)phenyl)methanaminium 
chloride (89) 
 
 
 
Tert-butyl (4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-yl)benzyl)carbamate 
(compound 88, 100 mg, 0.22 mmol) was dissolved in 4N HCl in 1,4-dioxane (1 ml) at 0 °C. The 
reaction mixture was stirred for 30 minutes at room temperature and it was monitored by 
thin layer chromatography (eluent phase dichloromethane:methanol/8.5:1.5). The solution 
was evaporated under reduced pressure and the obtained residue washed with ethyl ether. 
The obtained hydrochloride acid salt was used without further purification. 
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S-5-(4-(4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-ylcarbamoyl)phenylamino)-5-oxopentyl 
methanesulfonothioate (49) 
 
 
 
EDAC (23 mg, 0.12 mmol), DMAP (1 mg, 0.01 mmol) and 4-amino-N-(4-(4-chlorophenyl)-1,2,5-
oxadiazol-3-yl)benzamide (93, 25 mg, 0.08 mmol) were added to a solution of 5-
(methylsulfonylthio)pentanoic acid (1, 18 mg, 0.09 mmol) dissolved in anhydrous N,N-
dimethylformamide (1 ml). The reaction mixture was stirred for 24 h at room temperature under 
inert atmosphere and it was monitored by thin layer chromatography (eluent phase 
ethylacetate:cyclohexane/9:1). After the completion of reaction, the solution was evaporated 
under reduced pressure. The obtained residue was taken up with dichloromethane and washed 
firstly with a cold solution of 0.5N HCl, then with a cold solution of 5% NaHCO3, finally with cold 
water and brine. The organic layer was dried with anhydrous Na2SO4, filtered and evaporated to 
dryness to obtain a residue that was purified by CC (silica gel; ethyl acetate/cyclohexane; in 
gradient up to 40:60). The title compound was obtained as a grey-white solid. Yield: 7%. Mp 
194.8-198.1 °C. 1H NMR (300 MHz, acetone-d6): δ 10.28 (br s, 1H, NH collapsed with D2O), 9.51 
(br s, 1H, NH collapsed with D2O), 8.00 (d, 2H, J=8.8 Hz, ArH), 7.91-7.80 (m, 4H, ArH), 7.55 (d, 2H, 
J=8.8 Hz, ArH), 3.45 (s, 3H, CH3), 3.29 (t, 2H, J=6.6 Hz, CH2), 2.50 (t, 2H, J=6.6 Hz, CH2), 1.97-1.84 
(m, 4H, CH2) ppm. HRMS (ESI): m/z calculated for C21H22ClN4O5S2 [M+H]+: 509.0720; found 
509.0712. 
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4-(4-(4-(Trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-yl)phenyl 5-
(methylsulfonylthio)pentanoate (48) 
 
 
 
To a solution of N-(4-(4-hydroxyphenyl)-1,2,5-oxadiazol-3-yl)-4-(trifluoromethyl) benzamide (92, 
45 mg, 0.13 mmol), DCC (29 mg, 0.14 mmol) and DMAP (1.6 mg, 0.01 mmol) in anhydrous 
tetrahydrofuran (1.5 ml), 5-(methylsulfonylthio)pentanoic acid (1, 30 mg, 0.14 mmol) was added. 
The reaction mixture was stirred for 4 h at room temperature under inert atmosphere and it was 
monitored by thin layer chromatography (eluent phase ethylacetate:cyclohexane/1:1). After its 
completion, the formed DCU was filtered and the solvent evaporated. The obtained residue was 
crystallized with cold dichloromethane and rinsed firstly with cold diethyl ether and then with a 
solution of dichloromethane/methanol (9.5:0.5) to get the title compound as a white solid. The 
filtrate was evaporated to dryness and the residue was purified by CC (silica gel; ethyl 
acetate/cyclohexane in ratio 8:2; isocratic). The fractions containing the purified product were 
gathered up to provide a white solid. Yield: 48%. Mp 157.1-158.6 °C. 1H NMR (300 MHz, acetone-
d6): δ 10.59 (br s, 1H, NH collapsed with D2O), 8.25 (d, 2H, J=8.4 Hz, ArH), 7.95-7.88 (m, 4H, ArH), 
7.30 (d, 2H, J=8.4 Hz, ArH), 3.44 (s, 3H, CH3), 3.30 (t, 2H, J=7.1 Hz, CH2CO), 2.70 (t, 2H, J=7.1 Hz, 
CH2), 2.03-1.82 (m, 4H, CH2) ppm. 13C NMR (75 MHz, acetone-d6): δ 170.99, 165.24, 152.81, 
150.96, 149.95, 136.41, 128.91, 128.89, 125.68, 123.15, 122.58, 49.84, 35.45, 32.94, 28.93, 23.35 
ppm. HRMS (ESI): m/z calculated for C22H21F3N3O6S2 [M+H]+: 544.0824; found 544.0816. 
  
Chapter I: Experimental 
 
127 
S-5-Oxo-5-(4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-yl)benzylamino)pentyl 
methanesulfonothioate (47) 
 
 
 
N-(4-(4-(Aminomethyl)phenyl)-1,2,5-oxadiazol-3-yl)-4-(trifluoromethyl)benzamide (89, 50 mg, 
0.11 mmol) and 5-(methylsulfonylthio)pentanoic acid (1, 25.5 mg, 0.12 mmol) were mixed 
together in anhydrous N,N-dimethylformamide (1 ml) and after cooling at 0 °C, TBTU (42 mg, 
0.13 mmol) was added. After ice-bath removal, N-methylmorpholine (0.012 ml, 0.11 mmol) was 
added dropwise until pH turned to 8. The reaction mixture was stirred overnight at room 
temperature under inert atmosphere and it was monitored by thin layer chromatography (eluent 
phase dichloromethane:methanol/9:1). After the completion of reaction, the solution was 
evaporated under reduced pressure. The obtained residue was taken up with dichloromethane 
and washed firstly with a cold solution of 0.5N HCl, then with a cold solution of 5% NaHCO3, finally 
with cold water and brine. The organic layer was dried with anhydrous Na2SO4, filtered and the 
solvent was stripped off to obtain a residue which was rinsed three times with diethyl ether to 
provide white-cream crystals. Yield: 42%. Mp 179.4-181.3 °C. 1H NMR (300 MHz, acetone-d6): δ 
10.55 (br s, 1H, NH collapsed with D2O), 8.25 (d, 2H, J=8.4 Hz, ArH), 7.93 (d, 2H, J=8.1 Hz, ArH), 
7.78 (d, 2H, J=8.1 Hz, ArH), 7.61 (br s, 1H, NH collapsed with D2O), 7.42 (d, 2H, J=8.4 Hz, ArH), 
4.43 (d, 2H, J=6.0 Hz, CH2), 3.41 (s, 3H, CH3), 3.23 (t, 2H, J=6.9 Hz, CH2), 2.30 (t, 2H, J=6.9 Hz, CH2), 
1.84-1.71 (m, 4H, CH2) ppm. 13C NMR (75 MHz, acetone-d6): δ 171.82, 165.22, 151.42, 149.73, 
142.86, 136.27, 134.21, 128.91, 127.94, 127.54, 125.73, 124.17, 49.84, 42.19, 35.60, 34.79, 28.93, 
24.24 ppm. HRMS (ESI): m/z calculated for C23H24F3N4O5S2 [M+H]+: 557.1140; found 557.1132 
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4-(3-Thioxo-3H-1,2-dithiol-4-yl)-N-(4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-
yl)benzyl)benzamide (46) 
 
 
 
N-(4-(4-(Aminomethyl)phenyl)-1,2,5-oxadiazol-3-yl)-4-(trifluoromethyl)benzamide (89, 31 mg, 
0.08 mmol) and 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (14, 21.6 mg, 0.09 mmol) were mixed 
together in anhydrous N,N-dimethylformamide (1 ml) and after cooling at 0 °C, TBTU (30 mg, 0.1 
mmol) was added. After ice-bath removal, the reaction mixture was treated dropwise with N-
methylmorpholine (0.01 ml, 0.08 mmol) until pH turned to 8. The reaction mixture was stirred 
for 20 h at room temperature under inert atmosphere and it was monitored by thin layer 
chromatography (eluent phase dichloromethane:methanol/10:0.5). After the completion of 
reaction, the solution was evaporated under reduced pressure. The obtained residue was taken 
up with ethyl acetate and washed firstly with a cold solution of 0.5N HCl, then with a cold solution 
of 5% NaHCO3, finally with cold water and brine. The organic layer was dried with anhydrous 
Na2SO4, filtered and evaporated to dryness to obtain a residue which was rinsed three times with 
a solution of diethyl ether/dichloromethane (1:1) to get an orange solid. Yield: 78%. Mp 119.2-
124.5 °C. 1H NMR (300 MHz, acetone-d6): δ 10.58 (br s, 1H, NH collapsed with D2O), 9.10 (s, 1H, 
SCH=), 8.41 (br s, 1H, NH collapsed with D2O), 8.24 (d, 2H, J=8.4 Hz, ArH), 8.00 (d, 2H, J=8.6 Hz, 
ArH), 7.91 (d, 2H, J=8.4 Hz, ArH), 7.81 (d, 2H, J=8.6 Hz, ArH), 7.72 (d, 2H, J=8.2 Hz, ArH), 7.52 (d, 
2H, J=8.4 Hz, ArH), 4.68 (d, 2H, J=4.2 Hz, CH2) ppm. 13C NMR (75 MHz, acetone-d6): δ 214.20, 
166.06, 157.71, 151.40, 149.61, 147.73, 142.70, 136.25, 134.61, 129.02, 128.90, 128.03, 127.61, 
127.36, 127.08, 125.70, 124.58, 124.21, 119.07, 109.40, 42.68 ppm. HRMS (ESI): m/z calculated 
for C27H18F3N4O3S3 [M+H]+: 599.0493; found 599.0497. 
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(4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-yl)methyl 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoate (50) 
 
 
 
To a solution of 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (14, 53.4 mg, 0.21 mmol) in 
anhydrous N,N-dimethylformamide (1.25 ml) under inert atmosphere, EDAC (54.8 mg, 0.29 
mmol), DMAP (3.3 mg, 0.02 mmol) and (4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)methanol (90, 
40 mg, 0.19 mmol) were added. The reaction mixture was stirred for 24 h at room temperature 
under inert atmosphere and it was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/10:0.3). After the completion of reaction, the solution was 
evaporated under reduced pressure. The obtained residue was taken up with ethyl acetate and 
washed firstly with a cold solution of 0.5N HCl, then with a cold solution of 5% NaHCO3 and finally 
with cold water and brine. The organic layer was dried with anhydrous Na2SO4, filtered and 
evaporated to dryness to obtain a residue that was purified by CC (silica gel; dichloromethane; 
isocratic). The fractions containing the purified product were gathered up and the amorphous 
solid obtained was crystallized with petroleum ether/dichloromethane (2:0.5) and rinsed with 
the same blend to provide the title compound as an orange crystal solid. Yield: 63%. Mp 135.2-
134.5 °C. 1H NMR (300 MHz, CDCl3): δ 8.47 (s, 1H, SCH=), 8.02 (d, 2H, J=8.2 Hz, ArH), 7.72 (d, 2H, 
J=8.2 Hz, ArH), 7.62 (d, 2H, J=8.2 Hz, ArH), 7.48 (d, 2H, J=8.2 Hz, ArH), 5.65 (s, 2H, CH2) ppm. 13C 
NMR (75 MHz, DMSO-d6): δ 214.05, 165.24, 161.11, 153.71, 151.14, 147.29, 139.37, 136.64, 
130.93, 130.12, 129.95, 129.82, 128.94, 124.35, 56.65 ppm. HRMS (ESI): m/z calculated for 
C19H12ClN2O3S3 [M+H]+: 446.9693; found 446.9691. 
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(4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-yl)methyl 5-(methylsulfonylthio)pentanoate (51) 
 
 
 
(4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-yl)methanol (90, 40 mg, 0.19 mmol) was added to a 
solution of 5-(methylsulfonylthio)pentanoic acid (1, 54 mg, 0.25 mmol), DCC (64 mg, 0.31 mmol) 
and DMAP (2.3 mg, 0.02 mmol) in anhydrous dichloromethane (2 ml). The reaction was stirred 
for 20 h at room temperature under nitrogen atmosphere and it was monitored by thin layer 
chromatography (eluent phase cyclohexane:ethylacetate/8:2). After the filtration of the 
obtained DCU, the residue was taken up with dichloromethane and washed firstly with a cold 
solution of 0.5N HCl, then with a cold solution of 5% NaHCO3, finally with iced water and brine. 
The organic layer was dried with anhydrous Na2SO4, filtered and evaporated to dryness and the 
crude product was purified by preparative silica-TLC using dichloromethane/methanol (10:0.4) 
as eluent mixture. The title compound was obtained as a colourless oil. Yield: 35%. 1H NMR (300 
MHz, CDCl3): δ 7.65 (d, 2H, J=9 Hz, ArH ), 7.51 (d, 2H, J=8.7 Hz, ArH), 5.40 (s, 2H, CH2), 3.31 (s, 3H, 
CH3), 3.14 (t, 2H, J=7.3 Hz, CH2), 2.39 (t, 2H, J=7.3 Hz, CH2), 1.79-1.72 (m, 4H, CH2) ppm. 13C NMR 
(75 MHz, CDCl3): δ 171.89, 148.95, 137.35, 129.68, 129.49, 123.66, 54.88, 50.70, 35.81, 32.96, 
29.69, 28.90, 23.40 ppm. HRMS (ESI): m/z calculated for C15H21ClN3O5S2 [M+NH4]+: 422.06057; 
found 422.0606. 
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(5-(4-Chlorophenyl)-1-methyl-1H-imidazol-4-yl)methyl 4-(3-thioxo-3H-1,2-dithiol-4-
yl)benzoate (52) 
 
 
 
To a solution of 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (14, 37.5 mg, 0.15 mmol) in 
anhydrous N,N-dimethylformamide (1.25 ml) under inert atmosphere, EDAC (38.5 mg, 0.20 
mmol), DMAP (3.3 mg, 0.02 mmol) and (5-(4-chlorophenyl)-1-methyl-1H-imidazol-4-yl)methanol 
(91, 30 mg, 0.14 mmol) were added. The reaction mixture was stirred overnight at room 
temperature under inert atmosphere and it was monitored by thin layer chromatography (eluent 
phase dichloromethane:methanol/10:0.5). The solution was evaporated under reduced pressure 
and the obtained residue was taken up with dichloromethane and washed firstly with a cold 
solution of 0.5N HCl, then with a cold solution of 5% NaHCO3, finally with water and brine. The 
organic layer was dried with anhydrous Na2SO4, filtered and evaporated to dryness to get a 
residue that was purified by CC (silica gel; dichloromethane/methanol; in gradient up to 99.2:0.8). 
The amorphous solid obtained was crystallized with ethyl acetate/diethyl ether (0.3:1) and rinsed 
with the same mixture to reach the final product as an orange crystal solid. Yield: 59%. Mp 149.9-
152.1 °C. 1H NMR (300 MHz, CDCl3): δ 8.45 (s, 1H, SCH=), 8.07 (d, 2H, J=8.8 Hz, ArH), 7.59-7.55 
(m, 3H, ArH), 7.43 (d, 2H, J=8.8 Hz, ArH), 7.30 (d, 2H, J=8.5 Hz, ArH), 5.22 (s, 2H, CH2), 3.57 (s, 3H, 
CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ 214.10, 165.76, 165.76, 160.97, 147.48, 138.83, 
134.07, 133.89, 132.07, 131.26, 130.12, 129.86, 129.65, 129.51, 128.32, 61.15, 32.84 ppm. HRMS 
(ESI): m/z calculated for C21H16ClN2O2S3 [M+H]+: 459.0062; found 459.0055. 
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(5-(4-Chlorophenyl)-1-methyl-1H-imidazol-4-yl)methyl 5-((methylsulfonyl)thio)pentanoate 
(53) 
 
 
 
(5-(4-Chlorophenyl)-1-methyl-1H-imidazol-4-yl)methanol (91, 40 mg, 0.18 mmol) was added to a 
solution of 5-(methylsulfonylthio)pentanoic acid (1, 42 mg, 0.20 mmol), DCC (45 mg, 0.18 mmol) 
and DMAP (2.2 mg, 0.018 mmol), previously dissolved in anhydrous N,N-dimethylformamide (1.5 
ml). The reaction mixture was stirred for 20 h at room temperature under inert atmosphere and 
it was monitored by thin layer chromatography (eluent phase 
dichloromethane:methanol/10.8:0.2). After the completion of reaction, the DCU formed was 
filtered and the solvent was removed under reduced pressure. The obtained residue was than 
taken up with dichloromethane and washed firstly with a cold solution of 0.5N HCl, then with a 
cold solution of 5% NaHCO3, finally with cold water and brine. The organic layer was dried with 
anhydrous Na2SO4, filtered and evaporated to dryness to get an sticky oil that was purified by CC 
(silica gel; dichloromethane/methanol; in gradient); the product eluted with 0.1% of methanol. 
The fractions containing the purified product were rounded up to provide the product (53) as a 
pale yellow-green oil. Yield: 28%. 1H NMR (300 MHz, CDCl3): δ 7.45 (d, 2H, J=9 Hz, ArH), 7.30 (d, 
2H, J=9 Hz, ArH), 5.28 (s, 2H,CH2), 3.58 (s, 3H,CH3), 3.31 (s, 3H, SO2CH3), 3.14 (t, 2H, J=6.9 Hz, 
CH2CO), 2.39 (t, 2H, J=6.9 Hz, CH2), 1.79-1.72 (m, 4H, CH2) ppm. 13C NMR (75 MHz, CDCl3): δ 
172.71, 135.20, 133.62, 131.24, 129.19, 126.69, 60.43, 59.52, 50.74, 47.40, 36.03, 33.31, 32.55, 
28.91, 23.66 ppm. HRMS (ESI): m/z calculated for C17H21N2O4S2ClNa [M+Na]+: 439.0523; found 
439.0531. 
 
Chapter I: Biological Assays 
 
133 
5. BIOLOGICAL ASSAYS 
In vitro studies on the cytotoxicity assay and the Luciferase Reporter promoter activity assay have 
been carried out in the laboratory of Prof. Nicola Ferri, Department of Pharmacological and 
Biomolecular Sciences of the University of Milan. AlphaScreen-based assay and the STAT3 
Luciferase reporter gene assay have been performed in the laboratory of Prof. Akira Asai, School 
of Pharmaceutical Sciences of the University of Shizuoka (Japan). 
 
5.1 AlphaScreen-based assay  
AlphaScreen is a bead-based non-radioactive assay system for detecting biomolecular 
interactions in a microliter plate format. It is a technology capable of analysing protein-protein 
or protein-peptide interactions and it is an useful method to detect the interactions between the 
STAT3-SH2 domain and the pTyr-containing peptide.180 In details, sandwich antibody complexes 
are captured by streptavidin-coated donor bead and acceptor beads, bringing them into close 
proximity: the acceptor beads emitted their respective signals only when they were in close 
proximity to the donor beads, which meant that the labelled phosphorylated peptide and 
the biotinylated STAT protein were bound. Indeed the excitation of the donor bead provokes the 
release of a singlet oxygen molecules that triggers a cascade of energy transfer in the acceptor 
bead, resulting in a fluorescent signal between 520 and 620 nm (Figure 32). On the contrary, if 
the tested compound shows to directly bind the SH2 domain, it means that the pTyr-containing 
peptide is not able to interact with STAT3 and, for this reason, the donor bead and acceptor beads 
are distant from each other providing a lower fluorescence emission. In conclusion, with this 
assay it is possible to evaluate the percentage inhibition of STAT3, parameter directly correlated 
to the fluorescence emission. The AlphaScreen-based assays were performed in a final reaction 
volume of 25 μl of the assay buffer containing 10 mM HEPES-NaOH (pH 7.4), 50 mM NaCl, 1 mM 
EDTA (pH 8.0), 0.1% NP-40, and 10 ng/μl BSA in a 96-well microtiter plate at 25 °C. The Phospho-
Tyr (pTyr) peptide probes used in this study were 5-carboxyfluorescein (FITC)-GpYLPQTV for 
STAT3, which is able to selectively bind STAT3-SH2 domain reproducing the physiological STAT3 
monomer, and (FITC)-GpYDKPHVL for STAT1. The protocol procedure involves the incubation of 
75 nM SH2-containing protein with a test compound for 15 minutes. Each protein sample was 
then incubated for 90 min with 50 nM of its corresponding FITC-pTyr peptide, and mixed with 
streptavidin-coated donor beads and anti-FITC acceptor beads simultaneously before detection 
at 570 nm using EnVison Xcite (PerkinElmer). 
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Figure 32. Schematic diagram of the multiplexed AlphaScreen-based assay for STAT3. Adapted from181 
 
5.2 Cytotoxicity assay (MTT) on HCT-116 cell line 
The MTT assay is a colorimetric test which allows to estimate the number of live cells present in 
the culture and, in this case, it is performed on colon cancer human cell line (HCT-116). These 
cells are seeded in 48-well plates, at the concentration of 40.000 cells per well, which are 
incubated with McCOY's medium containing 10% FCS and, after 24 h, this is replaced by a 
McCOY's medium containing only 0.4% FCS, in order to minimize the results variability and to 
limit cell proliferation. After 24 h, the compounds are added to the cells in increasing 
concentrations and then they are incubated for 48 h. After that, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Figure 33), which is a yellow tetrazole able to reduce to 
purple formazan in living cells, is added. The yellow tetrazolium MTT is reduced by metabolically 
active cells, in part by the action of dehydrogenase enzymes. The formazan, product of the MTT 
tetrazolium, stays as an insoluble precipitate inside live cells and it is quantifiable by 
spectrophotometry (absorbance usually between 500 and 600 nm, depending on the solvent 
used). The medium is aspirated from each well and the crystals are dissolved with a solution of 
0.05N HCl isopropanol solution: now it is possible to evaluate the intensity of the dark blue/violet 
colouration and consequently the number of living cell in each well using the spectrophotometer 
at a 595 nm wavelength. The antiproliferative activity of the tested compounds is expressed as 
percentage of cell viability, measured by the colour intensity, compared to the control.182 
STAT3 binding (AlphaScreen) 
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Figure 33. Conversion of MTT in formazan.  
 
5.3 NfkB Luciferase Reporter promoter activity assay 
The Luciferase Reporter assay is a technique able to measure in vitro the activity, in this specific 
test, of NFkB signalling pathway. A commonly used reporter gene is the Luciferase gene from the 
firefly Photinus pyralis. This gene encodes an enzyme which is able, in presence of ATP, oxygen 
and Mg++, to oxidize luciferins into a fluorescent product (oxyluciferin) that can be quantified by 
measuring the released light (Figure 34). The emitted luminescence can be then detected by a 
luminometer (or β-counter) which is directly correlated to the transcriptional activation of 
luciferase, and then, to the NfkB activity.  
In particular, to measure the NFkB promoter activity, HCT-116 cells were seeded in 100 mm dish 
and transiently transfected with 6 g of DNA (NFkB plasmid, containing Luciferase Reporter 
gene181 with turbofect reagent (Carlo Erba Reagents). After 24 h, cells were seeded in 48-well 
plates (40.000 cells per well). On the next day, cells were incubated with our compounds for 2 h 
(pre-treatment) and then TNF-, physiological NfkB promoter, was added in every well at (10 
ng/ml). The tested compounds, potential inhibitors of NfkB, should decrease the NfkB 
transcriptional activity as well as of TNF-, which lead to a reduction of luciferase activity. After 
5-6 h, luciferase activity was measured by using Neolite reagent (PerkinElmer Life Sciences) 
according to the manufacturer’s instructions:183 greater is the registered emitted luminescence 
and higher is the gene expression of NfkB. 
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Figure 34. Schematic diagram of Luciferase Reporter promoter activity assay. Adapted from184 
 
5.4 STAT3 Luciferase Reporter gene assay 
Similarly to the Luciferase Reporter technique, STAT3 reporter assay is able to measure the 
transcriptional activity of STAT3 homodimers and STAT3/STAT1 heterodimers. Indeed, using a 
simple dual-Luciferase assay, it is possible to monitor the activity of the STAT3 signaling pathway 
and to understand the behavior of new chemical compounds on this pathway.  STAT3 reporter 
assay is a mixture of Luciferase construct under the control of multiple SIE (promoter sequence 
that induces the transcription of genes associated to cell growth and apoptosis) and a 
constitutively expressing Retinilla construct.185 
In particular, to measure the STAT3 promoter activity, STAT3 reporter HeLa stable cell lines 
(Signosis Inc) were incubated in a 96-well microplate for 24 hours. Cells were pretreated with 
test compounds for 2 hours, and 10 ng/ml (w/v) of oncostatin M were applied and incubated for 
4 hours. After that, cells were washed with medium not supplemented with phenol red, and 
Steady-Glo® reagent (Promega) was applied. After 15 minutes incubation, the signals were 
detected by ARVO Light 1420 (PerkinElmer Life Sciences). The relative signal intensity was 
calculated in each well as the ratio for the mean signal of vehicle.  
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6. RESULTS AND DISCUSSION 
The new sulfurated-drug hybrids together with their parent compounds have been submitted to 
the AlphaScreen-based assay,180 to investigate their ability to bind STAT3 directly, through the 
evaluation of the inhibition of the binding of SH2-containing proteins to their correspondent 
phosphopeptides, the physiological ligands. Moreover, in order to check the selectivity of action 
of our molecules on STAT3, their ability to interact with SH2-domain of STAT1, a family member 
protein exhibiting a high degree of sequence homology to STAT3 and tumor suppressive 
properties in many systems, has also been tested. In addition, the cytotoxic activity (MTT 
assay)182 of these compounds on HCT-116 cell line (a human colon carcinoma cell line which 
expresses high levels of STAT3)186 was also evaluated. Finally, the most active compounds were 
also submitted to the Luciferase promoter activity assay,183 to measure their ability to inhibit 
NFkB promoter activity. Moreover, the inhibition of STAT3 transcriptional activity by some of the 
most interesting hybrids, using a Luciferase Reporter gene assay is still under evaluation and, 
presently, only preliminary results are available for few compounds.185 
6.1 S3I-201 and related compounds 
Compound S31-201, the thiosulfonic analogue 15 and compound 17 were tested in vitro with 
the AlphaScreen-based assay:180 the results are expressed as % of protein inhibition at 30 µM 
and 3 µM or as IC50 (µM) (Table 1). In addition, the cytotoxic activity182 of these compounds on 
HCT-116 cell line was also tested and the results, expressed as IC50 (µM) and % cell viability at 
100 µM, are reported in Table 1. 
Table 1: STAT3 and STAT1 inhibitory activity and cytotoxicity on HCT-116 cell line of 15, 17 and parent 
compounds. 
 STAT3 STAT1 HCT-116 
Compound % inhibition 
IC50 
(µM)±SD 
% inhibition 
IC50 
(µM)±SD 
% cell 
viability 
IC50 
(µM)±SD 
  30 µM 3 µM   30 µM 3 µM   100 µM   
15 58.4±1.1 46.0±0.8 4.9±0.4 39.6±0.8 18.0±0.2 >30 100.1±3.4 NA 
17 41.8±0.9 n.t. >30 n.t. n.t. n.t. 35.6±3.8 26.3±11.6 
3 53.9±1.4 105.6±3.8 71.1±13.2 n.t. n.t. n.t. 106.56±25.2 NA 
S3I-201 7.2±1.7 n.t. >30 n.t. n.t. n.t. 9.14±2.5 39.5±7.7 
NA = not active up to 200 µM 
n.t. = not tested 
The new S3I-201 analogue (15) resulted to better interact with the STAT3-SH2 domain compared 
to the parent compound (58.4% versus 7.2% of inhibition at 30 µM respectively): this finding 
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indicates that the introduction of thiosulfonate moiety can favour the binding to STAT3-SH2 
domain, whereas the parent drug (3) was completely devoid of this activity at the highest 
concentration tested (30 µM). Unfortunately, compound 15 did not exhibit any cytotoxic effect 
up to 200 µM, suggesting that it does not reach the target in whole cells, maybe for its low 
stability or for permeability reasons, which should be better explored. Interestingly, compound 
17, characterized by an unusual sulfurated functionality, moderately inhibited STAT3-SH2 
domain at 30 µM (41.8% of inhibition) and exhibited a good cytotoxic activity on HCT-116 cell 
line (IC50=26.3±11.6 µM) which is comparable to that of S3I-201 and therefore it is worthy of 
further investigation.  
 
3.1 Curcumin and cinnamic acids derivatives 
The results from the AlphaScreen-based assay,180 expressed as % of protein inhibition at 30 µM 
or as IC50 (µM), the inhibition of the NFkB transcriptional activity on HCT-116 cell line, indicated 
as IC50 (µM), and the antiproliferative activity on HCT-116 cells, quantified as IC50 (µM) and % cell 
viability at 100 µM)182 for the new curcumin, cinnamic acid hybrids and for their parent 
compounds, are reported in Table 2 and Table 3. Unfortunately, studies on STAT3 reporter gene 
activity are still ongoing. Moreover, it should be noted that it was not possible to test compound 
22 because of its low solubility in conventional organic solvents, in the culture medium and low 
stability in DMSO.  
Table 2. Biological activities of curcumin (18-21), its hybrids and sulfurated parent compounds. 
 STAT3 STAT1 HCT-116 NFkB 
 
Compound 
% 
inhibition 
±SD 
IC50 
(µM) 
±SD 
% 
inhibition 
±SD 
IC50 
(µM) 
±SD 
% cell 
viability 
±SD 
IC50 
(µM) 
±SD 
IC50 
(µM) 
±SD 
 30 µM  30 µM  100 µM   
Curcumin -4.8±2.4 - -38.9±1.9 - 1.3±0.3 26.6±4.4 54.3±3.6 
18 101.0±0.1 0.3±0.0 98.7±0.2 4.6±0.2 18.7±2.0 60.2±3.3 NA 
19 50.2±3.2 29.8±6.3 -14.5±5.2 >30 80.9±6.1 NA n.t. 
20 45.6±0.7 >30 22.1±3.3 >30 94.4±36.6 NA n.t. 
21 49.2±3.1 >30 25.5±1.9 >30 91.27±7.6 NA n.t. 
1 72.5±4.8 4.7±1.1 n.t. >3a 68.5±20.1 NA NA 
8 3.8±2.8 >30 n.t. n.t. 101.7±5.4 NA n.t. 
2 99.6±0.1 1.9±0.2 70.8±1.2 20.1±0.4 71.5±10.9 NA n.t. 
9 43.9±3.6 >30 n.t. n.t. 100.0±0.8 NA n.t. 
14 101.2±6.0 >100 n.t. n.t. 71.3±8.7 157.2±41.7 NA 
n.t. = not tested 
NA = not active up to 100 µM 
ainhibition at 3 µM: 8.6±1.7% 
Chapter I: Results and Discussion 
 
139 
Table 3. Biological activities of ferulic, caffeic and other cinnamic acids, their hybrids (23-33) and 
sulfurated parent compounds. 
 STAT3 STAT1 HCT-116 NFkB 
 
Compound 
% 
inhibition 
±SD 
IC50  
(µM)  
±SD 
% 
inhibition 
±SD 
IC50 
(µM) 
±SD 
% cell 
viability 
±SD 
IC50  
(µM) 
±SD 
IC50  
(µM) 
±SD 
 30 µM  30 µM  100 µM   
FA 0.2±8.2 >30 n.t. n.t. 143.2±4.0 NA NA 
23 2.1±2.3 >30 n.t. n.t. 87.7±7.4 NA n.t. 
24 110.1±0.2 0.9±0.0 110.5±0.6 7.0±0.7 24.6±4.5 50.42±5.9 116.25±2.9 
25 100.0±0.1 0.3±0.0 86.0±6.7 1.8±0.4 6.7±1.5 64.35±9.1 94.01±4.6 
26 107.8±0.1 1.8±0.5 4.1±5.4 >30 105.7±17.9 NA n.t 
27 67.9±0.8 7.8±0.6 12.0±4.7 >30 87.2±11.5 NA n.t. 
28 51.3±0.7 28.5±0.7 44.2±1.9 >30 75.2±17.4 NA NA 
CA 11.0±5.4a >30 n.t. n.t. 92.8±23.8 NA NA 
29 12.8±1.1 >30 n.t. n.t. 33.9±4.5 90.8 n.t. 
30 100.1±0.1 0.8±0.2 85.7±4.3 17.0±1.2 63.0±6.1 123.2±17.3 127.84±8.9 
31 99.8±0.1 0.9±0.1 -17.8±0.3 >30 95.5±23.2 NA n.t.  
32 70.0±1.7 5.5±0.2 37.7±7.5 >30 25.4±4.6 72.98±8.0 163.29±11.1 
33 66.7±0.5 13.2±0.9 21.5±1.8 >30 10.9±0.7 46.73±4.1 40.61±3.0 
74 100.0±0.1 0.6±0.1 98.4±0.9 6.3±0.5 128.4±7.5 NA n.t. 
75 100.1±0.1 1.1±0.0 63.3±0.5 19.5±0.3 n.t. n.t. n.t. 
34 100.0±0.0 0.5±0.0 100.3±0.2 3.6±0.4 60.9±5.2 95.22±8.9 NA 
35 99.7±0.1 0.3±0.0 68.9±10.2 20.9±4.9 78.7±12.7 NA n.t. 
36 100.0±0.1 0.3±0.0 103.8±1.7 1.9±0.2 107.2±15.5 NA n.t. 
4 11.6 >30 n.t. n.t. 99.1±14.8 NA NA 
5 88.4±0.5 4.4±0.3 73.7±1.4 8.6±0.7 69.90±5.1 NA n.t. 
11 55.7±2.5 22.2±3.0 11.7±6.0 >30 80.8±3.4 NA n.t. 
6 -10.2b >30 n.t. >3c 88.3±3.8 NA n.t. 
12 43.7 >30 n.t. n.t. 37.7±19.0 71.24±15.0 36.7±11.4 
n.t. = not tested 
NA = not active up to 100 µM 
aInhibition at 300 µM: 61.8 ±2.5% 
bInhibition at 3 µM: 46.8±10.1% 
cInhibition at 3 µM: 14.5±7.1% 
 
Results showed that most of the new hybrids were able to strongly and selectively bind STAT3-
SH2 domain, whereas the parent polyphenolic drugs were devoid of this ability at the tested 
concentrations. Some of them were also able to moderately inhibit the NFkB transcriptional 
activity on HCT-116 cell line and inhibited HCT-116 cell proliferation in vitro with IC50 in 
micromolar range. It is worth noting that the curcumin diester 18 displayed a potent STAT3 
inhibition (IC50=0.3 µM) and a moderate cytotoxicity (IC50=60.24 µM) even if its high MW (757 
Da) could in some way hamper the protein binding and/or the cell permeation. Since STAT3 
inhibition has been tested in a cell-free assay, not always there is a correspondence between the 
potency of STAT3 inhibition and cytotoxicity, probably due to not optimal physicochemical 
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properties of the tested compounds, such as solubility and chemical stability in the culture 
medium and cell permeation. This aspect needs to be deeply studied in the future. 
In particular, all the methanthiosulfonate-drug hybrids showed a strong and selective inhibitory 
activity on STAT3 compared to STAT1, with IC50 in submicromolar range. Interestingly, their 
correspondent not sulfurated parent compounds, curcumin, ferulic acid and caffeic acid did not 
bind, at least at the tested concentrations, the STAT3-SH2 domain, confirming that they are not 
direct STAT3 inhibitors and that they act on other steps of STAT3 pathway.  
Even the parent sulfurated compounds 1 and 4-6 were much weaker inhibitors than the 
corresponding drugs hybrids, possibly for its higher hydrophilicity or too small size.  
It is worth noting that the methyl ester 2 exhibited a higher activity than the corresponding free 
acid 1, and the 4-(methanesulfonylthio)-butanol 5 was more active than the 2-
(methanesulfonylthio)ethanol 4. In both cases, the activity was increasing with the increasing 
lipophilicity of the whole molecule. The same observation holds for the feruloyl esters 25 and 24 
of the homologous alcohols. Moreover, the valuable IC50 value (0.3 µM) of 25 is shared by the 
3,4-dimethoxy- (35) and 3,4-dichlorocinnamic (36) esters of 2-(methanesulfonylthio)ethanol that 
were more lipophilic than the remaining esters considered. Indeed, the STAT3 inhibitory activities 
of the variously substituted cinnamic esters were confined within a rather narrow range (IC50 
from 0.3 µM to 0.9 µM), that includes also the IC50 value (0.7 µM) of the corresponding ester of 
the non-aromatic valproic acid, previously described.142 Thus, a valuable inhibition of STAT3 
seems mainly linked to the methanethiosulfonyl moiety, provided that a suitable degree of 
lipophilicity is warranted to the molecule, while the phenolic residue addresses the molecule to 
the other relevant targets.  
The activity of the unsubstituted cinnamic ester 34 is competitive with that of the caffeic and 
ferulic esters, suggesting that the phenolic function (and the consequent antioxidant activity) is 
not essential for a valid inhibitory action on the relevant parameters. This observation is further 
supported (at least concerning STAT inhibition) by the results of non phenolic 3,4-disubstituted 
cinnamic esters 35, 36, 74 and 75. Therefore, other esters of aromatic and aliphatic acids with 
methanesulfonylthioethanol and butanol could display interesting levels of STAT3 inhibition, 
deserving thorough evaluation. On the other hand, the esterification of caffeic and ferulic acids 
with methanol, while increasing lipophilicity did not improve their poor STAT3 inhibitory activity; 
however, a slight increase of cytotoxicity was observed in the case of caffeic acid methyl ester 29 
(IC50 =80.8±9.4 µM). 
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The IC50 values on STAT3 and STAT1 of the thiosulfonate subset of compounds (but also for the 
others) did not run parallel, indicating that the structural and physico-chemical requirements to 
hit the two proteins are rather different; particularly, it is observed that the two potent STAT3 
inhibitors 25 and 36 were only moderately selective (ratio IC50 for STAT1/IC50 for STAT3=6 and 
6.3, respectively), but the other potent STAT3 inhibitor 35 was ten-fold more selective (ratio 
IC50s=69.7 µM). 
As far as allyldisulfide derivatives, they seem to interact in a weaker way than 
methanthiosulfonates with the STAT3-SH2 domain. However, the caffeic acid derivative 32, 
besides STAT3 inhibition (IC50=5.5 µM), showed also NFkB inhibitory activity and antiproliferative 
activity on HCT-116 cells, thus exhibiting interesting properties to be further investigated for a 
potential multitarget anticancer activity. Dithiolethione drug hybrids were the weakest inhibitors 
on STAT3-SH2 domain compared to the corresponding methanethiosulfonate and allyldisulfide 
derivatives, however, the caffeic acid derivative 33, exhibited a very good profile, inhibiting both 
the transcription factors (STAT3: IC50=13.2 µM; NFkB: IC50=40.67 µM) and the HCT-116 cell 
proliferation (IC50=33.8 µM) at comparable concentrations.  
Finally, compound 8, which is the equivalent sulfone of compound 1, resulted unable to directly 
interact with STAT3-SH2 domain confirming that the methanethiosulfonate moiety is essential 
for the inhibition of the protein.  
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3.1 Celastrol hybrids 
The ability of celastrol hybrids to interact with STAT3 (and STAT1) has been determined by the 
AlphaScreen-based assay180 and through the Luciferase Reporter gene assay. The results, 
expressed as IC50 (µM), are reported in Table 4, together with the data regarding the 
antiproliferative activity on HCT-116182 cell line, expressed as IC50 (µM). 
 
Table 4: STAT inhibitory activity and cytotoxicity on HCT-116 cell line of celastrol and its hybrids 
(37-42). 
 AlphaScreen-based assay Cytotoxicity 
Reporter 
Assay 
 STAT3 STAT1 HCT-116 STAT3 
 
Compound 
% 
inhibition 
±SD 
IC50  
(µM)  
±SD 
% 
inhibition 
±SD 
IC50  
(µM) 
±SD 
IC50  
(µM) 
±SD 
IC50  
(µM) 
±SD 
 30 µM  30 µM    
37 100.1±0.0 0.6±0.1 99.1±0.0 6.5±0.2 7.3±0.6 28.9±3.6 
38 100.1±0.0 0.4±0.1 99.4±0.2 5.1±0.5 6.9±0.5 17.4±0.5 
39 100.8±0.2 0.9±0.1 46.0±1.4 >30 5.1±0.6 3.6±0.3 
40 100.1±0.0 0.6±0.1 53.5±1.5 23.3±2.3 10< IC50<25* >30 
41 0.5±0.1 1.0±0.1 n.t. n.t. NA n.t. 
42 99.7±0.0 1.0±0.1 39.5±3.3 >30 157.1±14.5 >30 
celastrol 88.5** 0.6±0.1 81.1±0.6 6.9±0.2 2.9±0.3 4.3±0.3 
n.t. = not tested 
NA = not active up to 100 μM 
* % cell viability of 12.2±2.26 at 25 µM 
** Average of two experiments 
The results from the AlphaScreen assay showed that all the tested new hybrids strongly interacted 
with the STAT3 SH2 domain with IC50 comparable with that of celastrol. Interestingly, compounds 
39, 40 and 42 demonstrated an improved selectivity toward STAT3. Data from the STAT3 reporter 
assay confirmed the good inhibitory activity for the sulfurated compounds, whereas the two 
hydrophilic derivatives 40 and 42 were not active. Concerning cytotoxicity, the 
methanethiosulfonates 37 and 38 and the allylcysteine derivative 39 appear to be only slightly 
less active than celastrol, whereas the dithiolethione derivative 41 resulted devoid of any activity 
on this cell line, maybe due to its very low solubility in the cell culture medium. Coherently with 
their gene reporter activity above mentioned, the moderate cytotoxicity of the glucosamine 
derivative 40 suggests that the introduction of a too hydrophilic moiety is not useful for the 
antiproliferative activity and this hypothesis seems to be confirmed by compound 42 which 
showed a very low cytotoxicity on HCT-116 cell line (IC50=157.05 µM). 
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Compound 42 was also tested on human osteotropic cell lines, MDA-MB-231 (breast cancer, 
osteolytic) and SaOs-2 (osteosarcoma, osteoblastic and osteolytic) in the laboratory of Dr. Aymen 
Idris at Department of Oncology and Metabolism, University of Sheffield (UK).  
The results indicate that the celastrol-folate conjugate (42) is less cytotoxic than the parent 
celastrol, although it is more cytotoxic than folic acid (Figure 35a and 35b). These results, which 
are in contrast with the hypothesis that folic acid hybrid can more easily drive drugs into cancer 
cells, may be due to an excessive stability of the amide linkage between celastrol and the 
ethylenediamine (spacer), which probably requires too much time to be hydrolysed to release 
the free active compound into the cells. Of course, this aspect needs to be fully investigated, while 
other kinds of celastrol-folate hybrids, endowed with a different stability, will be designed and 
synthesized in future by our research group. 
Figure 35. The activity of compound 42 on (a) human MDA-MB-231 (breast cancer cells) and (b) human 
SaOs2 (osteosarcoma cancer cells) in vitro. All the results are expressed in µM.  
(b) 
(a) 
42 
42 
42 
42 
42 
42 
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3.2 Rosmaricine and derivatives  
Rosmaricine and its new sulfurated derivatives were submitted to the AlphaScreen-based 
assay,180 in order to check their ability to interact with STAT3 and STAT1. Moreover, they were 
tested in vitro to evaluate the inhibition of the NfkB transcriptional activity on HCT-116 cell line 
and the inhibition of STAT3 reporter activity on HeLa cell lines, submitting them to the Luciferase 
Reporter gene assay. The results, expressed as % of protein inhibition at 3 µM or 30 µM and as 
IC50 (µM) are showed in Table 5. In addition, their antiproliferative activity on HCT-116 cell line 
was quantified as % cell viability at 100 µM as IC50 (µM) (Table 6). Finally, compound 44 was also 
tested on MCF-7 (human breast adenocarcinoma, cell line that does not overexpress STAT3) and 
on hSMC (human smooth muscle cells) cell lines to test its selectivity versus healthy cells (Table 
6).182 
Table 5: In vitro STAT3 and STAT1 SH2-domain inhibitory activity and inhibition of NFkB and 
STAT3 transcriptional activity of rosmaricine hybrids (43-45) and parent compounds. 
 AlphaScreen-based assay 
Promoter 
Activity  
assay 
STAT3 
Reporter 
Assay 
 STAT3 STAT1 NfkB STAT3 
Compound 
% 
inhibition 
IC50 (µM) 
±SD 
% inhibition 
IC50 (µM) 
±SD 
IC50 (μM)  
±SD 
% 
inhibition 
  3 µM   3 µM    30 µM 
43 99.1± 0.1 0.2±0.0 51.7±0.8 2.8±0.1 53.3±10.9  6.5±5.4 
44 55.5±4.7 2.3±0.4 6.9±0.2 >30 13.0±0.7  35.4±4.9 
45 50.6±1.1 2.9±0.2 11.8±11.9 19.7±4.0 73.0±13.2  34.0±3.1 
Rosmaricine 67.7* 1.9±0.1 18.2* 10±0.6 43.4±6.9  16.1±3.3 
1 6.7±5.2 4.7±1.1 8.6±1.7 >3 NA n.t. 
14 n.t n.t. n.t. n.t. NA n.t. 
9 20.6±3.8 >30 n.t. n.t. n.t. n.t. 
n.t. = not tested 
NA = not active up to 100 μM  
* Average of two experiments 
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Table 6: Cytotoxicity (HCT-116 cell line) of rosmaricine hybrids (43-45) and parent 
compounds and 44 cytotoxicity on MCF-7 and hSMC cell lines. 
 HCT-116 MCF-7 hSMC 
Compound 
%  
cell viability 
IC50 (µM) 
±SD 
IC50 (µM) 
±SD 
IC50 (µM) 
±SD 
  100 µM     
43 39.9±6.8 73.8±0.9  n.t. n.t. 
44 8.38±4.7 3.5±2.8  59.6±1.8 21.2±1.1 
45 26.7±4.0 65.4±3.9  n.t. n.t. 
Rosmaricine 53.6±6.8 65.2±2.3  n.t. n.t. 
1 68.5±20.1  NA n.t. n.t. 
14 71.3±8.7 157.2±41.7 n.t. n.t. 
9 100.0±0.8 NA n.t. n.t. 
n.t. = not tested 
NA = not active up to 100 μM  
 
Results show that rosmaricine and all the new hybrids were able to strongly and selectively bind 
STAT3-SH2 domain, to inhibit the NFkB transcriptional activity on HCT-116 cell line and to inhibit 
HCT-116 cell proliferation. Whereas, the sulfurated parent compounds were not or only very 
poorly active. Once again the methanethiosulfonate hybrid 43, exhibited the highest inhibition 
on STAT3 and the best selectivity toward STAT1. 
Compounds 43 and 45 inhibited NfkB and HCT-116 cell proliferation with IC50 comparable with 
those of rosmaricine, whereas the allyldisulfide hybrid 44 was the most active compound. 
Indeed, 44 displayed a better profile than rosmaricine exhibiting not only a significant 
antiproliferative activity (IC50=3.5±2.8 µM) on HCT-116 cell line, but also the ability to inhibit both 
the transcription factors at low micromolar concentrations. 
In addition, compound 44 showed lower cytotoxicity on hSMC cells, which indicates a moderate 
selectivity (21.2 versus 3.5 µM) whereas its higher cytotoxicity on HCT-116 cells, compared to 
MCF-7, could be related to the higher expression of STAT3 by the former which makes these cells 
more susceptible to STAT3 inhibitors. For this reason, it is worthy of further investigation as 
potential multitarget anticancer agent.151 Preliminary results from the STAT3 reporter assay 
indicate that rosmaricine and compounds 44 and 45 are able to inhibit the protein also in cells, 
although in a much weaker way than in AlphaScreen. Surprisingly, the methanethiosulfonate 
derivative 43 seems not to reach this intracellular target. However, these data need to be 
confirmed and new fresh samples will be tested again at higher concentrations. 
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3.3 Heterocyclic derivatives 
The effects of the new compounds on STAT3 dimerization were determined using the 
AlphaScreen-based assay,180 and the results are expressed as % of protein inhibition at 30 µM or 
as IC50 (µM) (Table 7). To check the selectivity on STAT3, the compounds were tested also on the 
highly homologous (78%) STAT1. In addition, the antiproliferative activity182 of these compounds 
on HCT-116 cell line was also tested and the results, expressed as IC50 (µM) are reported in Table 
7. Moreover, only for some compounds, the IC50s (µM) of the NFkB transcriptional activity on 
HCT-116 cell line are reported in Table 7. 
Table 7: Biological activities of the new hybrids (47-49) the sulfurated parent compounds. 
 STAT3 STAT1 HCT-116 NfkB 
Compound 
% 
inhibition 
IC50  
( µM) 
±SD 
% 
inhibition 
IC50  
(µM) 
±SD 
% cell viability 
IC50 
 (µM) 
±SD 
IC50 
(µM) 
±SD 
 30 µM  30 µM  100 µM   
46 26.6±2.2 >30 n.t. n.t. 71.6±19.2 NA  NA 
47 100.2±0.0 0.7±0.04 29.6±0.2 >30 45.7±5.0 84.5±9.8 NA 
48 99.8±0.1 0.6±0.05 63.8±0.3 7.5±0.4 62.02±1.6 117.9±22.2 n.t. 
49 100.6±0.4 1.2±0.1 75.1±1.9 13.4±0.8 139.9±9.0 NA n.t. 
50 58.7±0.9 21.2±0.7 50.2±1.6 29.8±2.3 115.1±5.7 NA n.t. 
51 100.1±0.0 0.6±0.02 100.4±0.0 5.8±0.3 72.4±10.6 180.2±8.8 NA 
52 33.4±2.3 >30 n.t. n.t. 57.7±5.6 NA NA 
53 99.9±0.1 1.5±0.0 40.0±1.7 >30 111.9±10.4 176.9±14.6 n.t. 
1 72.5±4.8 4.7±1.1 n.t. >3a 68.5±20.1 NA NA 
14 n.t.  n.t. n.t. n.t. 71.3±8.7 157.2±41.7 NA 
n.t. = not tested 
NA = not active up to 200 µM 
ainhibition at 3 µM: 8.6±1.7% 
The results showed that all methanethiosulfonate derivatives (51, 47, 48 and 49) strongly 
interacted with the SH2 domain of STAT3, whereas the corresponding dithiolethiones (50, 46 and 
52) possessed lower affinity, (58.7, 26.6 and 33.4% of inhibition at 30 µM, respectively) 
independently from the nature of the heterocyclic scaffold linked.  
Of note, compound 51 inhibited STAT3 dimerization with an IC50 value of 0.6±0.02 µM, though 
selectivity versus STAT1 was low (IC50=5.8±0.3 μM). By contrast, the equipotent 47 (IC50=0.7±0.04 
µM on STAT3) was provided with interesting selectivity (IC50= >30 µM versus STAT1), exhibiting 
also a moderate cytotoxicity (IC50=84.5±9.8 μM). Among the tested compounds, only three 
thiosulfonates (47, 51 and 48) exhibited a moderate antiproliferative activity on HCT-116 cell line. 
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Since the STAT3 inhibition has been tested in a cell-free assay, the reasons for the low 
correspondence between STAT3 inhibition and cytotoxicity could be related, probably to the not 
optimal physicochemical properties of the tested compounds, which need to be investigated.154 
Unfortunately, as showed in Table 7, none of the tested compounds were able to inhibit the NFkB 
transcriptional activity.  
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4. CONCLUSIONS 
Different sets of new sulfurated drug hybrids have been designed and synthetized and their 
ability to in vitro inhibit STAT3 and NFkB transcription factors as well as cytotoxicity on a human 
colon carcinoma cell line (HCT-116) has been evaluated. Some of them exhibited very interesting 
inhibitory activity of both transcription factors in the micromolar range and antiproliferative 
activity.  
Concerning our studies on the S3I-201 analogues, compound 15, although exhibiting better 
STAT3 inhibition than the parent compound from AlphaScreen assay, showed non-cytotoxic 
activity on HCT-116 cell line, suggesting that, probably, this compound does not reach easily its 
intracellular target due to unsuitable physicochemical properties. Therefore, further studies on 
chemical stability in the culture medium, as well as on solubility and cell permeability are needed. 
Moreover, worth of note is the occasional isolation of a compound with an unusual sulfurated 
functionality (17) and endowed with valuable antiproliferative activity on HCT-116 cell line, 
deserving further investigation. 
The most interesting compounds for the class of curcumin and cinnamic acids derivatives were 
the methanethiosulfonate-curcumin hybrid 18, the two methanethiosulfonate-ferulic acid 
hybrids 24 and 25, the methanethiosulfonate-caffeic acid hybrid 30, the allyldisulfide-caffeic acid 
hybrid 32 and the dithiolethione-caffeic acid hybrid 33, which inhibited both STAT3 and NFkB 
transcription factors and exhibited a moderate cytotoxicity, thus suggesting a potential 
anticancer activity. Studies are ongoing to better define the profile of these new hybrids as dual 
STAT3/NFkB inhibitors. Moreover, results from AlphaScreen based assay showed that all the the 
methanthiosulfonate drug hybrids of phenolic acids bind more potently and selectively to the 
STAT3-SH2 domain, compared to the corresponding allyldisulfide and dithiolethione derivatives, 
with IC50 in low micromolar or submicromolar range. Interestingly, the parent drugs were 
completely devoid of this ability at the tested concentrations. 
Furthermore, most of the celastrol hybrids showed a good antiproliferative activity on HCT-116 
cell line not very far from the parent compound celastrol. All of them were also able to directly 
inhibit STAT3 SH2-domain and compounds 39, 40 and 42 demonstrated an improved selectivity 
toward STAT1. 
In addition, all the rosmaricine hybrids were able to strongly and selectively bind STAT3-SH2 
domain and to inhibit the NFkB transcriptional activity on HCT-116 cell line. Among them, 
compound 44 showed a very interesting profile due to its ability to inhibit both STAT3 and NfkB 
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protein, as well as to its very good antiproliferative activity. For this reason, it is worthy of further 
investigation as potential multitarget anticancer agent. 
Finally, biological results of 1,2,5-oxadiazoles hybrids evidenced that methanthiosulfonates 
interacted stronger with STAT3-SH2 domain with respect to the corresponding dithiolethiones. 
In particular, 47 showed a higher affinity and selectivity (STAT3 versus STAT1), together with a 
moderate cytotoxic activity. Optimization of their physicochemical properties is still needed to 
increase their cytotoxicity.  
Taken together, the obtained results seem to suggest that in general, the methanethiosulfonate 
moiety represents a useful scaffold for the synthesis of new direct STAT3 inhibitors. However, 
only when all the data from STAT3 reporter gene activity assay will be available, we could really 
understand the value of this approach and, eventually, consider the methanethiosulfonate drug 
hybrids described in this thesis interesting hit compounds worthy of structural optimization. 
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ABSTRACT 
DNA-encoded combinatorial libraries (DECLs), promising tools of drug discovery , are collections 
of small organic chemical moieties individually coupled to distinct DNA fragments, serving as 
amplifiable identification barcodes. DNA-encoded chemical libraries are obtained and screened 
as combinatorial mixtures of compounds and are usually prepared by split-and-pool 
technologies. The DNA-tag simplifies the preparation and screening of libraries of very large 
dimension because binding compounds can be captured on a target protein of interest and they 
can be easily identified by polymerase chain reaction (PCR) amplification of the DNA barcode, 
followed by high-throughput DNA sequencing. The synthesis of DECLs crucially depends on the 
availability of robust synthetic methods and, in the majority of cases, requires at least one-step 
of amide bond formation between amino modified DNA and a carboxylic acid. In the second 
chapter of this thesis, we have investigated reaction conditions and optimized a new 
methodology by using 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide, 1-hydroxy-7-
azabenzotriazole and N,N′-diisopropylethylamine (EDC/HOAt/DIPEA) in combination, which 
provided conversions greater than 75% for 423/543 (78%) of the tested carboxylic acids. These 
reaction conditions worked efficiently not only with numerous primary and secondary amines, 
as well as with various types of amino-modified oligonucleotides, but also over a broad range of 
DNA concentrations and reaction scales. According to these results, this method will facilitate 
the synthesis of novel DNA-encoded combinatorial libraries. 
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1. INTRODUCTION 
1.1 Technologies for Drug discovery  
In virtually all cases, drugs are organic compounds, able to selectively interact with one or more 
target proteins, thus mediating a pharmaceutical effect for the prevention or treatment of a 
disease. In the past, the drug discovery process started with the identification of bioactive 
molecules from natural sources, on the basis of random screening assays. Nowadays, drugs are 
often discovered by screening libraries of small molecules (also called chemical libraries) using 
suitable bioassay readout.187 
A common approach mainly used by pharmaceutical industries is the “high-throughput 
screening” (HTS), which provided countless hits molecules for drug development. However, HTS 
programs are extremely complex and expensive because they rely on sophisticated management 
systems and costly compound collections. For this reason, there is a considerable interest in the 
development of new screening methodologies, which are cheaper and more rapid, compared to 
the "one-by-one" testing of individual component. 
In stark contrast to the conventional screening procedures for small organic molecules, the 
discovery of binding macromolecules (e.g., antibodies) by using display technologies (such as 
phage display,188 yeast display,189 mRNA display,190 ribosome display191) in which nucleic acids 
biosynthetically encode library members, can be considered more efficient and inexpensive.  
Display technologies generally depend on "selection/amplification" procedures for the 
identification of binding macromolecules. For instance, phage display allow the isolation of 
specific antibody fragments or protein-binding peptides against any new target protein within a 
few weeks of work using standard laboratory equipment.192 
Indeed, the phage particle is characterized by a physical link between a potential binding 
molecule (the “phenotype”, i.e. scFv antibody fragment) and the genetic information encoding 
for it (“genotype”, i.e. DNA sequence, plasmid) which allows to amplify the genetic information 
of the selected binders and, in this manner, the identification of the binding species (Figure 
36).193 Libraries containing numerous displayed entities (i.e. antibodies) can be rapidly obtained 
using recombinant DNA technology: after the affinity selection procedure (“panning”) on an 
immobilized antigen and washing out of the non-binding compounds, specific binders are 
recuperated by elution and then identified by genetic amplification.193 In analogy with the 
concept of display technologies, DNA-encoded chemical libraries (DECLs) can be considered an 
efficient tool for the screening of binding compounds, out of very large libraries.  
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DECLs can be assembled and screened as combinatorial mixtures of compounds prepared by 
parallel-synthesis or split-and-pool synthesis. They display a small organic molecules 
(“phenotype”) which is covalently linked to a DNA-tag (“genotype”), serves as an amplifiable bar 
code (Figure 36).  
 
Figure 36. Comparison of antibody phage display technology and DNA-encoded chemical libraries. (a) The 
phage particle provides a physical link between the "phenotype" (depicted in green and blue) and the 
gene encoding for it ("genotype"); (b) Conjugate of a small organic molecule (“phenotype”) and the DNA-
tag oligonucleotide ("genotype").193 
In 1992, Brenner and Lerner have introduced the concept of DECLs and they proposed to 
synthesize peptide libraries on individual beads that contain an oligonucleotide barcode, capable 
of unambiguously identification of the corresponding peptidic structure (Figure 37).194 In 
contrast with display technologies, DECLs do not represent a “biosynthetic” encoding method 
because the nucleic acid does not direct the synthesis of the binding molecule. Indeed, DNA 
fragments are identification barcodes, which are individually assigned to a single chemical 
structure during library synthesis procedures and can be easily identified by high-throughput 
DNA sequencing. During the last years, the DNA-encoded chemical procedures have been 
improved omitting beads in library construction in part by the research group of Prof. Dario Neri 
at ETH Zürich and by Prof. David Liu’s group at Harvard University.195 
DECLs provide an avenue for researchers from academia or small companies to identify hits that 
bind to targets of pharmaceutical interest. Numerous binders have been discovered from recent 
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DECL selections, like ADAMTS-5 inhibitors,196 tankyrase 1 inhibitors,197 XIPA inhibitors198 and 
integrin lymphocyte function-associated antigen 1 (LFA-1) antagonists,199 just to name a few.  
 
 
 
 
Figure 37. Schematic representation of different types of chemical libraries. DNA-encoded chemical 
libraries can be considered as an intermediate technology between the screening of compound libraries 
and the selection of encoded combinatorial libraries of polypeptides (e.g., phage display libraries).200 
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1.2 DNA-encoded chemical libraries 
As previously mentioned, DECLs are collections of small organic chemical moieties individually 
coupled to distinct DNA fragments, serving as amplifiable identification barcodes.192, 193, 200 Since 
DNA can be efficiently amplified by PCR and read by high-throughput DNA sequencing methods, 
the encoding of combinatorial libraries with DNA barcodes allows both the easy identification of 
specific ligands to protein targets immobilized on a solid support and the convenient handling of 
the libraries as mixtures of compounds. These libraries are typically synthesized by a stepwise 
assembly procedures, using a variety of chemical building blocks (BBs) which can be reacted to 
create the final structures of the library members. For the preparation and screening of DECLs 
several approaches have been proposed. Indeed, they can be tipically grouped in “single-
pharmacophore” and “dual-pharmacophore” chemical libraries: the first category displays an 
individual small molecule (it does not metter how complex it is) at the individual extremities of 
the double strand DNA-tag fragment, whereas in the second class two sets of small organic 
compounds are attached to the adjacent complementary strands of DNA (Figure 38).200 
 
 
Figure 38. Differences between “single-pharmacophore” and “dual-pharmacophore” chemical libraries.193 
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1.2.1 Single-pharmacophore DNA-encoded libraries 
Various methodologies have been developed for the construction of single-pharmacophore 
DECLs and the experimental strategies can be classified in two categories: those based on a 
stepwise split-&-pool synthesis and others implying DNA-template synthesis.201 The iterative 
assembly of sets of BBs in a “split-and-pool” methodology combined with the stepwise DNA-
tagging, is the most effective strategy used for the preparation of DECLs. This strategy facilitates 
the preparation of DECLs containing millions or even billions of compounds, starting from just 
few hundred small molecules and oligonucleotides and it consists in the following sequential 
steps (Figure 39): 193 
a) coupling reactions of a first set of chemical moieties (w BBs of type “A”) to amino-tagged 
oligonucleotides carrying code 1 (i.e. through amide bond formation); 
b) oligonucleotide conjugates pooling in a single mixture, as any single conjugates contain a DNA 
sequence necessary for the unambiguous identification of the corresponding compound, and 
then splitting into different reaction vessels; 
c) incorporation of the second group of small molecules  (x, type “B”) and encoding of the second 
building block “B” through hybridization and fill-in reaction mediated by Klenow DNA 
polymerase with an oligonucleotide fragment carrying code 2; 
d) pooling of all reactions and incorporation of the third set of building blocks (y, type “C”) 
resulting in a n x m x y member DECL. 
 
Figure 39. Schematic synthesis of a three building block DNA-encoded chemical library. Adapted from202 
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These steps can be repeated w x y x … times and, at the end of this synthesis procedure, libraries 
of very large size (usually is between 105 and 109 encoded small molecules) can be achieved. 
However, when the library size grows the efficacy, the purity and the quality may decrease. For 
example, it occurs if the chemical transformations for the coupling of individual small molecule 
do not proceed with quantitative yields and when the molecular weight of individual 
pharmacophore exceed 600 Da (i.e., using more than 3 sets of building blocks), thus violating the 
Lipinski’s rule of five.193 Another important parameter to consider for the design of DECLs, is not 
only the number of diversity points (including the sets of BBs and synthetic cycles) but also the 
assembly geometry which directly influences the chemical properties of the encoded BBs.192 
Among the DNA-templated synthesis, Harbury and its group developed an alternative strategy 
called “DNA-routing” for the assembly of single-pharmacophore DECLs in which both of the DNA-
fragments are recruited for library encoding193 and it includes the use of a solid phase containing 
complementary DNA-codons with purification-elution steps (Figure 38).203 Moreover, Hansen 
and co. described three-way DNA-hairpin-looped junctions able to assist the library synthesis 
through the transfer of appropriate donor chemical moieties into an acceptor site (Figure 38).204 
 
1.2.2 Dual-pharmacophore DNA-encoded libraries 
Dual-pharmacophore DECLs, also known as “Encoded Self-Assembling Chemical libraries” (ESAC 
library technology), are composed by two molecules coupled at the extremities (5’ and 3’ ends) 
of two complementary DNA strands: Professor Neri’s research group has pioneered in this field. 
205 The synthesis of ESAC libraries is based on combinatorial assembly of reciprocal sub-libraries 
(often called A and B) through DNA hybridization. Typically, sub-library A is composed by small 
chemical moieties connect to the 5’-extremity of single stranded encoded oligonucleotides, 
instead the sub-library B displays BBs attached at the 3’-extremity of the specifically tagged 
oligonucleotides (Figure 40). For example, the combination of two sub-libraries (A x B) with 1000 
members each provides a 1,000,000 member ESAC library. The hybridization domain allows the 
combinatorial assembly of the two sub-units thus permitting the formation of an individual DNA 
heteroduplex. The oligonucleotide conjugates are individually synthesized by coupling of 
chemical entities, purified by high-performance liquid chromatography (HPLC) and characterized 
by liquid chromatography-mass spectrometry (LC-MS).  
Moreover, the DNA tags in addition to their role as identification barcodes, confer enhanced 
solubility to small organic molecules in aqueous phase. Recently has been developed a new 
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strategy of ESAC synthesis by Winssinger and co. in which PNA-conjugate molecules are 
combinatorial self-assembled on a DNA template. In general, the linkers that connect two 
adjacent BBs to the individual DNA-tags are quite flexible thus producing an increase in binding 
affinity due to the simultaneous engagement of two distinct non-overlapping binding sites on the 
target.194 
 
Figure 40. General scheme of ESAC library construction.202 
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1.3 Library selection and decoding 
After the construction of large combinatorial DNA-encoded libraries, they can be rapidly 
screened by incubation with the target protein of interest, which is covalently or not-covalently 
immobilized onto a solid phase (Figure 41). After the incubation step, preferential binding library 
members remain attached to the protein, while non-binding components are removed by 
washing procedures. The DNA-tagged binders are eventually eluted and the DNA-codes can be 
amplified by PCR in order to obtain sufficient quantities of double-stranded DNA to sequence 
(Figure 41).  
 
Figure 41. “Panning” (Affinity selection procedure) for the identification of binding compounds. Adapted 
from206 
 
The modern sequencing techniques enable simultaneous analysis of multiple DNA fragments 
which determinate, by specific frequencies, the order and the relative concentration of each 
nucleotides, thus allowing the identification of the binding molecules. The technology used for 
DNA sequencing mainly involves the high-throughput sequencing (HTP, Figure 41) developed by 
Illumina/Solexa: the resulting data are submitted to statistical evaluation and represented by 
graphical display. The HTP results are visualized by using three-dimensional matrices where the 
code combinations are showed in the xy plane and the corresponding sequence counts for 
individual library components in the z axis. In the same way, the HTP data resulting from a library 
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composed by three sets of BBs requires four-dimensional matrices: the code combinations are 
visualized in xyz space, while the sequence count are represented by spheres of different colours 
and size (Figure 42). It is reasonable to assume that only compounds with high binding affinity 
for the target protein are detected with HTP, thus yielding “spikers” in the fingerprints of library 
selections. However, after the selection test, it is good practice to resynthesize enriched 
molecules, with the aim to better evaluate the binding affinities, using biophysical or biochemical 
methods.207 
 
Figure 42. Evaluation of DECLs selections after HTS decoding. (a) Sequence plot of a two BBs DECL and (b) 
sequence plot of a three BBs DECL.208 
 
1.3.1 High throughput DNA sequencing technologies  
DNA sequencing process includes any method which is used to determinate the exact order of 
nucleotides in a strand of DNA.209 Nowadays these new technologies, called high-throughput or 
ultra-high-throughput DNA sequencing, have greatly accelerated the medicinal and biological 
research because they allow the analysis of DNA fragments in a very short period of time and 
with high precision. For example, “Roche 454 technology”210, 211 uses emulsion-based PCR with 
the aim to amplify a single DNA strand on a bead. After doing PCR, the beads are divided on a 
microscopic wells on a picotiter plate and analysed by pyrosequencing followed by luminescence 
detection. Moreover, “illumina/Solexa technology”207 is a method based on the attachment of 
single stranded DNA fragments on a slide or flow cell, which are amplified with PCR on this 
surface and subsequently sequenced by synthesis using reversible terminators. Compared with 
Roche 454 technology, Illumina produces a much higher amount of sequence data (about 20 GB) 
per run. On the other hand, the Illumina platform generates shorter read lengths (currently up 
to 100 bp) and it needs a longer run time (several days) to obtain the final data. The libraries 
synthetized within the laboratory of Prof. Neri, based on two or three sets of building blocks, are 
encoded with DNA fragments shorter than 80 bases and for these reasons are compatible both 
(a) (b) 
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with 454 and with Illumina sequencing. Another used method is the “applied Biosystem’s SOLiD 
technology” which depends on a sequencing-by-ligation chemistry. In the same way of 454 
platform, DNA fragments immobilized on beads are amplified by emulsion PCR. However, the 
beads are then blocked on a slide and the DNA fragments are interrogated through ligation steps 
with labelled oligonucleotide probes: the result of the process is that each base is "sequenced" 
twice, allowing increased accuracy. The sequence output of SOLiD is comparable to that observed 
in Illumina sequencing. At the moment, about 15-30 GB of 50 bp reads can be achieved in a 
week.212 
 
1.3.2 Hit validation  
The preferential binders founded with the selection experiment are then typically resynthesized 
without DNA barcode in order to confirm the protein interaction and to define affinity constants. 
In literature have been reported many cases of good correlation between the sequencing counts 
after HTP and the final affinity of the organic compounds without DNA tag. However, big DECLs 
may identify hundreds of enriched molecules, making conventional hit-validation processes (i.e., 
affinity or inhibition measurements, fluorescence polarization measurements) more 
cumbersome. In this case, additional selections performed with an increased selection pressure 
might establish the number of hits to validate.213 
In addition, the potency or the affinity of the DNA-conjugated compounds can be alternatively 
directly defined on DNA. The advantage of using DNA-based hit validation depends on the fact 
that: (i) every single molecule of the library can be individually synthesized; (ii) the purification 
procedures (i.e. precipitation) and the quality control (e.g. ESI-MS) can be facilitated thanks to 
the DNA-tag; (iii) the DNA barcode can be employed for quantification (e.g. absorbance 
measurements), for detection and/or for immobilization purposes (Figure 43). Different hit-
validation strategies for DNA-conjugates in biological assays have been recently explored. Among 
them, there are the measurement of a solution-based reporter assay (e.g. inhibition assay or 
competition assay) using a DNA-tagged small molecule and the target protein (Figure 43a), the 
electromobility shift assay that measures the affinity of the DNA-conjugates with a protein 
(Figure 43b) and the affinity chromatography of radiolabeled DNA-conjugates able to rank the 
hits according to their retention time (Figure 43c).  
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Moreover, the target protein can be immobilized on a solid support (i.e., ELISA plate), and the 
oligonucleotide can be employed for detection (Figure 43d). Another used strategy is the reverse 
setup, which consists of DNA-conjugate immobilization and protein quantification (for example 
antibodies, Figure 43e).213 
 
Figure 43. Hit-validation strategies for DNA-tagged small molecules.213 
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1.4 DNA-compatible chemistry  
Until today, several strategies for the DECLs building have been successfully used to realize new 
ligands against pharmaceutically target proteins. The design and even the synthesis of DELs are 
very important topics because they define the quality of possible hit compounds, which may be 
analysed with affinity selection experiments.202 DECLs are typically prepared by using different 
types BBs which are assembled in prefined geometries (Figure 44) using a variety of chemical 
reactions (i.e. coupling, click…). The DNA conjugate starting material may be composed by a DNA-
encoding region, a synthetically chemical handle (usually an aliphatic primary amine where other 
BBs could be attached) and a linker between the handle and the DNA-tag.214  
The synthesis of DECLs crucially depends on the availability of robust synthetic methodologies 
and it requires protic solvents, basic aqueous solutions and, in general, conditions that will not 
degrade the DNA. These requirements exclude many ordinary synthetic strategies as the use of 
highly reactive reagents or water-degradable compounds (i.e. acyl chlorides, Mitsunobu 
intermediates), very strong bases (i.e. t-butyl lithium), strong reducing reagents (i.e. LiAlH4) and 
oxidants that degrade DNA. For these reasons, the reagents compatible with DECL chemistry not 
only should be stable in basic aqueous conditions, but also they do not have to interact with DNA 
bases. Moreover, many organic small molecules are soluble in organic solvents and that is why a 
mixture of water-miscible organic solvent (i.e DMSO) with aqueous buffer should be considered 
for running reactions containing DNA-conjugates.214 Finally, it is important to remark that the low 
scaffold diversity and also the low yields of chemical transformations for the attachment of 
individual small molecule compromise the efficacy, the purity and the quality of the final DECL. 
Therefore, in this context, it is important to optimize and find new synthesis procedure for the 
DECLs construction in order to improve library efficacy. 
 
Figure 44. Different geometries of library illustrating the combinatorial nature of DECLs (nBB: number of 
diversity points).192
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2. AIM OF THE RESEARCH PROJECT 
In the majority of DECLs disclosed so far, at least one synthesis step involved the formation of an 
amide bond between amino modified DNA and a carboxylic acid.192 The acylation of DNA-
attached amines with carboxylic acids can be performed on protected DNA structures linked to 
Controlled Pore Glass (CPG) supports197 or in solution,215 followed by deprotection and HPLC 
purification of the individual conjugates at early stages of library construction. Additionally, for 
unprotected DNA-attached amines, acylation can be performed either in solution or on “pseudo-
solid phase” (i.e., on amino-modified oligonucleotide derivatives non-covalently immobilized on 
solid supports, facilitating the use of large molar excess of reagents and repeated washing steps 
for purification).216 While reaction conditions with DNA on solid phase can work very efficiently, 
they typically consume several milligrams of each carboxylic acid for each coupling, which makes 
synthesis expensive and may limit the use of precious BBs for the construction of different 
chemical libraries. By contrast, the acylation in solution may allow the synthesis of large DECLs 
using only minute amounts of BBs. Amide bond-forming reactions, performed in solution with 
unprotected oligonucleotides, have been described using EDC/sulfo-NHS217 or 4-(4,6-dimethoxy-
1,3,5-triazin-2-yl)-4-methyl morpholinium chloride (DMT-MM) as coupling reagent for DECL 
synthesis purposes.218 Recently, Satz and co. have explored the scope and applicability of organic 
reactions in aqueous solution for the construction of DECLs, reporting also a sequential acylation 
method with DMT-MM for multistep synthesis.219  
For these reasons, the aim of the project was to find new conditions in solution phase of amide-
bond forming reaction to facilitate the synthesis of novel DNA-encoded combinatorial libraries. 
The new method worked efficiently with a variety of primary and secondary amines, with various 
types of amino-modified oligonucleotides and over a broad range of DNA concentrations and 
reaction scales.220 
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3. RESULTS AND DISCUSSION 
Motivated by previous experience in Prof. Dario Neri’s laboratory in the synthesis of DECLs, which 
involved carboxylic acids as building blocks, we decided to characterize the reaction of eight 
representative compounds, leading to very different conversion rates with DMT-MM as coupling 
reagent (Table 8, entry 1). While two carboxylic acids (CA-1 and CA-2) formed amides with 5’-
aminomodified DNA (ODN-1) with excellent conversion rates (>90%, determined by UV 
absorbance trace at 260 nm of UPLC), the remaining six structures exhibited suboptimal 
conversion (ranging between 0 and 11% for 4 out of 8 compounds).  
A systematic investigation for alternative coupling methods is summarized in Table 8 and 
different peptide coupling reagents were tested to enhance the yield of acylation.  
Coupling reagents like 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid hexafluorophosphate (HATU, Table 8, entries 2 and 3) and 1-cyano-2-ethoxy-2-
(oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU, 
Table 8, entry 4) consistently provided poor conversion rates for all the reactions tested.  
Coupling reagents as N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ, Table 8, entry 5) 
and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate (TBTU, Table 8, 
entry 6) afforded better conversion only for some acids, while the coupling efficacy remained 
very low for the other substrates. Promising results were obtained by using EDC/sulfo-NHS (Table 
8, entry 7) as coupling combination, a well-established and widely used method. This led to a 
complete conversion for 7 out of 8 compounds, while for one carboxylic acid (CA-8) no product 
was observed. Further optimization revealed a novel method, featuring the combination of 
EDC/HOAt/DIPEA (Table 8, entry 8), which yielded >90% conversion for all the tested compounds. 
For four tested acids, the coupling efficiency decreased dramatically by using only EDC/HOAt 
(Table 8, entry 9), highlighting the importance of DIPEA for proper activation.220  
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Table 8. General synthesis (above) and summary of coupling conversion yields by using different coupling 
reagents with eight representative carboxylic acids.220 
 
.  
Reagents and conditions. In all cases, 72 μL of ODN-1 (MOPS buffer pH 8.0, 0.5 nmol), 45 μL carboxylic 
acid (60 mM in DMSO) and coupling reagent (entry 1-9) were reacted for 16 h at rt, followed by an 
additional coupling step with the same activated carboxylic acid for 6 h at rt. 
 
Entry 1, 4 μL of DMT-MM (300 mM in water);  
entry 2, 4 μL of HATU (300 mM in DMSO), 4 μL of DIPEA (300 mM in DMSO);  
entry 3, 4 μL of HATU (300 mM in DMSO), 4 μL of HATU (60 mM in DMSO), 4 μL of DIPEA (300 mM in 
DMSO);  
entry 4, 4 μL of COMU (300 mM in DMSO);  
entry 5, 4 μL of EEDQ (300 mM in DMSO);  
entry 6, 4 μL of TBTU (300 mM in DMSO), 4 μL of NMM (300 mM in DMSO); 
entry 7, 4 μL of EDC (300 mM in DMSO), 4 μL of sulfo-NHS (60 mM in  DMSO:water = 2:1);  
entry 8, 4 μL of EDC (300 mM in DMSO), 4 μL of HOAt (60 mM in DMSO), 4 μL of DIPEA (300 mM in DMSO); 
entry 9, 4 μL of EDC (300 mM in DMSO), 4 μL of HOAt (60 mM in DMSO). 
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Moreover, the conversion yields have been detected by UPLC-MS analysis (at 260 nm): Figure 45 
(and also Figure 50 reported in the experimental part) shows representative LC and MS profiles 
for CA-5, one carboxylic acid that did not couple at all using DMT-MM as coupling reagent, which 
however provided excellent conversion (>90%) with the new discovered EDC/HOAt/DIPEA 
methodology. 
 
 
Figure 45. UPLC profiles of (a) 5’-C12-amino oligonucleotide (ODN-1). (b) Crude reaction mixture after 
coupling with CA-5 using DMT-MM. (c) Crude reaction mixture after coupling with CA-5 using 
EDC/HOAt/DIPEA. Detection at 260 nm.220 
In order to compare the performance of the DMT-MM and EDC/HOAt/DIPEA methods over a 
broader range of substrates, we performed reactions using ODN-1 and a structurally diverse set 
of 543 carboxylic acids. Using an optimized DMT-MM protocol, 42% of the compounds exhibited 
a conversion lower than 50%, while 14% had a conversion between 50% and 75%, as assessed by 
UPLC analysis and MS confirmation (Figure 46a).  
Conversely, the EDC/HOAt/DIPEA method exhibited a conversion rate of >75% for 78% of the 543 
carboxylic acids. However, no clear correlation between structural features and conversion rate 
was found. For instance, different types of carboxylic acids (i.e., benzoic acids; primary, 
secondary, and tertiary carboxylic acids; aromatic or heterocyclic acids) provided similar coupling 
efficiencies (Figure 46b). The experimental findings underline the importance of screening all 
building blocks in model reactions before DECL construction, rather than studying coupling 
conditions on a small set of test compounds.  
(a) (b) (c) 
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Figure 46. (a) Pie chart analysis of the coupling yields of ODN-1 with 543 carboxylic acids using DMT-MM 
and EDC/HOAt/DIPEA-mediated coupling, according to the conditions described in Table 8, entries 1 and 
8. (b) Histogram analysis of the coupling yields of structurally diverse carboxylic acids to ODN-1 with 
EDC/HOAt/DIPEA method. Benzoic (79 acids), primary (246 acids), secondary (47 acids), and tertiary 
carboxylic acids (17 acids) and heterocyclic acids (154 acids).220 
 
In a previous report, it was described that adduct formation of EDC and G- and T-nucleobases 
could occur during the formation of the acylation product by using EDC as coupling reagent on 
“pseudo-solid phase”.216 While the impact of such possible base modifications on the 
performance of PCR amplification is so far unexplored, it may also compromise the integrity of 
the DNA-barcodes.221 We systematically checked the mass spectra of all obtained conjugates 
from the solution phase EDC/HOAt/DIPEA method and found no detectable EDC adducts 
associated with the conjugates (i.e., <5%). Figure 47 shows an exemplary MS profile for CA-9 
(trans-4-hydroxycyclohexane-1-carboxylic acid)-DNA conjugate, one of the carboxylic acids that 
exhibited significant EDC adduct formation with the “pseudo-solid phase” method. No adduct 
was detected with the EDC/HOAt/DIPEA methodology. 
 
DMT-MM 
EDC/HOAt/DIPEA 
(a) (b) 
79 CAs       246 CAs         47 CAs          17 CAs           154 CAs 
Ar-CO2H      RCH2-CO2H        R,R’CH-CO2H      R,R’,R’’C-CO2H  
 
Heterocycle-CO2H 
Total of 543 CAs 
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Figure 47. Deconvoluted mass spectrum of DNA-conjugate yielded from CA-9 (trans-4-
hydroxycyclohexane-1-carboxylic acid) and ODN-1 by the DEC/HOAt/DIPEA method. Observed: 13451.7; 
expected: 13451.2. There is no detectable EDC adduct (expected: 13605.0) was observed for CA-9, which 
gives significant EDC adduct alongside the expected DNA-conjugate by the pseudo-solid phase method. 
216 
 
Furthermore, it has been also tested the coupling efficiency between eight representative 
carboxylic acids and six DNA scaffolds, containing amines with different chemical features (Table 
9). The DNA-conjugate of glycine (SC-1) and the DNA-conjugate linked to 4-
(aminomethyl)benzoic acid (SC-2) provided fair to good conversion yields for all the eight tested 
acids. Good conversions were also achieved with two cyclic secondary amines SC-5 and SC-6 
respectively. 
Using the previously mentioned EDC/HOAt/DIPEA coupling protocol, conversions of amide bond 
forming reactions were distinctly lower for sterically hindered substrates (SC-3). More steric bulk 
at the α-carbon further decreased the coupling efficiency extensively. For example, poor coupling 
results were obtained with a DNA-conjugate of 2-aminoisobutyric acid (SC-4).  
With the exception of CA-1, all the remaining seven carboxylic acids had conversion yields <30% 
under the optimized conditions. 
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Table 9. Coupling yields of six different DNA-Scaffold Conjugates with eight representative carboxylic 
acids, according to the condition described in Table 8, entry 8.220 
 
  
 SC-1 SC-2 SC-3 SC-4 SC-5 SC-6 
CA-1 >90% >90% >90% 48% >90% >90% 
CA-2 >90% >90% >90% 29% >90% >90% 
CA-3 >90% >90% 61% 0% >90% >90% 
CA-4 >90% 89% 70% 6% 85% >90% 
CA-5 81% >90% 50% 12% >90% >90% 
CA-6 >90% >90% >90% 17% >90% >90% 
CA-7 >90% 87% >90% 3% >90% >90% 
CA-8 77% 60% 21% 5% >90% 81% 
 
In order to further investigate the dependence of reaction yields on the nature of amines on DNA, 
five additional amino-modified oligonucleotides bearing different tethers were used.  
Such reactions are particularly useful for the construction of encoded self-assembling chemical 
libraries.222 Compared to ODN-1, which featured a long C-12 tether, amino-modified 
oligonucleotides (i.e., ODN-2, ODN-3 and ODN-4) with various short linkers at the 5’ end were 
examined. Good conversions were observed in 22/24 reactions and, in all cases, a conversion 
>60% was achieved (Table 10). ODN-5, carrying an aminohexyl-tether at the 3’ end, was also 
efficiently converted into the corresponding acylated conjugates (>75%).  
As the chemical modification of internal sites within the DNA structure may be used for the 
construction of DECLs using the Yoctoliter reactor method,204 the conversion of a primary amine 
on the side chain of a thymine modified at the C-6 position in ODN-6 was investigated and led to 
good yields for 7 out of 8 reactions, while only one carboxylic acid (CA-8) yielded a slightly lower 
conversion (66%).  
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Table 10. Coupling yields of five different amino-modified oligonucleotides with eight representative 
carboxylic acids, according to the condition described in Table 8, entry 8.220 
 ODN-2 ODN-3 ODN-4 ODN-5 ODN-6 
CA-1 >90% >90% >90% >90% >90% 
CA-2 >90% >90% 89% >90% >90% 
CA-3 >90% >90% >90% >90% >90% 
CA-4 >90% >90% >90% 79% 85% 
CA-5 81% 78% >90% 86% 76% 
CA-6 >90% >90% >90% >90% >90% 
CA-7 >90% >90% >90% >90% >90% 
CA-8 60% 66% 80% 75% 66% 
 
 
Importantly, the EDC/HOAt/DIPEA method worked well also at different scales of amino-
modified DNA (ranging between 2 and 10 nmol), which are customarily utilized for library 
construction (Table 11). Moreover, we also decided to investigate the reaction scales of 
compounds CA-1 and CA-3 at 25 and 50 nmol which provided, in both cases, conversion yields 
greater than 90%. 
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Table 11. Coupling yields of ODN-1 at 2 nmol and 10 nmol scale with eight representative carboxylic acids, 
according to the condition described in Table 8, entry 8.220 
 2 nmol 10 nmol 
CA-1 >90% >90% 
CA-2 >90% >90% 
CA-3 >90% >90% 
CA-4 >90% >90% 
CA-5 >90% >90% 
CA-6 >90% >90% 
CA-7 >90% >90% 
CA-8 >90% 87% 
 
The execution of synthetic steps with high yields and good purity is particularly important for the 
construction of DNA-encoded combinatorial libraries that require multiple steps of assembly 
(e.g., those based on split-and-pool methodologies). While individual DNA conjugates can be 
purified and analysed after the first step of library construction, the processing of synthetic 
intermediates at later stages becomes more complicated. In order to minimize the presence of 
incomplete reaction products (e.g., residual unreacted amines) in the library, methods have been 
developed for the modification and removal of such truncated products.223 While these methods 
can be useful and may lead to improved library purity, they inevitably lead to an uneven 
distribution of library members, thus complicating decoding procedures. The method described 
in this letter should facilitate library synthesis without the need for “cap-and-catch” strategies.  
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4. EXPERIMENTAL 
4.1 General procedures 
4.1.1 Materials and Instruments 
Unless otherwise noted, all reagents and solvents were purchased from commercial sources and 
used as received. Water was purified with a Thermo Scientific Barnstead Nanopure system. 
Oligonucleotides were purchased from DNA Technology (Denmark). Carboxylic acid building 
blocks were purchased from several commercial suppliers including ABCR (Karlsruhe, Germany), 
ChemBridge (SanDiego, CA), Sigma-Aldrich (St. Louis, MO), TCI Europe (Zwijndrecht, Belgium), 
Alfa Aesar (Ward Hill, MA), Matrix Scientific (Columbia, SC), and Acros Organics (Geel, Belgium). 
Universal indicator paper (pH 1-11) was purchased from Macherey-Nagel (Germany). 
For UPLC-MS analysis, an X-Bridge Oligonucleotide BEH C18 2.1 x 50 mm column, using an A=TEA 
(10 mM), HFIP (5 mM) in water to B=methanol, gradient from 10% B to 40% B in 6.5 minutes. 
Xevo G2-XS Q-TOF with electrospray ionization source was used for detection. MaxEnt1 software 
was used to deconvolute the multiple charge states. HPLC purifications were performed on a 
CT18-XTerra 10 x 150 mm column, using an A=TEAA (0.1 M in water) to B=CH3CN (80% in water) 
gradient from 10% B to 40% B in 15 minutes. 
 
4.1.2 Ethanol Precipitation 
To aqueous DNA solutions, 10% by volume of 5 M NaCl was added, followed by 2.5-3 volumes of 
cold ethanol. The colloidal solution was allowed to sit for 16-18 h at -20 °C, prior to a 
centrifugation step at 17,000 g for 15 minutes at 4 °C. The resulting supernatant was discarded 
and the pellet was rinsed once with cold 70% ethanol. After centrifugation at 17,000 g for another 
5 minutes at 4 °C, the supernatant was discarded and the pellet was dried on a speedvac. The 
recovered samples were dissolved in appropriate buffer for subsequent analysis or experiments. 
This procedure was generally performed after each chemical reaction. 
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4.1.3 General Protocol for Functionalization of Amino-modified DNAs with 
Carboxylic Acids by the EDC/HOAt/DIPEA method  
To a solution of DNA (500 pmol) in MOPS buffer (50 mM, pH 8.0, 0.5 M NaCl, 72 μL) was added a 
mixture of carboxylic acid (60 mM, 45 μL), EDC (300 mM, 4 μL), HOAt (60 mM, 4 μL) and DIPEA 
(300 mM, 4 μL) in DMSO, previously activated for 15 minutes at room temperature. The reaction 
was agitated at room temperature for 16 h. The reaction solution was then treated with a second 
addition of freshly activated carboxylic acid in DMSO (same activation mixture as above) and it 
was agitated for further 6 h at rt. The reaction was quenched by addition of NH4OAc (500 mM, 
25 μL) at room temperature for 30 minutes and the DNA-conjugates were isolated by ethanol 
precipitation. The pellet was re-dissolved in water (200 μL) and analysed by UPLC-MS. 
 
Table 12. pH values at different stages of the EDC/HOAt/DIPEA method. 
 MOPS Buffer (50 mM, 
pH 8.0, 0.5 M NaCl) 
MOPS Buffer (500 mM, 
pH 8.0, 0.5 M NaCl) 
No Buffer (pH 7.0, 0.5 M 
NaCl) 
Carboxylic 
Acids 
A B C A B C A B C 
CA-1 8 8 8 8 8 8 7 7 7 
CA-2 8 8 8 8 8 8 7 7 7 
CA-3 8 8 8 8 8 8 7 7 7 
CA-4 8 8 8 8 8 8 7 7 7 
CA-5 8 8 8 8 8 8 7 7 7 
CA-6 8 8 8 8 8 8 7 7 7 
CA-7 8 8 8 8 8 8 8 8 8 
CA-8 8 8 8 8 8 8 7 7 7 
A: pH value at 5 minutes after the first time addition of activation mixture.  
B: pH value at 5 minutes after the second time addition of activation mixture.  
C: pH value before the quenching of reaction mixture. All pH values were measured by universal 
indicator paper (pH 1-11). 
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Table 13. Reaction conversions with different buffer systems. 
Carboxylic Acid 
MOPS Buffer (50 
mM, pH 8.0, 0.5 M 
NaCl) 
MOPS Buffer (500 
mM, pH 8.0, 0.5 M 
NaCl) 
No Buffer (pH 7.0, 
0.5 M NaCl) 
CA-1 90% 90% 90% 
CA-2 90% 90% 90% 
CA-3 90% 90% 90% 
CA-4 90% 90% 0% 
CA-5 90% 90% 60% 
CA-6 90% 90% 90% 
CA-7 90% 90% 90% 
CA-8 90% 90% 90% 
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4.2 Oligonucleotide sequences 
The oligonucleotide sequence reported in Table 8 and Figure 45 is: 
- ODN-1: 5’-(NH2-C12)-GGA GCT TGT GAA TTC TGG ATC TTA GGA CGT GTG TGA ATT GTC; 
 
The oligonucleotide sequences reported in Table 10 are: 
- ODN-2: 5’-(NH2-C6)-GGA GCT TGT GAA TTC TGG ATC TTA GGA CGT GTG TGA ATT GTC; 
- ODN-3: 5’-(NH2-C3)-GGA GCT TGT GAA TTC TGG ATC TTA GGA CGT GTG TGA ATT GTC; 
- ODN-4: 5’-(NH2-PEG)-GGA GCT TGT GAA TTC TGG ATC TTA GGA CGT GTG TGA ATT GTC; 
- ODN-5: GGA GCT TGT GAA TTC TGG ATC TTA GGA CGT GTG TGA ATT GTC-(C6-NH2)-3’; 
- ODN-6: 5’- CGT CGA TCC GGC GCC AT*G GGA CTC G; T*=Amino-C6-dT 
 
Table 14. ESI-MS characterization of DNAs used in this section. 
Oligonucleotide Expected mass (Da) Observed mass (Da) 
ODN-1 13324.9 13325.4 
ODN-2 13240.8 13240.9 
ODN-3 13198.6 13199.0 
ODN-4 13229.3 13228.8 
ODN-5 13240.8 13241.0 
ODN-6 7814.2 7814.5 
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4.3 Representative mass spectrum of DNA-conjugates characterization 
In this section deconvoluted mass spectrum of 5’-C12-amino oligonucleotide (ODN-1, Figure 48) 
and deconvoluted mass spectra of DNA-conjugate of compound CA-5 using DMT-MM (Figure 49) 
and EDC/HOAt/DIPEA (Figure 50) are reported. 
 
 
Figure 48. Deconvoluted mass spectrum of DNA-conjugate at 4.36-minute in Figure 45a. Observed: 
13325.4; expected: 13324.9. 
 
 
 
Figure 49. Deconvoluted mass spectrum of DNA-conjugate at 4.35-minute peak in Figure 45b. Observed: 
13325.4; expected: 13324.9. 
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Figure 50. Deconvoluted mass spectrum of DNA-conjugate at 5.03 minute peak in Figure 45c. Observed: 
13480.3; expected: 13480.5. 
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4.4 DNA-conjugates characterization in Table 8 
The following table shows the conversion yields (%) and the masses (Da) of the eight 
representative compounds using EDC/HOAt/DIPEA method. 
Table 15. ESI-MS characterization of the eight representative compounds using EDC/HOAt/DIPEA 
method. 
Carboxylic Acid Conversion Yield (%) Expected mass (Da) Observed mass (Da) 
CA-1 >90 13448.8 13449.0 
CA-2 >90 13521.3 13521.0 
CA-3 >90 13534.9 13535.0 
CA-4 >90 13488.8 13489.0 
CA-5 >90 13479.8 13480.5 
CA-6 >90 13511.8 13512.0 
CA-7 >90 13515.9 13516.0 
CA-8 >90 13511.9 13512.8 
CA-9 >90 13451.2 13451.7 
Conversion was determined by integration of absorbance trace (260 nm) peak areas from LC-MS 
traces.  
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4.5 DNA-Scaffold conjugates’ structures, synthesis, purification, and 
characterization 
Fmoc-protected amino acid (100 mM in DMSO, 50 μL), sulfo-NHS (100 mM stock solution in 2:1 
DMSO/H2O, 20 μL) and EDC*HCl (100 mM in DMSO, 50 μL) were added to DMSO (100 μL) and 
allowed to stand at room temperature for 15 minutes.  
Subsequently, a mixture of the amino-modified oligonucleotide (ODN-1, 50 nmol) dissolved in 
TEA*HCl buffer (250mM, pH 10.0, 100 μL) was added and the reaction kept at room temperature 
for additional 8 h. The reaction was precipitated with ethanol. 
To the resulting pellet, piperidine was added (10% v/v aqueous stock solution, 100 μL) and the 
deprotection reaction was allowed to stand at room temperature for 30 minutes. The DNA-
scaffold conjugate was precipitated with ethanol and purified by HPLC. The separated and 
collected conjugate was vacuum-dried overnight, re-dissolved in H2O and characterized by ESI-
MS. 
 
Scheme 1. (a) Synthesis scheme of DNA-scaffold conjugates SC-1 to SC-6. (b) Structures of the Fmoc-
protected amino acids used for conjugation. 
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Table 16. ESI-MS characterization and chromatograms of DNA-conjugates used in this section. 
SC Yield (%) 
Expected mass 
(Da) 
Observed mass 
(Da) 
SC-1 53 13381.6 13382.4 
SC-2 18 13457.0 13457.9 
SC-3 34 13449.8 13450.6 
SC-4 38 13410.4 13411.7 
SC-5 57 13436.1 13436.9 
SC-6 80 13421.9 13422.5 
 
Figure 51. (a) HPLC trace of the purification of DNA-scaffold conjugate SC-3.The fraction at 11.40 min was 
collected. (b) UPLC profile of the DNA-scaffold conjugate SC-3. Detection at 260 nm. 
  
(a) (b) 
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4.6 DNA-conjugates characterization in Table 9 and Table 10 
In this section the ESI-MS characterization of DNA-conjugates using EDC/HOAt/DIPEA method 
are reported. 
Table 17. ESI-MS characterization of DNA-conjugates used in Table 9. 
SC Carboxylic Acid Expected mass (Da) Observed mass (Da) 
SC-1 CA-1 13505.8 13506.8 
SC-1 CA-2 13578.2 13579.4 
SC-1 CA-3 13591.8 13593.1 
SC-1 CA-4 13545.7 13546.7 
SC-1 CA-5 13536.7 13537.8 
SC-1 CA-6 13568.0 13569.7 
SC-1 CA-7 13572.0 13573.9 
SC-1 CA-8 13568.9 13570.0 
SC-2 CA-1 13582.0 13583.0 
SC-2 CA-2 13654.4 13655.3 
SC-2 CA-3 13668.0 13669.1 
SC-2 CA-4 13622.0 13622.9 
SC-2 CA-5 13612.9 13613.9 
SC-2 CA-6 13644.8 13645.7 
SC-2 CA-7 13648.8 13650.1 
SC-2 CA-8 13645.0 13646.2 
SC-3 CA-1 13574.0 13575.2 
SC-3 CA-2 13646.4 13647.7 
SC-3 CA-3 13660.0 13661.2 
SC-3 CA-4 13614.0 13615.0 
SC-3 CA-5 13605.0 13606.2 
SC-3 CA-6 13636.8 13637.9 
SC-3 CA-7 13640.8 13642.4 
SC-3 CA-8 13637.1 13638.3 
SC-4 CA-1 13533.7 13534.9 
SC-4 CA-2 13606.1 13607.3 
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SC-4 CA-3 13620.2 nd 
SC-4 CA-4 13573.2 nd 
SC-4 CA-5 13565.1 13566.2 
SC-4 CA-6 13596.3 nd 
SC-4 CA-7 13600.8 nd 
SC-4 CA-8 13596.7 13598.1 
SC-5 CA-1 13559.8 13560.5 
SC-5 CA-2 13631.3 13632.7 
SC-5 CA-3 13645.1 13646.3 
SC-5 CA-4 13488.8 13600.3 
SC-5 CA-5 13590.1 13591.5 
SC-5 CA-6 13622.7 13623.7 
SC-5 CA-7 13627.7 13628.1 
SC-5 CA-8 13622.1 13623.5 
SC-6 CA-1 13546.1 13547.1 
SC-6 CA-2 13618.6 13618.0 
SC-6 CA-3 13632.2 13633.1 
SC-6 CA-4 13586.1 13587.1 
SC-6 CA-5 13577.1 13578.3 
SC-6 CA-6 13608.9 13609.7 
SC-6 CA-7 13612.9 13614.1 
SC-6 CA-8 13609.2 13610.1 
nd: Masses were determined only for conversion >10%, because of limited sensitivity of the instrument. 
  
Chapter II: Experimental 
 
185 
Table 18. ESI-MS characterization of DNA-conjugates used in Table 10. 
ODN Carboxylic Acid Expected mass (Da) Observed mass (Da) 
ODN-2 CA-1 13365.0  13365.0 
ODN-2 CA-2 13437.5  13437.0 
ODN-2 CA-3 13451.1  13451.0 
ODN-2 CA-4 13405.0  13405.0 
ODN-2 CA-5 13396.0  13396.0 
ODN-2 CA-6 13427.8  13428.4 
ODN-2 CA-7 13431.8  13432.7 
ODN-2 CA-8 13428.1  13428.0 
ODN-3 CA-1 13320.8  13322.9 
ODN-3 CA-2 13435.6  13437.0 
ODN-3 CA-3 13408.1  13409.1 
ODN-3 CA-4 13362.3  13363.0 
ODN-3 CA-5 13394.7  13396.0 
ODN-3 CA-6 13385.1  13386.6 
ODN-3 CA-7 13389.2  13390.7 
ODN-3 CA-8 13384.8  13386.1 
ODN-4 CA-1 13353.5  13353.2 
ODN-4 CA-2 13426.0  13425.7 
ODN-4 CA-3 13439.6  13439.2 
ODN-4 CA-4 13393.5  13393.6 
ODN-4 CA-5 13384.5  13384.4 
ODN-4 CA-6 13416.3  13416.5 
ODN-4 CA-7 13420.3  13420.8 
ODN-4 CA-8 13416.6  13416.4 
ODN-5 CA-1 13365.0  13365.2 
ODN-5 CA-2 13437.5  13437.6 
ODN-5 CA-3 13451.1  13451.2 
ODN-5 CA-4 13405.0  13405.2 
ODN-5 CA-5 13396.0  13396.3 
ODN-5 CA-6 13427.8  13428.6 
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ODN-5 CA-7 13431.8  13432.8 
ODN-5 CA-8 13428.1  13428.2 
ODN-6 CA-1 7938.4  7938.6 
ODN-6 CA-2 8010.9  8010.5 
ODN-6 CA-3 8024.5  8024.6 
ODN-6 CA-4 7978.4  7978.6 
ODN-6 CA-5 7969.4  7969.7 
ODN-6 CA-6 8001.2  8002.1 
ODN-6 CA-7 8005.2  8006.2 
ODN-6 CA-8 8001.5  8001.7 
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5. CONCLUSIONS 
In summary, with the aim to improve synthetic methods used in DECLs construction, we have 
systematically investigated different experimental conditions for amide bond formation on DNA 
in solution phase and established a novel efficient methodology (EDC/HOAt/DIPEA as coupling 
combination). We tested 543 structurally diverse carboxylic acids as building blocks and found 
that the method provides good conversion yields for the majority of the compounds.  
The reaction works well with various types of amino-modified oligonucleotides and at different 
reaction scales. While the EDC/HOAt/DIPEA method worked well in most experimental 
conditions, additional research efforts will be needed for certain substrates (e.g., amines 
featuring a substantial steric hindrance), as chemical purity greatly contributes to the 
performance of DECL technology. 
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